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Understanding the Impact of BCRP and PGP Efflux Transporters on the
Disposition of Their Endogenous, Xenobiotic and Dietary Substrates
Abstract
Breast Cancer Resistant Protein (BCRP) and P-glycoprotein (PGP) are membrane-bound efflux
transporters that transport multiple chemical classes of compounds and act as barriers to tissue
permeability, thereby regulating tissue exposure of their substrates. The role of these transporters in
therapeutic resistance of their xenobiotic substrates due to their expression and efflux function at target
organs/tissues, especially in brain and intestine, is well established, which has fueled investigation toward
identification of their inhibitors. Multiple clinically used drugs and dietary chemicals have been reported to
inhibit these transporters and potentially increase the exposure of concomitantly administered BCRP and/
or PGP substrates, which might be desirable (to increase efficacy of the substrate drug) as well as
undesirable (as it can affect the disposition of the substrate in tissues where it might cause toxicity).
Therefore, drug-drug and food-drug interactions with BCRP and PGP are a major concern in drug
development, as recognized by US Food and Drug Administration (FDA), European Medicines Agency
(EMA) and International Transporter Consortium (ITC).
BCRP and PGP transporters are also known to transport endogenous substrates and have been
associated with important physiological functions. This includes an inflammatory bowel disease-like
phenotype associated with a non-functional PGP polymorphism (Ala893), while a loss of function
mutation in BCRP (Q141K) is known to be positively associated with gout and negatively associated with
Parkinson’s syndrome. Although a few endogenous substrates of BCRP and PGP have been identified, a
systemic understanding of their physiological function and effect on the endogenous metabolome is still
lacking.
In the current studies, utilizing untargeted metabolomics, coupled with transcriptomic analysis, we sought
to understand the endogenous function of Bcrp and/Pgp transporters in rats, by comparing the plasma
and cerebrospinal fluid metabolome of wild-type and Bcrp-Pgp double knockout rats. Our findings
revealed several putative novel endogenous/dietary substrates of Bcrp and Pgp transporters and
established a novel understanding of the physiological function of these transporters. We also identified
the anesthetic/analgesic ketamine as a putative substrate of Bcrp and Pgp, and found that ketamine
pharmacokinetics (PK), as well as pharmacodynamics (PD), are affected by these efflux transporters.
Importantly, the Bcrp-Pgp inhibitor, elacridar, was found to alter the PD of ketamine, indicating that
ketamine might be prone toward drug-drug interactions (DDIs) associated with Bcrp-Pgp inhibitors.
Finally, utilizing a Bcrp dietary substrate, Pheophorbide A (PhA), we developed an in vivo assay for the
assessment of DDI due to inhibition of Bcrp at enterocytes. Our results demonstrated that PhA can be
potentially used to create a reliable, high-throughput and less expensive in vivo assay for determining
Bcrp-mediated DDIs.
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ABSTRACT
Breast Cancer Resistant Protein (BCRP) and P-glycoprotein (PGP) are
membrane-bound efflux transporters that transport multiple chemical classes of
compounds and act as barriers to tissue permeability, thereby regulating tissue exposure
of their substrates. The role of these transporters in therapeutic resistance of their
xenobiotic substrates due to their expression and efflux function at target organs/tissues,
especially in brain and intestine, is well established, which has fueled investigation
toward identification of their inhibitors. Multiple clinically used drugs and dietary
chemicals have been reported to inhibit these transporters and potentially increase the
exposure of concomitantly administered BCRP and/or PGP substrates, which might be
desirable (to increase efficacy of the substrate drug) as well as undesirable (as it can
affect the disposition of the substrate in tissues where it might cause toxicity). Therefore,
drug-drug and food-drug interactions with BCRP and PGP are a major concern in drug
development, as recognized by US Food and Drug Administration (FDA), European
Medicines Agency (EMA) and International Transporter Consortium (ITC).
BCRP and PGP transporters are also known to transport endogenous substrates
and have been associated with important physiological functions. This includes an
inflammatory bowel disease-like phenotype associated with a non-functional PGP
polymorphism (Ala893), while a loss of function mutation in BCRP (Q141K) is known to
be positively associated with gout and negatively associated with Parkinson’s syndrome.
Although a few endogenous substrates of BCRP and PGP have been identified, a
systemic understanding of their physiological function and effect on the endogenous
metabolome is still lacking.
In the current studies, utilizing untargeted metabolomics, coupled with
transcriptomic analysis, we sought to understand the endogenous function of Bcrp
and/Pgp transporters in rats, by comparing the plasma and cerebrospinal fluid
metabolome of wild-type and Bcrp-Pgp double knockout rats. Our findings revealed
several putative novel endogenous/dietary substrates of Bcrp and Pgp transporters and
established a novel understanding of the physiological function of these transporters. We
also identified the anesthetic/analgesic ketamine as a putative substrate of Bcrp and Pgp,
and found that ketamine pharmacokinetics (PK), as well as pharmacodynamics (PD), are
affected by these efflux transporters. Importantly, the Bcrp-Pgp inhibitor, elacridar, was
found to alter the PD of ketamine, indicating that ketamine might be prone toward drugdrug interactions (DDIs) associated with Bcrp-Pgp inhibitors. Finally, utilizing a Bcrp
dietary substrate, Pheophorbide A (PhA), we developed an in vivo assay for the
assessment of DDI due to inhibition of Bcrp at enterocytes. Our results demonstrated that
PhA can be potentially used to create a reliable, high-throughput and less expensive in
vivo assay for determining Bcrp-mediated DDIs.
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CHAPTER 1.

INTRODUCTION

Membrane Drug Transporters
Membrane drug transporters are protein molecules in the membranes of cells or
cellular organelles where they help in either uptake or efflux of their substrates into or out
of the cells, respectively. Transporters are well-known for regulating the disposition of
their xenobiotic substrates and a notable few, such as organic anion transporting
polypeptide 1B1 (OATP1B1) or solute carrier organic anion transporter 1B1
(SLCO1B1), organic cation transporter 2 (OCT2) or solute carrier family 22 member 2
(SLC22A2), organic anion transporters 1/3 (OAT1/3) or solute carrier family 22
members 6/8 (SLC22A6/8), breast cancer resistant protein (BCRP) or ATP-binding
cassette sub-family G member 2 (ABCG2), P-glycoprotein (PGP) or ATP-binding
cassette sub-family B member 1 (ABCB1) and multidrug and toxin extrusion protein
(MATE) or solute carrier family 47 members 1/2 (SLC47A1/2) are recognized by US
Food and Drug Administration (FDA) and European Medicines Agency (EMA) for their
impact on drug development [1, 2]. These transporters also function as an integral part of
the biological system, and are involved in maintaining metabolic homeostasis and
transporting essential or non-essential endogenous metabolites such as amino acids,
cofactors, proteins, lipids, secondary bile acids, purines, pyrimidines as well as versatile
metabolites contributed by environment, diet or the microbiome [3-7]. For example,
organic cation/carnitine transporter 2 (OCTN2) or solute carrier family 22 member 5
(SLC22A5) transports carnitine, an essential metabolite required for the uptake of longchain fatty acids in cells for fatty acid β-oxidation [8]. In addition, BCRP / ABCG2
transports riboflavin (vitamin B2) [9], from which flavin adenine dinucleotide (FAD) and
flavin adenine mononucleotide (FMN) are generated, that are important co-factors for
many enzymes [10]. Therefore, polymorphisms / mutations in the membrane transporters
are often associated with disease phenotypes such as hyperuricemia (in case of BCRP),
inflammatory bowel disease (in case of PGP), macular degeneration (in case of ABCA4)
or other metabolic abnormalities [11-13] [14] [15] [16].
Transporters can be passive, transporting substrates following the concentration
gradient, or active, transporting substrates against the concentration gradient [14, 17-19].
The active transporters can obtain their energy for working against the concentration
gradient from ATP hydrolysis (ATP-binding cassette transporters) or transporting one
metabolite/substrate in exchange of another substrate (antiporter) or along with another
substrate (symporter / cotransporter) [14, 18]. In addition, there are ion channels, that can
assume open and closed conformations and maintain an ion gradient across the cell
membrane, as well as the aquaporins or water transporters, that transport uncharged water
utilizing energy from the osmotic gradient [18, 19].
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Uptake transporters
The uptake transporters comprise of the solute carrier (SLC) superfamily.
Currently, there are 65 SLC genes, with almost 450 SLC transporters of varying
functions (http://slc.bioparadigms.org) and are divided into 4 main categories:
cotransporters (transport along with another substrate), exchangers (transport in exchange
of another substrate), facilitated transporters (transport along the concentration gradient)
and orphan transporters (function has not been determined yet) [14, 19]. Several
physiologically important transporters are uptake transporters, such as those transporting
choline, amino acid, fatty acid, serotonin, dopamine, glutamine, glucose, and ion
exchangers etc. [14, 19, 20]. Polymorphisms in these transporters are associated with
multiple disease conditions such as cardiovascular diseases, Crohn’s disease, posttraumatic stress, gout, etc. [12, 21-24]. As mentioned before, among the many SLC
transporters, OATP or SLCO transporters, the SLC22 group comprising of OCT and
OAT transporters and the SLC47 group comprising of MATE transporters are of
particular importance for their effect on xenobiotic disposition [1, 25]. The SLC group of
transporters also comprise of Reduced Folate Carrier (RFC) or SLC19A1, and ProtonCoupled Folate Transporter (PCFT) or SLC46A1, both of which transport folate and
antifolate chemotherapeutic drugs [26].
OATP uptake transporters. OATP or SLCO or SLC21 gene family transporters
are of great interest for their capacity to transport bile salts, steroids, organic anions and
several xenobiotics at the intestine (enterocytes) and liver (hepatocytes) [27, 28]. These
transporters also have important endogenous functions and altered expression of OATP
transporters has been noted in different cancerous tissues as well [29]. While most of the
OATP transporters have a direct ortholog in rodents, OATP1A1, OATP1B1 and
OATP1B3 are only found in humans [27]. OATP1B1 and OATP1B3 are liver-specific
transporters, while OATP1A2 has the highest expression in blood-brain barrier (BBB)
and is also expressed in intestine, and OATP2B1 is expressed ubiquitously in almost all
tissues [27, 29]. OATP transporters, especially OATP1B1 and OATP1B3, as well as
OATP1A2 and OATP2A1, have very wide substrate-recognition capacity, with a large
number of drugs / xenobiotics being their substrates as well as inhibitors [28, 30].
Significant polymorphism of OATP transporters and their impact on xenobiotic
metabolism and disposition in humans has been recognized by the International
Transporter Consortium (ITC) [13]. Due to their significant impact on xenobiotic
pharmacokinetics (PK) and a large amount of substrate and inhibitor overlap with other
transporters and drug metabolizing enzymes, OATP1B1 and OATP1B3 have also been
recognized by FDA as important to be considered during drug development, for the
assessment of drug-drug interactions (DDIs) when dosed concomitantly with an inhibitor
[1, 25]. Numerous publications have documented such interactions and guidelines, and
reports by the ITC are of great interest in this regard [25, 31].
Organic anion and cation transporters. SLC22 group of transporters are most
diverse in nature as they comprise of both organic cation (OCT) and organic anion (OAT)
transporters. Organic anion transporters comprise of OAT1-10 and the uric acid
transporter URAT1, encoded by the SLC22A12 gene. Although mainly present at kidney

2

proximal tubules, expression of these transporters has been found in other tissues as well
such as liver, placenta, olfactory epithelium, choroid plexus and blood-brain barrier [20].
These transporters play a significant role in transporting diverse endogenous metabolites
and xenobiotics of different chemical and therapeutic classes such as amino acids,
microbiome metabolites, fatty acids, angiotensin converting enzyme (ACE) inhibitors,
diuretics, antibiotics and statins [7, 20]. URAT1 is the major transporter of uric acid and
loss of function polymorphism in this transporter is associated with hyperuricemia and
gout [32, 33]. Both OAT1 and OAT3 are recognized by FDA as transporters important to
be considered during drug development for substrate or inhibitor liability for the new
chemical entity [1].
Organic cation transporters of the SLC22 family are the OCT1-3, OCTN1 and
OCTN2 transporters [5]. The SLC47 family or MATE transporters are also cation
transporters. While SLC22 are uptake transporters, MATE family transporters SLC47A1
and SLC47A2 are cation antiporter efflux pumps [5]. OCTs are mainly present in the
kidney and liver, but expression is also noted in lung, placenta and intestine [27].
Although these transporters are involved in the transport process of multiple important
endogenous metabolites including neurotransmitters, hormones and purine metabolites, a
knockout mouse model of these transporters does not present with apparent physiological
abnormalities, possibly due to a large amount of substrate overlap between the SLC
group of transporters [5]. Due to their significant effect on xenobiotic transport and a
diverse chemical class of drugs being their inhibitors, MATE1 and 2, as well as OCT2
are FDA-recommended important transporters to be considered for drug development
purposes [1, 25].
Efflux transporters
The efflux transporters comprise of the ATP-bound cassette (ABC) transporters
that transport their substrates against the concentration gradient by utilizing the energy
from ATP hydrolysis [34]. In the mammalian system, there are 49 ABC genes (with 21
pseudogenes) encoding 7 subfamilies of ABC transporters (A-G) [18]. Currently there are
35 mammalian ABC transporters with assigned functions as endogenous and/or
xenobiotic transporters [14, 34]. ABC transporters are also important for the microbial
system and are often associated with treatment resistance in antibacterial therapy [35, 36].
Bacterial ABC transporters display striking structural similarity with those in the
mammalian system, raising the possibility that they are important for host-microbiome
interactions [17, 35]. The major human ABC drug efflux transporters are ATP-binding
cassette subfamily B member 1 (ABCB1) or multidrug resistance protein 1 (MDR1) or Pglycoprotein (PGP), ATP-binding cassette subfamily C member 2 (ABCC2) or
multidrug-resistance associated protein 2 (MRP2), ATP-binding cassette subfamily C
member 4 (ABCC4) or multidrug-resistance associated protein 4 (MRP4) and ATPbinding cassette subfamily G member 2 (ABCG2) or Breast Cancer Resistance Protein
(BCRP) [14, 34].
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Structure of ABC transporters. The ABC superfamily of transporters have
transmembrane domains (TMDs) and nucleotide binding domains (NBDs). The NBDs
comprise of the well-conserved Walker A and Walker B motifs. The TMD is membranebound is usually more variable in nature and contains 6 membrane-spanning loops, while
the NBDs are more conserved and sit in the cytosol [14, 17, 18]. Most of the ABC
transporters contain two NBDs and two TMDs, hence termed as “full” transporters. But
ABCG and ABCD family transporters contain only one TMD and one NBD and are thus
termed “half-transporters” and require homodimerization (ABCG2) or heterodimerization
(ABCG5 and ABCG8) to become functionally active [14, 37].
Clinical significance of ABC transporters. The mammalian ABC transporters
are of immense physiological importance, known to transport diverse chemical classes of
compounds [38] and loss of function mutation in these transporters are associated with
several diseases [14, 18, 34]. For example, the ABCA group of transporters are wellknown cholesterol transporters, and a loss of function mutation is known to cause
defective cholesterol and phosphatidylcholine transport (Tangier disease) [39]. In
addition, ABCA3 is related to surfactant transport in the lung and is associated with
respiratory distress syndrome [40]; ABCA4 is a retina-specific transporter and loss of
function of this transporter is associated with early-onset macular degeneration and loss
of vision (Stargardt disease) [41]; and the ABCA7 transporter has been recently
associated with Alzheimer’s disease [42]. While ABCB1 or PGP is a multidrug
transporter, ABCB4 transports phosphatidylcholine [14] and ABCB11 or BSEP (bile salt
export pump) transports glycochenodeoxycholic acid, and loss of function of ABCB11 is
associated with intrahepatic cholestasis [43]. ABCC group of transporters are multidrug
efflux transporters as well and also transport important endogenous metabolites, such as
cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP),
uric acid and bilirubin [14]. A genome-wide association study of Kawasaki disease
patients has suggested a possible role of ABCC4 transporter in this disease [44].
Mutations in ABCC7 are known to be associated with cystic fibrosis disease [45]. ABCG
group of transporters are cholesterol transporters and loss of function mutation in ABCG5
or ABCG8 is associated with sitosterolemia [37].
ABC efflux transporters are present in different tissues and organelles, and their
effect on drug transport has been mostly studied at the epithelial or endothelial cells of
different tissues and blood vessels, bile canaliculi, kidney tubular cells, blood brain
barrier (BBB) and the enterocytes [14, 34, 38]. Efflux transporters, such as ABCB1 or
PGP, ABCG2 or BCRP, ABCC1-4 or MRP1-4 are well known for their effect on the
pharmacokinetics and/or pharmacodynamics and also toxicity and/or side effect of their
substrates [38, 46] [47]. A significant impact of Pgp transporter is observed in regulating
the brain permeability of its substrates and thereby reducing the toxicity due to unwanted
brain exposure of toxic chemicals, such as ivermectin, in mice [48]. Pgp present at the
BBB endothelial cells, effluxes its substrates and limits their permeability in brain.
Therefore, lack of Pgp function at the BBB often shows a dramatic increase in brain
exposure of its substrate drugs, e.g., digoxin and vinblastine [49, 50]. Also, of interest, it
has been previously noticed that Pgp knockout (Pgp KO) mice develop a pathological
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condition similar to inflammatory bowel disease (IBD) [51] and a polymorphism of
MDR1 or PGP has been recently associated with IBD in humans as well [16].
Endogenous substrates of ABC transporters. As briefly discussed before, the
ABC efflux transport system has important physiological functions and thus are often
associated with pathological conditions [35]. ABCA and ABCG class of transporters are
mainly cholesterol transporters [14, 18], with specialized function for ABCA4,
transporting N-retinylidene-phosphatidylethanolamine at the retina [52]. ABCG class of
transporters are reported to transport choline phospholipids and ABCG2 in this subfamily
is a multidrug transporter with important endogenous substrates such as uric acid [53,
54]. ABCB subfamily transporter ABCB1 or PGP has been studied extensively for its
effect on xenobiotic transport, treatment resistance and unwanted toxicity at the
distributing tissues [38, 46, 48-50, 55, 56], but also known to transport glucocorticoids
[57], endogenous opioids [58] etc. ABCB11 or Bile Salt Export Pump (BSEP) is an
important bile salt transporter [43]. ABCC subfamily transporters have great
physiological significance, transporting prostaglandins, leukotrienes, conjugated
bilirubin, cAMP, cGMP and uric acid among many important endogenous substrates [59,
60].
Efflux transport and xenobiotic substrates. The ABC efflux transporters are
well-known to transport a wide variety of xenobiotics as their substrates, such as
chemotherapeutics, immunosuppressants, antibacterial, antiviral, etc. [3, 6, 59].
Identification of several efflux transporters is related to their drug resistance in cancer
treatment, and their role is much appreciated now as transporters of relatively broad
chemical specificity [6, 38, 46, 61-63]. Certain structural or physicochemical features
have been identified to be preferred than others for substrate specificity, which are
thereby utilized to formulate a structure-property-based approach to identify substrates
and inhibitors of these transporters. For example, in case of PGP, pharmacophore and
machine-learning based approaches have identified newer inhibitors [64-66]. Some
structural features for PGP transporter substrates are aromatic hydrophobic rings,
uncharged or weak basic molecules, but often amphipathic in nature [38]. Similar to PGP,
another promiscuous transporter ABCG2 inhibitor/interaction identification has also been
approached via ligand-based computational methods and were further confirmed by cellbased studies, as well as cell-based screening methods utilizing diverse structural classes
of molecules [67, 68]. BCRP substrates tend to have aromatic hydrophobic rings, with a
large number of H-bond donors such as nitrogen residues and sometimes display weak
acidic properties [69]. Although PGP has been observed to have broad substrate
specificity [70], other transporters often display some structural preferences. For
example, the MRP group of transporters usually transport amphiphilic organic anions and
glutathione-conjugated cations [59]. Further information specifically about the BCRP and
PGP transporters have been detailed later in this Chapter.
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Drug-drug interactions and transporter/enzyme substrate overlap
Drug transporters are known to share common substrates and inhibitors with other
transporters as well as drug metabolizing enzymes. Many drugs such as rifampicin,
cyclosporin and tyrosine kinase inhibitors interact with multiple drug transport systems as
well as enzymes [71]. This may result in clinical pharmacokinetic drug-drug interactions
(DDIs) which can further lead to undesired over-exposure to a drug that is concomitantly
dosed with a medication which is an inhibitor of a transporter or enzyme system [72].
Besides inhibition of an enzyme by competitive or noncompetitive mechanisms,
transporters and enzymes may also be regulated by direct or indirect mechanisms. For
example, chemotherapeutic kinase class of drugs and protein-protein interactions affect
the expression of ABC drug transporters as well as organic cation transporters, leading to
possible DDIs [73-75]. Apart from interaction with a co-treatment, significant clinical
interactions have also been reported for dietary and natural compound transporter and/or
enzyme inhibitors such as St. John’s wort and grapefruit juice among several others [7679]. These interactions have often been identified and studied extensively, thereby
leading to distinct guidelines by the regulatory agencies [1, 80].
It is important to recognize that drug transporters and metabolizing enzymes are
the major clearance mechanism of a foreign chemical entity in our system. Therefore,
major drug metabolizing enzymes and transporters often co-exist in major barrier tissues,
such as intestinal epithelial cells, hepatocytes and kidney [81-83]. Drug metabolizing
enzymes are less frequent in the blood-brain barrier, kidney and lung, [84] where the
major clearance mechanism is mediated by the transporters. Hence, often, the substrate of
a metabolizing enzyme is also a substrate of the transport machinery, such as the statin
class of drugs which are substrates of multiple transporters as well as metabolizing
enzymes and prone to clinical drug-drug interactions [85]. Many drugs are also inhibitors
of multiple transporters, e.g., tyrosine kinase inhibitor lapatinib inhibits BCRP, PGP and
URAT1 [71], elacridar inhibits PGP, BCRP as well as OATPs [86, 87], etc. Therefore, a
complete understanding of determinants of drug pharmacokinetics is important, with the
identification of at least the major enzymes and transporters in different tissues of
interest.
Assays for identification of transporter substrates and inhibitors
In vitro assays. Identification and/or confirmation of substrates or inhibitors of
transporters are often performed in vitro and several assay systems have been developed
for such purposes. The White papers from ITC provide a great guideline on data analysis,
usefulness and advantages or disadvantages of these systems [88, 89]. The following four
types of in vitro transporter assays are usually widely used:
1. Membrane vesicles: An inside-out membrane vesicle system is used for the
identification of efflux transporter substrates, as well as inhibitors. In this case, an
analytical method capable of detecting low concentration of the metabolite is required, or
else, fluorescent or radioactive materials are used for these assays. Meaningful kinetic

6

properties of the transporter-substrate interaction are obtained from these assays. For
highly lipophilic and diffusible compounds, binding to the vesicles may lead to false
negative results [88].
2. Recombinant cell lines: Stable transfection of host mammalian cells with fulllength transporter cDNA is used for generation of different transporter cell lines. Human
embryonic kidney (HEK), canine kidney (MDCK), Chinese hamster ovary (CHO) and
porcine kidney (LLC-PK) cells are among the many cell lines that are used for transporter
substrate identification. MDCK and LLC-PK cells usually grow faster and form polarized
monolayer with tight junctions and are thereby very suitable for transwell permeability
studies and uptake / efflux assays for substrate or inhibitor identification. Changes in cell
viability in presence of a transporter inhibitor and a cytotoxic substrate (e.g.
mitoxantrone) can also be used for inhibitor identification. Although used as an indirect
proof of substrate, the inhibitory effect of a compound on transporter substrate
accumulation or transport is mainly a proof of interaction and should be used with
caution, since many transporter inhibitors were eventually not found to be substrates.
Moreover, presence of endogenous transporters should also be noted for such assays. In
addition, multiple cell culture variables need to be kept in mind when developing or
running the assays, such as culture time, passage number, media component (albumin
content) etc. [88]. Use of multiple transporter substrates or inhibitors as positive controls
are recommended by ITC and the regulatory agencies which also detail the methods for
data analysis [88, 89].
3. Bidirectional assays: Bidirectional assays utilizing recombinant cell lines
(LLC-PK, MDCK or Caco-2) is the recommended system by the regulatory agencies for
identification of transporter substrates and inhibitors [1, 88]. A transwell format is used
where cells are grown on a transwell insert, the substrate is added on either basolateral or
apical side of the chamber (donor compartment) with or without the inhibitor, and
concentration of the substrate transported to the other side of the chamber (receiver
compartment) is measured. Different analytical methods can be utilized to calculate the
final outcome to measure apparent permeability (Papp) values that can be utilized in vivo
in different PBPK models incorporating transporter kinetics. ITC provides a thorough
guideline for execution and data analysis of such assays [89, 90]. Presence of endogenous
transporters is a factor in this assay as well. Moreover, compounds with low permeability
might be difficult to study in this assay [88].
4. Hepatocytes: The hepatocyte culture system is used to study in vitro uptake,
efflux and metabolism of xenobiotics in the liver. Suspension-cultured and sandwichcultured hepatocyte systems exist, with a preference for the later, as it mimics closely the
complicated network in human liver and creates the biliary duct system in vitro in a 3D
cell culture model. This is a very complex system and use of specific inhibitors are
required to tease out the effect of each transporter or enzyme on the transport or
metabolism of the compound tested. But due to its closeness to the physiological
complexity, this method has a high translational relevance [88].
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Apart from ITC, the regulatory agencies also provide a detailed guideline on how
to use in vitro assays for identification of transporter substrate or inhibitors and their
utilization for identification of DDIs [1].
In vivo models. Transporter knockout models as well as inhibitor-based studies in
mice and rats have been utilized for substrate identification [48, 91, 92]. Studies with
inhibitors are required to confirm the findings in the knockout models to rule out the
effect of compensatory pathway effects. Although prototypical Bcrp and Pgp substrates
are known to have increased brain permeability in absence of the transporters at the
blood-brain barrier [50, 93, 94], caution must be taken to avoid misinterpretation of
results for high permeability drugs that may not show increased accumulation in brain in
a knockout model, but whose pharmacokinetics and pharmacodynamics are still affected
by the transporters [95-98]. Apart from the knockout models, noninvasive powerful
imaging techniques such as positron emission tomography (PET) and whole-body
autoradiography may also be used with carefully designed probes for identification of
transporter substrates and/or inhibitors, or even to understand the pharmacodynamics of a
drug [99, 100]. Another technique used is gamma-scintigraphy that utilizes gammaemitting isotopes such as 99mTc to assess drug disposition. However, these methods are
expensive and have their own practical limitations as well [25].
BCRP and PGP Efflux Transporters
BCRP or ABCG2 and PGP or ABCB1 are two major drug efflux transporters,
which are present at major drug absorption and/or elimination sites as intestine, liver,
kidney, blood brain barrier, and their major function is to reduce systemic exposure of
their substrates.
BCRP efflux transporter
Breast cancer resistant protein (BCRP) or ABC sub-family G member 2 (ABCG2)
is a half transporter, as it contains two subunits of one TMD and one NBD domain, that
requires homodimerization to become active [14]. BCRP is a 72 kDa protein with 665
amino acids and is highly conserved across the mammalian as well as vertebrate species,
suggestive of its conserved function across all species [101, 102]. Using BXP-34 and
BXP-21 antibodies, Maliepaard et al. were the first to provide an extensive report of
BCRP expression in normal human tissues [103], showing high expression in the
placental syncytiotrophoblast, the small intestinal epithelium, the canalicular membrane
in liver and in the duct and lobules of breast. Interestingly, it was found to have high
expression in vein endothelium but not in the arteries. Expression of BCRP was later
confirmed at choroid plexus and blood-brain barrier in the brain, kidney proximal tubules
and cardiomyocytes among several other tissues [102, 104]. Expression of BCRP has
been extensively studied in human intestine and found to have a high expression in the
duodenum with decreasing expression further down the gastrointestinal tract [105]. Other
important expression compartments of BCRP include the normal hematopoietic stem
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cells [106, 107] as well as cancer stem cells [108]. Although its expression is not required
for having stem cell-like properties, BCRP expression on the stem cells (side population
cells) help in their identification [108-110].
Clinical significance of BCRP. BCRP transporter polymorphisms Q141K and
V12M are well-characterized, with the loss of function polymorphism Q141K exhibiting
a high frequency of occurrence in the Asian population [111-113]. Several other
important polymorphisms, such as Q126X, in this transporter have also been noted [11,
114]. BCRP polymorphism has also been associated with pathological conditions such as
gout [24], apart from its effect on the oral bioavailability of its substrates such as
topotecan [115]. Of particular interest, Matsuo et al. showed a positive correlation of
BCRP polymorphism with gout, but negative correlation with Parkinson’s disease [116].
In addition, due to BCRP-mediated transport of drugs, it has been associated with several
treatment-resistant diseases, especially cancer [117, 118]. BCRP polymorphism has also
been associated with a Jr(a-) blood group phenotype in which the affected individuals
lack a Jr(a) antigen on their red blood cells, thereby making them prone to transfusion
reaction or hemolytic disease [119, 120].
Xenobiotic substrates or inhibitors of BCRP. A diverse group of compounds,
belonging to different chemical classes, such as anthracene drugs (mitoxantrone,
bisantrene), camptothecin (topotecan), nucleoside analogues (zidovudine), statins
(rosuvastatin), tyrosine kinase inhibitors (gefitinib, sorafenib), proton pump inhibitors
(pantoprazole) and fluoroquinolone antibiotics are substrates of BCRP transporters [6,
121, 122]. Apart from in vitro studies, the mouse Bcrp KO model has also been utilized
to determine substrates and inhibitors of Bcrp. Mouse Abcg2 or Bcrp has 81% protein
sequence similarity with human ABCG2 or BCRP [55], and mutation in the amino acid at
482 position affected substrate specificity in both species [123]. Therefore, substrate and
inhibitor profile of BCRP in humans could be compared to that in mice. Extensive
reviews articles have been published with a detailed list of substrates and inhibitors of
BCRP [6] [102] [121], with new molecules being added as well.
Endogenous substrates of BCRP. BCRP is also known to play an important role
in transporting endogenous and dietary substrates. Endogenous metabolites uric acid,
riboflavin, folic acid and protoporphyrin IX have been reported as substrates of BCRP
transporter [9] [54] [114] [124] [92]. BCRP is also associated with heme transport [109]
[125], though a direct evidence of heme transport by BCRP does not exist yet. In
addition, dietary chlorophyll catabolite Pheophorbide A was found to be a highly
selective BCRP substrate [92], and many gut microbiota-derived uremic toxins and
metabolites are known to interact with BCRP as well [126] [83]. BCRP has also been
shown to have a high affinity for sulfated metabolites, sulfated steroid conjugates as well
as phytoestrogen sulfates [127] [128] [129].
Physiological significance of BCRP. BCRP transporter expression at the
enterocytes and blood-brain barrier (BBB) as well as blood CSF barrier (BCSFB) has
been shown to limit oral bioavailability and brain permeability of its substrates. At the
bile canaliculi and kidney proximal tubules, BCRP increases the clearance of its
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substrates and is known to protect the fetus from undesired chemical exposure at the
placental barrier [6] [105, 130] [104]. While absence or inhibition of BCRP has been
shown to increase the brain penetration of its substrates [94] [131], previously published
reports also show that inhibition or absence of Bcrp at the choroid plexus (CP) epithelial
cells leads to reduced ventricular CSF concentration of Bcrp substrate topotecan in mice
[132] [133], whereas the brain concentration of topotecan still increases.
Immunohistochemical labeling of Bcrp using BXP-53 antibody demonstrated that
Bcrp is present on the apical membrane of choroid plexus epithelial cells, facing the CSF
[133]. This compartment-specific effect of Bcrp in the mouse brain can also be observed
for another Bcrp substrate/inhibitor, lapatinib. A tissue distribution study using 14Clabeled lapatinib exhibited higher lapatinib radioactivity in CSF compared to brain in rats
[134]. This highlights the physiological role of BCRP as an efflux transporter at BCSFB,
effluxing its substrates into CSF. This is further strengthened by the fact that high
concentration of uric acid (a BCRP substrate) in serum is negatively associated with
Parkinson’s disease, but positively associated with gout [116]. Results published by
Yasuda K et al. demonstrated that Bcrp is also present at the arachnoid barrier epithelial
cells, part of the BCSFB, both on the apical as well as basolateral side [135]. On the
apical side, it faces the blood and the normal function would be regulating blood-to-brain
permeability of its substrates, whereas at the basolateral side, it faces the CSF, and
therefore probably effluxes its substrates that are important for the metabolic content of
CSF (Figure 1-1).
BCRP-mediated transport / interaction with heme has been reported to provide
hypoxic cell survival [109, 125]. In addition, its presence on cancer stem cells [129]
might further explain the treatment resistance observed in cancer therapy. Apart from
cancer and hematopoietic stem cells, BCRP is also found to be expressed in cardiac stem
cells and cardiomyocytes and reported to be involved in ischemic cardiac diseases as well
[110, 136, 137].
Uric acid is a well-known BCRP substrate [114] and BCRP has been found to
play an important role in the extrarenal or intestinal secretion of uric acid [138]. Hosomi
et al. also reported that treatment with Bcrp inhibitor elacridar can reduce the intestinal
secretion of uric acid [138]. In this regard, it has recently been noted that intestinal
microbiota in gout patients is significantly different compared to the normal population
[139]. Gout patients related to BCRP polymorphism are known to secrete less uric acid in
the intestine [114]. While Guo et al. did not investigate the presence of BCRP
polymorphism in their studied gout patient population, it is important to understand the
effect of BCRP, if any, in this context.
While multiple studies have been performed to identify BCRP substrates and
inhibitors, including endogenous substrates, a systemic effort to understand the
physiological role of BCRP transporter and the consequences of its absence or inhibition
by different xenobiotic/dietary inhibitors is still lacking. Due to the effect of multiple
transporters on the endogenous metabolites, an investigation of a single metabolite or
known metabolic signatures, coupled to a single transporter perturbation system, may
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Figure 1-1. Effect of BCRP transporter on its substrate disposition at the Blood
Brain Barrier, Choroid Plexus and Arachnoid Barrier
Note: BBB: Blood Brain Barrier; CP: Choroid Plexus; AB: Arachnoid Barrier; CSF:
Cerebrospinal Fluid
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provide limiting and often misleading information. The recently developed remote
sensing and signaling hypothesis [20, 140-142] with regard to OAT transporters is of
particular note in this context. Therefore, a global or systemic approach needs to be
undertaken to unravel the mystery of physiological interactions and functions of BCRP
transporter.
Moreover, an understanding of the endogenous metabolites of BCRP might help
identify an endogenous biomarker of this transporter, which might provide further
information for identification of clinical DDIs, as well as identification of clinical
conditions involving change in expression of BCRP.
PGP efflux transporter
Compared to BCRP transport system, P-glycoprotein (PGP) or ATP-binding
cassette subfamily B member 1 (ABCB1) has been studied more extensively and its
clinical significance with respect to drug disposition is better understood [46]. ABCB1 is
a 170 kDa protein and a “full transporter” in that it contains 2 TMDs containing 12
membrane-spanning loops and 2 NBDs. [143]. Impact of PGP on the brain penetration of
its substrate drug was accidentally noted first with ivermectin, leading to a 100-fold
higher neurotoxicity in the Pgp KO mice [48]. Later the effect of PGP transport system
was investigated on the brain penetration of multiple xenobiotics such as digoxin,
cyclosporine, dexamethasone and tyrosine kinase inhibitors such as dasatinib and
ponatinib [50] [144] [143]. PGP is found to be expressed in several tissues and organs,
mainly providing protective function from exogenous toxins / chemicals [46] [70]. It has
high expression at the intestinal epithelial cells (reducing oral absorption of its
substrates), canalicular cells at the hepatocytes (increasing biliary excretion), kidney
(increasing urinary elimination) and placenta (protection of the fetus) among many other
tissues [56]. Expression of PGP in the human liver was reported to be lower than that in
enterocytes, and hepatocyte expression was found to have almost 50-fold inter-individual
variability [143, 145]. Recently pro-inflammatory Th17 cells in intestine were found to
express PGP and were refractory to glucocorticoid therapy [146], raising the possibility
that Pgp might be involved in maintaining normal colorectal physiology [15].
Clinical significance of Pgp. Multidrug resistance in cancer cells was identified
as early as 1986 by Shen et al. [63] which was later linked to PGP [147], and its
expression in normal human tissues was established as well [148]. Since then, multiple
studies have established the clinical importance of PGP in chemo-resistance, resistance to
anti-HIV therapy and its effect on xenobiotics of diverse chemical and therapeutic classes
[38] [149] [46] [3]. Pgp is expressed at the BBB and affects the brain permeability of its
substrates, thereby limiting efficacy or increasing toxicity risk in case of DDIs [150]
[151] [48]. Lack of Pgp function has also been noted to cause IBD-like conditions in
animal models [16], raising the concern that this transporter might have an important role
in the gastrointestinal tract [51]. A large number of single nucleotide polymorphism
(SNPs) in the coding region of PGP has been observed, leading to decreased mRNA or
sometimes protein expression of the transporter, but a significant impact on the drug
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pharmacokinetics or pharmacodynamics is yet to be established [70]. Moreover, in
several disease conditions, especially in central nervous system (CNS) diseases such as
epilepsy [152] [153] [154], expression of PGP can change, leading to a possible increase
in PGP substrate exposure in the CNS [155].
Xenobiotic substrates or inhibitors of PGP. Due to its effect on chemoresistance, and on the disposition of a large number of therapeutic class of compounds
such as antibiotics, immunosuppressants, anticancer and cardiovascular drugs etc. [156],
researchers have been looking for PGP inhibitors with higher specificity and clinical
usefulness [38]. At least 3 generations of PGP inhibitors exist based on their chemical
classification, specificity and toxicity properties and several comprehensive lists of
inhibitors have been published [157] [38]. While the first generation of inhibitors were
cytotoxic (verapamil) or nonspecific inhibitors of multiple transporters or enzymes
(pantoprazole), PSC833 or valspodar belong to the second generation, and the third
generation comprises of elacridar and similar drugs such as zosuquidar and tarquidar,
which have been developed to be used in the clinic [158].
Endogenous substrates of PGP. Although the effect of PGP on xenobiotic
substrates is well established, the endogenous function of this transporter is not well
understood. PGP has been reported to transport endogenous opioids such as adrenorphin,
endomorphin 1 and 2, neurokinin [58], glucocorticoids such as cortisol and aldosterone,
[159] [57] and possibly bilirubin [160]. In addition, using conjugated phosphocholines
and other short chain fatty acids, it was shown that PGP is a broad specificity lipid
translocase [161].
Physiological significance of PGP. The physiological significance of PGP
transporter is mainly assigned to its protective function at enterocytes and BBB, and its
importance as a broad specificity chemical transporter, with the possibility of lipid
translocation and of other known endogenous substrates [3, 70]. The absence of Pgp had
been reported to express an IBD like symptoms [16] along with a change in gut
microbiome [162] [51], and association with colorectal carcinoma and ulcerative colitis is
also suggested [163] [15]. Expression of Pgp on the glucocorticoid treatment-resistant
Th17 cells in intestine [146] also points towards the important role that Pgp might play in
regulating intestinal health or even on the microbiome homeostasis. Alteration in Pgp
expression at the BBB due to pathological conditions [153], effect of amyloid beta
protein on the expression of Pgp [164] at the BBB and the significant role of Pgp at the
BBB, suggest some important endogenous functions of this transporter. Understanding of
the endogenous function of PGP and the effect of its expression changes, especially at the
BBB, might be extremely helpful in avoiding serious DDIs. Identification of a possible
biomarker might also be helpful in assessing the functional level of the transporter in the
system.
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Substrate or inhibitor overlap of BCRP and PGP
Due to their broad substrate specificity, BCRP and PGP transporters show a
significant overlap in their substrate and/or inhibitors, with differences in affinities for
either transporters [102]. Several tyrosine kinase inhibitor class of drugs are
substrates/inhibitors of both the transporters [165] [166] [134], with many other
xenobiotic inhibitors, such as pantoprazole and elacridar displaying similar properties as
well [71]. This could be particularly useful for drug permeability in difficult-to-treat
tissues, such as brain tumor. It has often been found that both BCRP and PGP expression
plays an important role in controlling brain concentration of their substrates [167].
Therefore, dual substrates of Bcrp and Pgp transporters are well studied in literature due
to the dramatic effect on their brain permeability in absence of these transporters in
rodents. For example, a 25-fold increase in brain permeability of ponatinib, a tyrosine
kinase inhibitor, is observed in female mice in absence of Bcrp and Pgp [144]. In mice,
Pgp has a much higher expression at the blood-brain barrier than Bcrp [168], leading to
dramatic increase in the brain permeability of Pgp substrates. For example, a 35-fold
increase in brain permeability of digoxin is observed at 4 hours after its intravenous
injection in mice [50]. But in higher mammals, such as monkeys, dogs and humans,
BCRP and PGP are expressed in almost similar abundance [168, 169]. In dog brain
capillaries, BCRP expression has been reported to be remarkably higher than PGP [170],
whereas it was not detected at the choroid plexus. Therefore, the effect of BCRP could be
underestimated from preclinical study, than what would be observed in the clinic. On the
other hand, Uchida et al. reported a higher PGP than BCRP expression at the choroid
plexus in humans, but are almost the same in rats [171]. Moreover, Pgp expression at the
choroid plexus in mice has not been reported yet and is controversial in literature [133,
135, 172-174]. This limits the usefulness of knockout mouse models for observations
related to brain concentrations of BCRP and PGP substrates and specifically their effect
on the CSF concentration of their substrates.
Due to their affinity for compounds from similar Biopharmaceutical
Classification System (BCS) class and their significant expression at enterocytes, BCRP
and PGP are expected to have a significant impact on the oral absorption of their
substrates [1, 25, 175]. Moreover, often, the inhibitors may not achieve sufficiently high
systemic concentrations to display the systemic inhibition of these transporters [71].
Therefore, except for the loss of function polymorphism related cases, systemic inhibition
and related overexposure of BCRP and/or PGP substrates are not so frequent. Hence, the
meaningful clinical impact of these transporters is their effect on oral absorption. Still,
caution must be taken for compounds such as lapatinib, which has high hydrophobicity,
and therefore can have high tissue distribution and sufficient concentration to impart
systemic inhibition of the transporters [134].
Overall, BCRP and PGP transporter function causes a net decrease in
permeability, thereby reducing abundance or exposure of their substrates in plasma and
brain/CSF. Therefore, absence or inhibition of these transporters would lead to an
increase in permeability / abundance / exposure of their substrates in plasma as well as
brain/CSF (Figure 1-2, Figure 1-3).
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Figure 1-2. Effect of BCRP and PGP mediated efflux on brain/CSF and blood
concentration of its substrates
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Figure 1-3. Effect of inhibition or absence of BCRP and PGP on the Brain/CSF
and blood concentration of its substrates
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Guidance about drug-drug interaction and substrate and/or inhibitor identification
of BCRP and PGP
ITC and FDA have provided important guidelines for identification of substrates
and inhibitors of BCRP and PGP transporters [25] [1, 80]. These two transporters are
expected to have significant clinical drug-drug interaction (DDI) liabilities for orally
administered drugs, due to their impact on oral absorption of their substrates [176] [177].
An efflux ratio of ≥2 is recommended for a compound to be considered as a substrate,
which should also be inhibitable by a known inhibitor at a concentration 10 times its
coefficient of inhibition (Ki). For the selected highest clinical doses, dose/250 ml (Igut)
should be 10-fold or greater than IC50 (concentration for 50% inhibition) (Igut/IC50 ≥
10) for considering an oral DDI, and maximum plasma concentration (Cmax) should be
greater than 1-fold than IC50 for systemic interaction (Cmax/IC50≥1.1) [71] [1]. In
addition, concomitant medications that could be potential inhibitor(s) of BCRP/PGP need
to be considered for making a clinically meaningful decision. For FDA recommended
clinical substrate sulfasalazine, an AUC ratio change, in presence of the inhibitor, of ≥
1.5-fold should be considered for DDI studies. Drug distribution into tissues where it can
have potential safety concerns should also be considered for DDI studies.
Metabolomics
Metabolomics is the understanding of endogenous metabolites in a normal or
disease condition, or after a drug treatment, or exposure to any chemical entities [178].
Metabolites are the terminal products of the principle of “Central Dogma” and could be
useful by themselves, or in conjunction with proteomic and/or transcriptomic data for
better understanding of biological processes and could be more closely related to a
phenotype [179] [180]. While a focused study of metabolomic fingerprinting has been in
use for a long time [181], metabolomics as a means of fingerprinting, phenotyping and
understanding physiological functions and altered endogenous metabolites or biomarkers,
has been recently employed as a remarkable tool [182] [183] [184]. Recently,
metabolomics has been proposed to be used in “precision medicine” as a tool capable of
defining the population variability in response to therapy [185]. Development of
analytical tools such as LC-MS/MS, GC-MS and NMR or LC-NMR has created the
opportunity for scientists to specifically detect multiple metabolites on a high throughput
scale [186]. Different databases are used for analyzing the data obtained and develop
meaningful pathway analysis of identified metabolites such as Kyoto Encyclopedia of
Genes and Genomes (KEGG) and The Human Metabolome Database (HMDB) [187].
HMDB maintains a comprehensive list of metabolites identified in the human body,
which have been detected and reported in various studies (http://www.hmdb.ca).
Currently, there are 114,064 metabolite entries in this database, but only 18,602
metabolites have been detected and quantified, and 4,158 metabolites have only been
detected. Majority of these metabolites are found in blood (18,669), followed by feces
(6738), urine (2407), saliva (1233) and few in CSF (450) (http://www.hmdb.ca/statistics).
Of note, metabolites identified from animal studies may not often be found on either
HMDB or KEGG databases.
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The metabolome comprises of all endogenous metabolites, those derived from
microbiome and metabolites which are dietary or due to any medication. Study of
metabolomics includes understanding changes in basal metabolites in response to
changes in the environment, which includes disease, treatment, exercise and even
alteration in the gut microbiome in response to the altered environment [180, 185].
Untargeted and targeted metabolomics
Study of metabolomics can be untargeted or targeted [179]. Untargeted
metabolomics is, in theory, the study of the entire metabolome or metabolites identifiable
within the limits of the protocol employed. Whereas it can be useful for novel
understanding and identification of unknown pathways, or in cases lacking prior
knowledge of the possible outcome, untargeted metabolomics generates a huge raw
dataset that is difficult to analyze, hard to interpret and usually needs complex analytical
procedures to render the results to a meaningful manageable dataset. Untargeted
metabolomics is also not quantitative in nature.
In contrast, targeted metabolomics is more focused and may be semi-quantitative
or quantitative depending on the project goals. Because it is more focused, targeted
metabolomics involves determination of predefined metabolite changes or metabolic
pathway changes and is easier to analyze and interpret. However, targeted metabolomics
is limited by the amount of information that can be obtained, an example of which is the
identification of dietary phytoestrogen glucuronide metabolites as MRP3 substrate [188].
Analysis of untargeted metabolomics
As discussed before, untargeted metabolomics requires extensive protocol
development for the analytical procedure as well as identification of the metabolite signal
with specificity and confidence [179]. For example, Metabolon®, a company that
performs metabolomic analysis for clients, maintains a library of carefully detected and
identified metabolites by UPLC-MS, GC-MS based methods, with their spectral
information, retention index(RI) and molecular weight/charge (M/Z) values for massspectrometry identified peaks [186].
For analysis of untargeted metabolomics data, a complex multivariate statistical
approach similar to the analysis of genomic data is employed. Many online available
tools such as MetaboAnalyst can be used for analysis [189]. Other methods such as
metaXCMS [190], metal-server [191], InCroMap, MetacoreTM, 3Omics etc. also exist
among other platforms [192].
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Integration of untargeted metabolomics and transcriptomics
Integration of metabolomics with transcriptomic or gene expression change data
can be a very useful method for complete understanding of perturbed or altered biological
pathways [193]. Although some research articles using this approach have been
published, integration of two very different datasets is quite complicated, and complex
statistical approaches along with a carefully designed study is required for proper
integration [194]. One major complexity is that change in one metabolite may be
regulated by multiple genes, thereby rendering a simple association analysis useless.
However, despite the complexity, integration of these two datasets is often attempted in
literature [178] [195] [196].
Use of metabolomics to understand endogenous function of transporters
The physiological importance of drug transporters and their impact on the
endogenous metabolome can be investigated using metabolomic analysis. Both targeted
and untargeted metabolomic approaches have been reported, such as the use of
untargeted metabolomics for identification of endogenous substrates or metabolites
associated with OAT3 and OAT1 transporters in mice and targeted metabolomics to
understand the effect of rosiglitazone treatment on the lipid metabolome [20, 140-142,
197].
Analysis of the metabolome may also lead to the identification of biomarkers or
novel substrates of drug transporters, as shown by the identification of putative biomarker
for OATP1B1 using metabolomics and genome-wide association study (GWAS)
database [198].
The Metabolomic-GWAS server (http://metabolomics.helmholtzmuenchen.de/gwas/) needs a special mention in this regard, which comprises data from
mostly two clinical GWAS-metabolomic analysis datasets [199, 200], that is extremely
useful for identification of gene-metabolite association in humans.
Study Purpose and Specific Aims
BCRP and/or PGP transporters are known to transport xenobiotics as well as
endogenous substrates. Lack of function polymorphisms of these transporters are also
known to impact the disposition of their substrates in humans, as well as associated with
pathological abnormalities. Although efforts are being taken to develop inhibitors of
these transporters to overcome therapeutic resistance, studies are lacking towards a
systemic understanding of the biological/endogenous role of these transporters. An
understanding of the endogenous role of these transporters would be extremely helpful
for identification of the effect of long-term inhibition of these transporters on the
biological pathways. Therefore, the purpose of the current study was to elucidate the
effect of Bcrp and/or Pgp transporters on the systemic metabolome and their
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physiological function in rats, towards developing a novel understanding of the effect of
Bcrp and/or Pgp transporters on their endogenous, xenobiotic and dietary substrates.
Specific aim 1
The first aim of the current studies was to determine the role of Bcrp and Pgp
efflux drug transporters on the systemic metabolome in rats. We hypothesized that
untargeted metabolomics combined with transcriptomic analysis can help understand the
endogenous function of these transporters.
Specific aim 2
The second aim of the current studies was to understand the effect of Bcrp and
Pgp on ketamine, used as the animal anesthetic and identified as a putative dual substrate
of these transporters in Aim 1 analysis. We hypothesized that Bcrp and/or Pgp can affect
the pharmacokinetics (PK) and pharmacodynamics (PD) of ketamine in mice.
Specific aim 3
The third aim of the current studies was to utilize pheophorbide A (PhA), a
dietary substrate of Bcrp, also identified in Aim 1 analysis, as an in vivo marker of Bcrp
function. We hypothesized that PhA can be utilized for identification of oral drug-drug
interactions due to Bcrp inhibition in mice.
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CHAPTER 2.

ELUCIDATION OF ENDOGENOUS FUNCTION OF BCRP AND
PGP DRUG TRANSPORTERS
Introduction

Drug transporters play an important physiological role by regulating the
disposition of important endogenous metabolites. Efflux transporter multi-drug resistant
protein 4 (Mrp4; Abcc4) is known to transport Prostaglandin E2 [60] and cAMP [201],
while uptake transporters such as organic cation transporter (Octn2; Slc22a5) transports
carnitine [202] and dopamine [203] and organic anion transporters (Oats) are known to
transport uremic toxins [142]. P-glycoprotein (Pgp; Abcb1) and breast cancer resistant
protein (Bcrp; Abcg2) are multi-drug efflux transporters that are ubiquitously present in
different tissues and cell types in human and other mammals [46, 104]. The major
function of Bcrp and Pgp is to control absorption of their substrates into blood from
intestine, or increase their clearance at liver, kidney and other tissues, thereby regulating
tissue exposure of their substrates. Thus, absence or inhibition of these transporters may
lead to accumulation of their substrates, leading to toxicity or altered efficacy of their
substrate drugs. These properties make Bcrp and Pgp among the most important FDAregulated efflux transporters for drug-approval processes [31].
Bcrp and Pgp are broad chemical specificity efflux transporters, with a substantial
overlap in their substrates and inhibitors [102, 204] and a similar tissue distribution [205].
In addition, these transporters have been associated with the transport of important
endogenous metabolites. For example, Bcrp is known to transport riboflavin (Vitamin
B2) [9], uric acid [54] and folic acid [124], while Pgp-mediated transport has been
reported for cortisol, aldosterone [57], phospholipids [161], bilirubin [160] and
endogenous opioid peptides [58]. Both Bcrp and Pgp are well-conserved in the
eukaryotic system and alteration in expression or association of these transporters has
been reported in different disease conditions [54, 150, 173, 206, 207], implying their
important physiological function. In addition, we have previously reported that apart
from its expression on the apical surface of choroid plexus (CP) in mice [208], Bcrp is
present on both apical and basolateral side at the arachnoid barrier (AB) epithelial cells,
thus facing both blood and CSF [135]. Thus, role of Bcrp in CSF disposition of its
substrates is complicated by the two opposing factors: (i) Bcrp reduces permeability of its
substrates at BBB to brain and thus eventually in CSF and (ii) Bcrp increases efflux of its
substrates from BCSFB into CSF. It also raises the possibility that Bcrp might have some
important endogenous function at the BCSFB.
Metabolomic analysis is widely utilized to understand altered biological function
in disease states [209], identification of biomarkers for disease [210] and drug treatment,
[211] as well as for elucidation of endogenous functions or biomarkers for enzymes and
transporters [198]. While untargeted metabolomics can lead to a broad systemic
understanding, targeted metabolomics can answer questions related to specific
metabolites in certain biological pathways [141, 179, 212]. Recently, untargeted
metabolomics has been effectively utilized to identify endogenous substrates of OATP
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and OAT transporters [140, 142, 198]. An understanding of the transporter effect on
metabolome can help elucidate pharmacometabolomics of drugs (that are transporter
substrates or inhibitors), which might be useful to analyze pharmacokinetic variabilities,
pharmacokinetic-pharmacodynamic relationships and toxicities or side effects associated
with the drug treatment [213, 214]. Several marketed drugs are known inhibitors of Bcrp
and Pgp transporters, of which many are used for chronic therapy. Thus, a systems level
understanding of the metabolomic impact and altered biological function thereof, due to
lack of function of Bcrp and Pgp transporters, can lead to better understanding of the
desired/ undesired effects of such therapy.
Therefore, to understand the effect of Bcrp/Abcg2 and Pgp/Abcb1a absence on
the systemic metabolome, we performed an untargeted metabolomics study of plasma
and CSF, as well as tissue transcriptomics of kidney, liver and brain (frontal cortex) from
Bcrp-Pgp double knockout (dKO) and wild type (WT) rats. We chose to compare WT vs
dKO male rat CSF and plasma because (a) BCRP shows significant sexual dimorphism
(Male >Female) in many tissues [215], hence male dKO would be expected to show the
largest difference in substrate concentration; (b) CSF volume would be significantly
higher in rats vs. mice; (c) dKO animals show a significantly higher concentration of dual
Pgp/Bcrp substrates compared to single Pgp or Bcrp KO animals [94]; and (d) the
CSF/brain concentration of Pgp or Bcrp KO mice is routinely different from WT while
the plasma concentration does not always vary [144] hence sampling only the plasma
would miss identifying some Pgp or Bcrp substrates.
Our results demonstrate a significant effect of Bcrp and Pgp transporters on
plasma as well as CSF metabolome of rats, including a distinct impact in plasma vs. CSF
compartment metabolomes. Utilizing the transcriptomic analysis and biological pathway
information, our results also indicated important biological functions of Bcrp and Pgp
efflux transporters. We also utilized an in silico Bcrp and Pgp-interaction prediction
model to further identify metabolites that could be putative substrates of Bcrp and/or Pgp.
To our knowledge, this is the first effort for complete systemic understanding of the
endogenous biological function of efflux transporters.
Materials and Methods
Chemicals and reagents
Ketamine (JHP Pharmaceuticals, Rochester, MI, USA), Xylazine (LLOYD
Laboratories, Shenandoah, Iowa, USA), scalp vein set (27G X ¾” T.W.) for CSF
collection (Exelint International,Co., LA, CA, USA), RNAlaterTM, TrizolTM and
Affymetrix Rat 2.0 St Array (ThermoFisher Scientific, Little Rock, AR, USA) were
purchased and used for the study.
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Animal experiments and sample collection
24 male wild-type (WT) and Bcrp – Pgp double knockout (dKO) Sprague-Dawley
rats (n=12 each group), 10 weeks of age, obtained from SAGE Laboratories (Saint Louis,
MO, USA), were used for the study. All animals were provided water and food ad
libitum. All experimental procedures were approved by the Institutional Animal Care and
Use Committee at St. Jude Children’s Research Hospital.
Rats were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10
mg/kg) and fixed on a stereotaxic apparatus. CSF was collected via the cisterna magna
using a scalp vein set and a 100 µL Hamilton syringe (Reno, Nevada, USA). CSF was
immediately kept on dry ice, and later stored at -80°C. Immediately after CSF collection,
blood was collected by cardiac puncture in EDTA-coated tubes, centrifuged at 5000g for
5 minutes at 4°C, and plasma collected and stored at -80°C. Kidney, liver and brain
frontal cortex were also isolated from each rat. The liver was frozen at -80°C and brain
frontal cortex and kidney were kept in RNAlaterTM following the manufacturer’s
instructions.
CSF and plasma samples were sent to Metabolon® for untargeted metabolomic
analysis, and kidney, liver and brain frontal cortex tissues were utilized for
transcriptomics analysis. A brief outline of the study design is illustrated in Figure 2-1.
Metabolomic analysis
Untargeted metabolomics of CSF and plasma samples from WT and dKO rats
(n=8 each genotype) was performed by UPLC-MS/MS and GC-MS based methods at
Metabolon® (Durham, NC, USA) [186]. Metabolon® maintains a metabolite library
consisting of retention index (RI), mass/charge (m/z) and chromatographic data of
authenticated standard metabolites including the MS/MS spectral information. Named
metabolites in the sample were identified by comparing the mass (± 0.005 amu), RI and
spectral data of the sample peaks with the library standards, the area under the peak
quantified, median normalized and then compared between the WT and dKO groups
using the two-sample t-test with Welch’s correction. An estimate of false discovery rate
(q-value) was also calculated because of multiple comparisons and q < 0.1 was
considered to have higher confidence in the data. Significant metabolites were identified
based on p< 0.05 and highlighted dark red for increase or dark green for decrease in CSF
of dKO compared to WT rats. Trending significant is considered when 0.1>p>0.05 and
highlighted light red for increase or light green for decrease in CSF and plasma of dKO
compared to WT rats. Principal component analysis was used to identify the data pattern
[216] in the samples (WT vs dKO plasma and WT vs dKO CSF). Results were further
analyzed by Random Forest Analysis to identify important metabolic features that
contribute the most towards the group separation. The final output of fold change and
associated p and q values were log2-transformed and volcano plots created on Tibco®
Spotfire® 7.5 for better visualization and identification of the significant metabolites.
Based on the hierarchical clustering analysis (heatmap) by Metabolon ®, three CSF
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Figure 2-1.

Outline of the study design
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samples were assumed to be contaminated with plasma and this information was used to
calculate ‘no contamination’ fold change and p-values for the CSF samples, and is listed
along with the uncorrected result for all CSF metabolite results generated by
Metabolon®. The non-normalized raw data from Metabolon® was used to calculate the
ratio of the signal intensity of metabolites that were detected both in CSF and plasma
(CSF/plasma ratio). CSF/plasma ratio of the metabolites were analyzed by two sample ttest considering unequal variance to identify metabolites that have significant alterations
in CSF abundance in the dKO rats compared to WT rats. Fold change of (CSF/plasma)
_dKO/ (CSF/plasma) _WT were log2-transformed and plotted against log2 (t values) on
Tibco® Spotfire® 7.5 for further identification and better visualization of metabolites
with significantly altered CSF abundance in the dKO rats.
Metabolomic analysis using MetaboAnalyst 3.0
Raw metabolite intensity data from Metabolon® was further analyzed separately
using the MetaboAnalyst software. Briefly, raw data was first screened for missing values
and any metabolite with more than 50% missing values was omitted from further
analysis. Due to a low number of features (<2000), the data filtration step was skipped.
Data was further median-normalized and log-transformed to obtain a Gaussian data
distribution for further statistical analysis. Significant metabolites were identified based
on ≥1.5- fold increase or decrease in median intensity in dKO compared to WT CSF or
plasma, and a p-value less than 0.05. Partial least square discriminant analysis and
hierarchical clustering analysis was performed to assess the group separation (WT vs.
dKO). The list of significant metabolites was compared with the Metabolon® data to
assess the reproducibility of the significant features.
RNA extraction and microarray analysis
Brain, kidney and liver tissues were weighed, diluted 10 times with TriazolTM,
homogenized and RNA isolated according to the manufacturer’s instructions. RNA
samples were analyzed for quality and integrity on the Agilent 2100 Bioanalyzer and the
concentration of RNA was determined using NanoDropTM 8000 spectrophotometer. A
hundred nanograms (100 ng) of total RNA was processed for use on the microarray using
the Ambion WT kit and the Affymetrix Terminal labeling kit according to the
manufacturer’s instructions. The resultant single-stranded cDNA was labeled, fragmented
and then hybridized to the Rat Gene 2.0 ST array for sixteen hours at 45 at 60 rpm. The
arrays were then washed, stained, and scanned using the Affymetrix Model 450 Fluidics
Station and Affymetrix Model 3000 7G scanner using the manufacturer's recommended
protocols.
Affymetrix Rat 2.0 ST array was used to perform the gene expression level
analysis using Affymetrix Expression Console software and results saved as RMA
(Robust Multiarray Averaging) level signal. The RMA signal file was uploaded into
Nexus expression 3.0 software (BioDiscovery Inc., El Segundo, CA, USA) along with
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the biological pathway information for the Affymetrix Rat Gene 2.0 ST Array, pooled
based on intensity, corrected for multiple test comparisons at q < 0.05 and fold change
≥1.2, to identify the significantly altered genes and biological pathways.
In silico prediction of BCRP and/or PGP putative substrates or inhibitors
Metabolites identified by the Metabolon® as significant (p< 0.05) or trending
significant (0.05<p< 0.1) were analyzed for their interaction with BCRP and/or PGP by a
predictive Bayesian Machine learning model implemented in Assay Central at
Collaborations Pharmaceuticals according to the previously published methods [217,
218]. Models were generated for human PGP using 1217 molecules and human BCRP
with 392 molecules. A five-fold cross-validation was performed to assess the receiver
operator characteristic (ROC). The metabolites were then scored with these models to
output a score. Further, physicochemical descriptors, e.g. AlogP, molecular polar surface
area, hydrogen bond acceptor and donor counts, molecular weight, for the metabolites
were obtained from the public database. Regression analysis employing standard least
square method was used to predict observed fold changes (dKO/WT) in the plasma and
CSF for each metabolite using the molecular descriptors, along with the ABCG2 or PGP
Bayesian model score to determine a structure-property relationship and understand if the
metabolites detected in CSF and plasma have any predictive property of BCRP and / or
PGP substrate.
Results
Bcrp and Pgp gene deletion in rats results in altered metabolome of CSF and plasma
The following four sections describe the overall findings of the metabolomic
analysis:
1. Metabolomics analysis identified differentially expressed metabolites between
WT and dKO rats, in both CSF and plasma. To identify the effect of Bcrp and Pgp gene
deletion on metabolite expression, we performed untargeted metabolomics analysis in
CSF and plasma of WT and Bcrp-Pgp dKO rats. A total of 564 named metabolites were
identified in both WT and dKO rats, with 306 metabolites uniquely identified in plasma,
25 metabolites identified only in CSF and 233 metabolites identified in both CSF and
plasma (Figure 2-2A). Data analysis for significant metabolite changes was performed
independently at Metabolon® and in-house using the MetaboAnalyst software 3.0.
Principal component analysis (PCA) (Figure 2-3A and B) and Partial Least Square
Discriminant Analysis (PLS-DA) (Figure 2-2B and C) identified distinctly different
patterns for the metabolites expressed by WT and dKO rats in both CSF and plasma. In
addition, hierarchical clustering analysis performed at Metabolon® (Figure 2-3C and D),
and on MetaboAnalyst (Figure 2-2D and E) demonstrated that majority of the samples
clustered within their own group (WT or dKO) in both CSF and plasma.
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Figure 2-2. Metabolites in CSF and plasma are differentially expressed between
WT and Bcrp-Pgp dKO rats (MetaboAnalyst)
Notes: Venn-diagram showing number distribution of detected named metabolites in CSF
and plasma samples (A). PLS-DA analysis 2D-scores plot performed on MetaboAnalyst
3.0, showing clear group separation between WT and dKO in CSF (B) and plasma (C).
Hierarchical clustering of the normalized metabolomic data clusters each of WT and dKO
groups together based on their metabolite features in CSF (D) and plasma (E).
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Figure 2-3. Metabolites in CSF and plasma are differentially expressed between
WT and Bcrp-Pgp dKO rats (Metabolon®)
Notes: Principal Component Analysis of median normalized named metabolites in CSF
(A) and plasma (B) identified significant pattern separation between WT and dKO rats.
Hierarchical clustering analysis of the fold change (dKO/WT) data in CSF (C) and
plasma (D) showed overall separation between WT and dKO rats.
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2. Significantly altered metabolites in CSF and plasma of dKO rats (compared to
WT) displayed unique signatures. A total of 169 metabolites were found to be
significantly altered together in the CSF and plasma of dKO rats compared to WT rats.
Of these, 79 metabolites were significantly altered only in the plasma, 71 only in the CSF
and 19 metabolites were altered in both CSF and plasma of dKO rats, compared to WT
rats (Figure 2-4A). The features of the metabolites altered in CSF and plasma were found
to be strikingly different. While majority of the metabolites altered in CSF were amino
acid-related metabolites (57%) (Figure 2-4B), lipids comprised the major metabolites
(49%) significantly altered in the plasma of dKO rats, compared to WT rats (Figure
2-4C).
Volcano plots (log10(q) vs log2(fold change)) of the metabolome data revealed
those metabolites that were significantly increased vs. decreased (Figure 2-5 and
Figure 2-6). In addition, we found that most of the metabolites in CSF were increased in
dKO rats, compared to WT (Figure 2-5), while an equal number of metabolites were
increased as were decreased in the dKO plasma (Figure 2-6). The metabolites with the
highest fold-change increases in dKO rats were O-methyl catechol sulfate in CSF (5.5fold) and 4-hydroxychlorothalonil (3.6-fold) in plasma. Only one metabolite, indolin-2one, was found to be significantly decreased (0.29-fold) in the CSF of dKO rats while
many lipid metabolites were significantly decreased in dKO plasma.
Random Forest Analysis (RFA) was performed to identify the metabolites with
the greatest effect on group separation (WT and dKO) in CSF and plasma. RFA
identified group separation with 100% prediction accuracy and results were plotted based
on effect of each metabolite on mean decrease accuracy, displaying 30 metabolites with
increasing order of their importance to group separation from bottom to top (Figure 2-7
and Figure 2-8). Among the metabolites with a significant effect on group separation,
RFA identified known Bcrp substrates riboflavin and urate in the CSF metabolome and
riboflavin and pheophorbide A in the plasma metabolome. RFA also confirmed our
previous results that CSF and plasma maintain unique metabolomic signatures with
significant metabolites being related to amino acids in the CSF and lipids in the plasma.
Analysis of the data with MetaboAnalyst using a more stringent data filtering
protocol identified 29 metabolites altered significantly in the CSF (Figure 2-9) and 47
metabolites in the plasma (fold change ≥ 1.5) (Figure 2-10) of dKO rats compared to WT
rats, with metabolites listed in increasing order of significance from top to bottom. A list
of metabolites which were significantly altered in CSF (Supplement_Chapter
2_Metabolites.Table S1A) and plasma (Supplement_Chapter 2_Metabolites Table
S1B) of dKO vs WT rats when analyzed by both Metabolon® and MetaboAnalyst is
provided, identifying a common list of altered metabolites, thereby incorporating
robustness in our data analysis.
As expected, known endogenous and dietary substrates of Bcrp were increased in
both CSF and plasma of dKO rats, compared to WT rats (Figure 2-11). While riboflavin,
a known Bcrp substrate, was found to be increased in both CSF and plasma of dKO rats,
urate was found to be significantly higher in abundance only in the CSF of dKO rats.
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Figure 2-4. Significantly altered metabolites in CSF and plasma of dKO rats
(compared to WT) display unique class signatures
Notes: Venn-diagram showing distribution of significant (p< 0.05) metabolites in CSF
and plasma of dKO vs. WT rats (A). Pi-chart showing distribution of percentage of
significant (p<0.05) metabolites in different metabolite classes as designated by the
colors in CSF (B) and plasma (C) of dKO vs. WT rats.
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Figure 2-5. Significantly altered metabolites in CSF of dKO rats (compared to
WT) display unique class signatures: Volcano plot in CSF
Notes: Volcano plot of CSF metabolites identified by pathway information (color of
markers) and their significance (p-value) (size of marker). Data is plotted as log2
(dKO/WT metabolite raw signal intensity) on X-axis vs. negative log (Q-value of
metabolite comparison dKO vs WT) on Y-axis. Horizontal purple and red lines designate
p < 0.05 and q < 0.05 respectively. Significant metabolites (p< 0.05) are identified above
the purple line. Similarly metabolites with 1.5-fold increase or decrease are identified
with vertical red and green lines respectively. Metabolites on the right side of red line or
on the left side of green line and above the horizontal purple line are significantly
increased (>1.5 fold) or decreased (<1.5 fold) in CSF.
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Figure 2-6. Significantly altered metabolites in plasma of dKO rats (compared to
WT) display unique class signatures: Volcano plot in plasma
Notes: Volcano plot of plasma metabolites identified by pathway information (color of
markers) and their significance (p-value) (size of marker). Data is plotted as log2
(dKO/WT metabolite raw signal intensity) on X-axis vs. negative log (Q-value of
metabolite comparison dKO vs WT) on Y-axis. Horizontal purple and red lines designate
p < 0.05 and q < 0.05 respectively. Significant metabolites (p< 0.05) are identified above
the purple line. Similarly, metabolites with 1.5-fold increase or decrease are identified
with vertical red and green lines respectively. Metabolites on the right side of red line or
on the left side of green line and above the horizontal purple line are significantly
increased (>1.5 fold) or decreased (<1.5 fold) in plasma.
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Figure 2-7. Random forest analysis identifies metabolites that significantly
distinguishes between WT and dKO group of rats in CSF
Notes: Random forest analysis (RFA) was used to calculate group separation and identify
metabolites with highest importance for group separation. RFA identified two groups
(WT and dKO) with 100% accuracy in CSF. Metabolites were plotted against their Mean
Decrease in Accuracy, calculated by RFA. Metabolites have higher importance on group
separation as we move up along the Y-axis and they are also color coded to identify
which pathway the metabolites belong to.
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Figure 2-8. Random forest analysis identifies metabolites that significantly
distinguishes between WT and dKO group of rats in plasma
Notes: Random forest analysis (RFA) was used to calculate group separation and identify
metabolites with highest importance for group separation. RFA identified two groups
(WT and dKO) with 100% accuracy in plasma. Metabolites were plotted against their
Mean Decrease in Accuracy, calculated by RFA. Metabolites have higher importance on
group separation as we move up along the Y-axis and they are also color coded to
identify which pathway the metabolites belong to.

34

Figure 2-9. Independent analysis of metabolome data with MetaboAnalyst
identifies similar metabolites, along with known Bcrp substrates in CSF
Note: Raw data from Metabolon were reanalyzed using MetaboAnalyst 3.0. Significant
metabolites were identified based on p < 0.05 and fold change > 1.5. Fold change of all
significant metabolites were plotted against their p-value. The red arrow indicates known
substrates of Bcrp and/or Pgp.
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Figure 2-10. Independent analysis of metabolome data with MetaboAnalyst
identifies similar metabolites, along with known Bcrp substrates in plasma
Notes: Raw data from Metabolon were reanalyzed using MetaboAnalyst 3.0. Significant
metabolites were identified based on p < 0.05 and fold change > 1.5. Fold change of all
significant metabolites were plotted against their p-value. The red arrow indicates known
substrates of Bcrp and/or Pgp.
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Figure 2-11. Known endogenous substrates of Bcrp were increased in abundance
in both plasma and CSF of dKO rats
Note: Raw LCMS median signal intensities are plotted for each genotype (n=8), with
significance calculated at p < 0.05 by Mann-Whitney test.
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The dietary Bcrp substrate pheophorbide A [92] signal was detected only in the plasma of
dKO, but not WT, rats. Another dietary Bcrp substrate the soy isoflavone daidzein (2.05fold) and its metabolite daidzein sulfate (2.41-fold) were also significantly increased in
the plasma of dKO compared to WT rats.
One interesting observation was alteration of few xenobiotics in the dKO rat
plasma (Supplement_Chapter 2_Metabolites Table S5). Among many xenobiotic
metabolites ketamine, the anesthetic drug, was found 1.74-fold high in dKO plasma and
1.93-fold high in dKO CSF. Also, a 3.6-fold higher level of 4-hydroxychlorothalonil, a
metabolite of pesticide chlorothalonil [219], was found in the plasma of dKO rats
compared to WT (Supplement_Chapter 2_Metabolites Table S5).
3. CSF/plasma intensity ratio identified metabolites with greater CSF
accumulation in dKO rats, compared to WT. Bcrp and Pgp are known to have a
significant impact on the brain permeability of their substrates [167] and many Bcrp and
Pgp substrates show accumulation in CSF or brain over plasma in the absence or
inhibition of these transporters [130, 144, 165]. Therefore, we calculated and compared
the CSF/plasma ratio of the raw LC-MS/MS signal intensity of metabolites identified in
WT and dKO rats. Assuming no significant difference in plasma protein binding between
WT and dKO rats, the above-mentioned ratio of CSF/plasma can be utilized to identify
metabolites that have significantly accumulated in the CSF of dKO rats, compared to WT
rats. Figure 2-12 shows all metabolites with significantly increased (50 metabolites)
(dark red) or decreased (3 metabolites) (dark green) CSF/plasma ratio in dKO vs WT
rats. While urate, a known Bcrp substrate, was found to have significantly higher
CSF/plasma ratio (3.23 fold) in dKO compared to WT rats (Figure 2-13), riboflavin,
another known substrate of Bcrp, while significantly increased in both plasma and CSF of
dKO rats compared to WT, and had a similar CSF/plasma ratio between WT and dKO
rats (1.11-fold dKO/WT) (Figure 2-14). Other interesting metabolites with greater
accumulation in CSF were catechol sulfate, O-methyl catechol sulfate, methionine
sulfoxide, isovalerylcarntine and pyridoxate (Figure 2-13). A list of metabolites with
significantly altered CSF/plasma ratios between WT and dKO rats, along with their
biological pathway information are provided in Supplement_Chapter
2_Metabolites_Table S2. 60% of these metabolites were related to amino acids. Phenol
sulfate, a known gut microbiome contributed tyrosine metabolite and isovalerate
metabolites, which could be contributed by the gut microbiome, were also altered. 13%
of the metabolites were xenobiotic in nature, which may be either contributed by dietary
metabolites, or could also be metabolites of dietary fiber metabolism by gut microbiota.
Furthermore, metabolites such as catechol sulfate (pyrocatechol sulfate) and O-methyl
catechol sulfate maybe of interest as putative Bcrp substrates with 2.13- and 13-fold
higher CSF/plasma ratio in the dKO rats, compared to WT, respectively. Pyrocatechol
sulfate is a known uremic toxin, supporting a role of Bcrp and Pgp transporters in
controlling toxin exposure in the brain. Interestingly, while 11-dehydrocorticosterone was
unchanged in the CSF and in the plasma of dKO compared to WT rats, a CSF/plasma
ratio of 1.4 indicated an increase in CSF abundance of this steroid metabolite in the dKO
rats. Since glucocorticoids are known Pgp substrates [57], 11-dehydrocorticosterone is
likely an endogenous Pgp substrate.
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Figure 2-12. Identification of metabolites with significant accumulation in CSF of
dKO compared to WT rats: Volcano plot
Notes: Fold change is calculated by dividing CSF/plasma ratio of metabolite raw signal
intensity in dKO with that of WT rats. Log2 (Fold change) is plotted on X-axis and log
10 (t-value of CSF/plasma dKO vs CSF/plasma WT metabolite ratio) is plotted on Yaxis. Metabolites that are significantly higher (p< 0.05) in CSF of dKO over WT rats are
identified by dark red marker and metabolites that are significantly decreased (p<0.05) in
CSF of dKO over WT rats are identified with dark green marker. Metabolites in dark red,
with > 1.5-fold (red vertical line) significant increase in CSF/plasma ratio in dKO
compared to WT signifies metabolites with significant accumulation in dKO CSF.

39

Figure 2-13. Identification of metabolites with significant accumulation in CSF of
dKO compared to WT rats
Notes: Box plots of metabolites with significantly higher CSF/plasma ratio in the dKO
rats, similar to urate, is plotted as median value ± range and significance is calculated by
comparing the mean CSF/plasma of dKO with WT by two sample t-test assuming
unequal variance.
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Figure 2-14. Unlike urate riboflavin did not accumulate in CSF
Notes: Box plot of median ± range of riboflavin intensity in plasma and CSF of dKO and
WT are significantly different, but median ± range CSF/plasma ratio is not different
between WT and dKO rats
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4. Metabolites related to specific metabolic pathways were altered in the CSF and
plasma of dKO rats, compared to WT. Apart from significant changes in many
metabolites, the following three significantly altered metabolic pathways were of
particular interest:
(a) dKO rats show a significantly altered plasma lipid metabolome: Significant
alteration in fatty acid metabolites was observed particularly in the plasma metabolome
of dKO rats, compared to WT (Table 2-1). While Bcrp or Pgp substrates are expected to
increase in abundance in dKO rat plasma, we observed a significant decrease in medium
and long chain fatty acids, unsaturated fatty acids, dicarboxylate, and monohydroxy fatty
acids, amide and amino fatty acids in the plasma of dKO rats, indicating a significant
alteration in the fatty acid metabolism pathway.
Unlike the fatty acid metabolites, there was a significant increase in the lysolipid
metabolites in the plasma (Table 2-2). Similarly, few fatty acid metabolites were also
found to increase in abundance in the dKO rat CSF, e.g. butyrylcarnitine showed a > 3.5fold increase in CSF abundance in the dKO rats (Table 2-3). The significant increase in
few fatty acid metabolites in CSF could be related to Bcrp and/or Pgp mediated transport,
as well as possible compensatory transporter expression or metabolic pathway changes.
(b) dKO rats show significant exposure of microbiome, xenobiotic and sulfated
metabolites in CSF and plasma: Absence of the Bcrp and Pgp efflux transporters in the
intestinal epithelial cells is expected to increase absorption of dietary metabolites as well
as gut microbiota metabolites. The metabolomic analysis clearly showed significant
alteration of gut microbiota metabolites in both CSF and plasma (Table 2-4). Of
particular interest, gut microbiota metabolites of the amino acid tyrosine, p-cresol sulfate
and phenol sulfate decreased 0.45-fold and increases 1.93-fold, respectively, in the CSF
of dKO rats. In addition, sulfated metabolites, many of which are contributed by the gut
microbiota, were also altered (Table 2-5 and Table 2-6). Among these metabolites, pcresol sulfate, equol sulfate (daidzein metabolite) and daidzein sulfate are known Bcrp
substrates [170, 220]. Due to high affinity of Bcrp for sulfated metabolites, these
metabolites may be of particular interest as putative Bcrp substrates.
(c) Altered purine and pyrimidine biosynthesis pathway metabolites: The purine
catabolites xanthosine, urate, allantoin, and allantoic acid, as well as, the pyrimidine
degradation products uracil, pseudouridine, and N-acetyl-beta-alanine accumulated in the
CSF and plasma of dKO rats (Supplement_Chapter 2_Metabolites _Table S5 and S6).
The pyrimidine metabolites orotate and orotidine were also higher in dKO CSF and to
less of an extent in plasma compared to WT rats (Supplement_Chapter 2_Metabolites
_Table S5 and S6). Bcrp transporter shows affinity towards purine analogues [221] and
thus the alteration in purine pathway metabolites could be the direct result of a lack of
Bcrp function. Accumulation of the pyrimidine analogues in the CSF could also indicate
these being putative Bcrp and/or Pgp substrates.
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Table 2-1.

Decrease in fatty acids in dKO rat plasma

Sub Pathway
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Fatty Acid, Branched
Fatty Acid, Branched
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Amide
Fatty Acid, Amide
Fatty Acid, Amino
Fatty Acid, Amino
Fatty Acid Metabolism(Acyl Glycine)
Fatty Acid Metabolism(Acyl Carnitine)
Carnitine Metabolism
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Dihydroxy
Endocannabinoid
Inositol Metabolism
Phospholipid Metabolism
Phospholipid Metabolism
Monoacylglycerol
Sphingolipid Metabolism
Sterol
Sterol
Steroid
Steroid
Primary Bile Acid Metabolism
Primary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism

Biochemical Name
heptanoate (7:0)
10-undecenoate (11:1n1)
5-dodecenoate (12:1n7)
myristoleate (14:1n5)
eicosenoate (20:1n9 or 11)
erucate (22:1n9)
docosahexaenoate (DHA; 22:6n3)
docosatrienoate (22:3n3)
arachidonate (20:4n6)
adrenate (22:4n6)
docosapentaenoate (n6 DPA;
22:5n6)
mead acid (20:3n9)
isocaproate
15-methylpalmitate
azelate (nonanedioate)
tetradecanedioate
hexadecanedioate
octadecanedioate
eicosanodioate
docosadioate
stearamide
erucamide
2-aminoheptanoate
2-aminooctanoate
N-palmitoyl glycine
myristoleoylcarnitine*
carnitine
2-hydroxyoctanoate
2-hydroxydecanoate
5-hydroxyhexanoate
16-hydroxypalmitate
13-HODE + 9-HODE
12,13-DiHOME
oleic ethanolamide
pinitol
glycerophosphorylcholine (GPC)
glycerophosphoethanolamine
1-oleoylglycerol (1-monoolein)
palmitoyl sphingomyelin
7-Hoca
campesterol
corticosterone
11-dehydrocorticosterone
chenodeoxycholate
glycochenodeoxycholate
deoxycholate
glycodeoxycholate
taurodeoxycholate
tauroursodeoxycholate
taurocholenate sulfate
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Fold
Change
0.79
0.44
0.56
0.64
0.52
0.61
0.59
0.64
0.75
0.52
0.42

pValue
0.08
0.05
0.04
0.06
0.01
0.00
0.01
0.07
0.07
0.01
0.00

0.51
0.45
0.76
0.76
0.6
0.6
0.66
0.6
0.68
0.31
0.25
0.58
0.65
0.54
0.71
1.14
0.39
0.45
0.67
0.7
0.69
0.65
0.85
1.67
1.61
2.00
0.52
1.49
0.57
1.38
0.64
0.8
0.51
0.11
0.55
0.1
0.57
0.58
1.99

0.02
0.07
0.06
0.08
0.07
0.02
0.01
0.01
0.01
0.00
0.01
0.00
0.01
0.01
0.05
0.03
0.00
0.00
0.02
0.02
0.09
0.09
0.07
0.01
0.01
0.09
0.04
0.00
0.00
0.00
0.00
0.07
0.10
0.09
0.06
0.03
0.06
0.08
0.01

Table 2-1.

Continued

Note: Raw signal intensity of the metabolites was used to compute the fold change (dKO/
WT) and p-value was calculated using Welch’s two sample t-test to identify metabolites
as significant (p<0.05) (in dark green & red) or trending significant (0.1>p>0.05) (light
green & red) metabolites.
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Table 2-2.
Sub Pathway
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid

Increase in lysolipids in dKO rat plasma
Biochemical Name
1-stearoylglycerophosphocholine (18:0)
2-stearoylglycerophosphocholine
1-linoleoylglycerophosphocholine (18:2n6)
1-arachidonoylglycerophosphocholine (20:4n6)
1-oleoylglycerophosphoethanolamine
1-linoleoylglycerophosphoethanolamine
1-palmitoylglycerophosphoinositol
1-linoleoylglycerophosphoinositol
oleoyl-linoleoyl-glycerophosphoinositol (1)
palmitoyl-linoleoyl-glycerophosphocholine (1)
palmitoyl-linoleoyl-glycerophosphocholine (2)
palmitoyl-linoleoyl-glycerophosphoinositol (1)
palmitoyl-oleoyl-glycerophosphocholine (1)
stearoyl-arachidonoyl-glycerophosphocholine (2)
oleoyl-linoleoyl-glycerophosphocholine (1)
oleoyl-linoleoyl-glycerophosphocholine (2)
stearoyl-arachidonoyl-glycerophosphoethanolamine (1)
stearoyl-linoleoyl-glycerophosphoethanolamine (1)
2-behenoylglycerophosphocholine
stearoyl-arachidonoyl-glycerophosphoinositol (2)

Fold Change
0.77
0.63
1.09
0.91
1.39
1.37
2.09
2.17
1.43
1.34
1.33
1.7
1.24
0.68
1.18
1.39
1.68
2.18
0.24
0.87

p-Value
0.03
0.06
0.00
0.08
0.00
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.01
0.00
0.01
0.04
0.00
0.00
0.02
0.01

Note: Fold change (dKO/ WT) was computed from raw signal intensity of metabolites
and Welch’s two sample t-test was used to identify metabolites as significant (p<0.05) (in
dark green & red) or trending significant (0.1>p>0.05) (light green & red).
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Table 2-3.

Increase in fatty acids in dKO rat CSF

Sub Pathway
Fatty Acid,
Dicarboxylate
Fatty Acid Synthesis
Fatty Acid Synthesis
Fatty Acid
Metabolism (also
BCAA Metabolism)
Carnitine Metabolism
Carnitine Metabolism
Ketone Bodies
Inositol Metabolism
Mevalonate
Metabolism
Sterol

Biochemical Name
dimethylmalonic
acid
malonylcarnitine
2-methylmalonyl
carnitine
butyrylcarnitine

Fold Change
(dKO/WT)
All
No Cont.
Sample
Sample
1.36
1.42

deoxycarnitine
carnitine
3-hydroxybutyrate
(BHBA)
chiro-inositol
3-hydroxy-3methylglutarate
7-alpha-hydroxy-3oxo-4-cholestenoate
(7-Hoca)

p-Value
All
No Cont.
Sample
Sample
0.03
0.05

1.24
1.43

1.33
1.60

0.02
0.00

0.01
0.00

3.77

3.84

0.00

0.00

1.42
1.18
0.80

1.41
1.14
0.75

0.00
0.09
0.04

0.00
0.18
0.02

1.51
0.83

1.70
0.82

0.02
0.07

0.01
0.04

0.56

0.69

0.05

0.18

Notes: Fold change (dKO/ WT) was computed from raw signal intensity of metabolites
and Welch’s two sample t-test was used to identify metabolites as significant (p<0.05) (in
dark green & red) or trending significant (0.1>p>0.05) (light green & red). CSF samples
were analyzed without contamination compensation or with contamination compensation
(No Cont. Sample).
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Table 2-4.
dKO rats

Gut microbiota metabolites identified altered in the plasma or CSF of

Metabolites
riboflavin (Vitamin B2)
creatine
4-hydroxycinnamate
taurocholenate sulfate
p-cresol sulfate
phenyllactate (PLA)
daidzein
indolelactate
phenylacetylglutamine
glycodeoxycholate
3-(2-hydroxyphenyl)
propionate
phenylacetate
indoleacetate
deoxycholate
indole-3-carboxylic
acid
tauroursodeoxycholate
phenol sulfate
Isovalerate
creatinine

Plasma
Fold
pChange
Value
2.64
0.0002
0.7
0.0016
0.53
0.0023
1.99
0.009
0.45
0.0091
1.72
0.0117
2.05
0.0181
1.45
0.0201
0.46
0.0215
0.1
0.0309
0.62
0.0314
0.44
0.75
0.55
0.64
0.58
1.27
0.86
1.07

CSF
Fold
Change
3.09
0.95

1.56

0.0338
0.0539
0.0607
0.0742
0.0769
0.1189
0.3158
0.4987

1.53

1.93
1.25
1.21

pValue
2.00E07
0.35

0.0004

0.14

0.0078
0.0084
0.0005

Reference
(PMID)
26283345
26283345
26861391
26283345
26283345
27505423

Exclusive
Biome?

26283345
26283345
26283345
27505423

Y
Y
Y

26283345

Y

26283345
26283345
26283345

Y
Y
N

Y
Y

Notes: Metabolites of gut microbiota origin were identified based on previously
published papers as well as microbiome metabolite list maintained at Metabolon ®. Only
significant (p<0.05) and trending significant (0.1>p>0.05) metabolites are listed from
both plasma and CSF. Fold change is the ratio of dKO/WT metabolite signal intensity
and Welch’s two sample t-test is used to compare WT vs dKO and calculate significance.
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Table 2-5.

Sulfated metabolites significantly altered in the plasma of dKO rats

Sub Pathway
Phenylalanine and Tyrosine Metabolism
Secondary Bile Acid Metabolism
Benzoate Metabolism
Food Component/Plant
Food Component/Plant
Food Component/Plant
Drug
Chemical
Chemical
Chemical

Biochemical Name
p-cresol sulfate
taurocholenate sulfate
catechol sulfate
equol sulfate
4-vinylguaiacol sulfate
daidzein sulfate (2)
4-acetylphenol sulfate
sulfate*
2-aminophenol sulfate
3-hydroxypyridine sulfate

Fold
Change
0.45
1.99
1.4
1.57
0.41
2.41
2.29
0.87
1.44
2.53

p-Value
0.01
0.01
0.08
0.02
0.04
0.00
0.00
0.07
0.05
0.00

Notes: Sulfated metabolites of different pathway origin that were significantly increased
or decreased in dKO rat plasma are listed. Welch’s two sample t-test was used to identify
metabolites as significant (p<0.05) (in dark green & red) or trending significant
(0.1>p>0.05) (light green & red) metabolites.

Table 2-6.

Sulfated metabolites significantly altered in the CSF of dKO rats

Sub Pathway
Phenylalanine and
Tyrosine Metabolism
Dipeptide
Benzoate Metabolism
Benzoate Metabolism
Chemical

Biochemical
Name

Fold Change (dKO/WT)
No Cont.
All Sample
Sample

p-Value
All
No Cont.
Sample
Sample

phenol sulfate

1.93

1.84

0.01

0.04

prolylglycine
catechol sulfate
O-methylcatechol
sulfate
2-aminophenol
sulfate

1.17
3.05

1.15
3.31

0.02
0.00

0.06
0.00

4.04

5.52

0.00

0.00

2.71

2.93

0.00

0.00

Notes: Sulfated metabolites of different pathway origin that were significantly increased
or decreased in dKO rat CSF are listed. Welch’s two sample t-test was used to identify
metabolites as significant (p<0.05) (in dark green & red) or trending significant
(0.1>p>0.05) (light green & red).
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Bcrp and Pgp gene deletion in rats results in altered transcriptome of brain, kidney
and liver
To understand the effect of compensatory pathways on metabolomic signatures,
we performed a microarray analysis comparing gene expression in the brain (frontal
cortex), kidney and liver of WT and dKO rats. A total of 435 genes in kidney, 398 genes
in liver and 240 genes in brain frontal cortex was found to be significantly different
(Figure 2-15A). 75 genes were common between kidney and liver, 45 genes between
kidney and brain and 40 genes between brain and liver. Hierarchical clustering analysis
revealed striking differences in gene expression in all tissues between the WT and dKO
rats (Figure 2-15B). A list of significantly altered genes in all tissues, along with their
associated p-values, identified by both Nexus expression analysis and GSEA analysis
method are provided in the supplement (Supplement_Chapter 2_Genes. S7 and S8)
Gene expression analysis exhibited significant changes in gene expression of few
Cytochrome P450 enzymes (Table 2-7), few ABC efflux transporters, mainly the Abcg
group of transporters (Table 2-8) and few solute carrier (SLC) uptake transporters (Table
2-9), but none of the major renal drug efflux or uptake transporters. A significant increase
(2.93-fold) in Cyp2b1 gene expression was observed in the liver of dKO rats, compared
to WT rats. Many SLC uptake transporters in kidney and liver were also found to have
altered expression (Table 2-9), e.g. Slc22a5 or OCTN2 is a carnitine transporter,
significantly decreased in the kidney of dKO rats. Similarly, an alteration in the Abcg
group of transporters in kidney (Abcg1, 1.5-fold) and liver (Abcg3, 0.5-fold and Abcg1,
1.5-fold) indicates compensatory alteration of these transporters due to absence of Abcg2
or Bcrp. Upregulation of Abcg1, sterol and choline phospholipid transporter [14], might
have an impact on steroid and sterol metabolism thus impacting the lipid metabolome.
Cholesterol and steroid metabolic pathway was also found to be altered in the kidney and
liver of dKO rats, respectively (Table 2-10). Table 2-10 lists the significantly altered top
20 common biological pathways between brain, liver and kidney of, dKO rats, compared
to WT rats. Of particular interest among altered pathways were urate biosynthetic process
and response to lipopolysaccharide in brain, oxidation-reduction process and response to
oxidative stress in kidney and circadian rhythm in liver, a majority of which were found
to be altered in all three tissues (Table 2-11). These altered pathway information, in
conjunction with the metabolomic signatures, indicated a possible impact of Bcrp and
Pgp transporters at the physiological level.
Use of gene expression and known substrate knowledge for understanding
metabolomic features
Significantly altered biological pathways and the associated gene expression
changes indicated that a part of the observed metabolomic changes was due to either
direct effect of compensatory pathways or indirect effect of many metabolites. Figure
2-16, Figure 2-17 and Figure 2-18 show few proposed models of possible genemetabolite interactions and impact of Bcrp and/or Pgp on biological pathway,
respectively, derived from a knowledge-based integration of metabolite-gene expressionbiological pathway alterations.
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Figure 2-15. Gene expression in brain, kidney and liver of the dKO is significantly
different from the WT rats
Notes: Venn diagram showing the number of significant (p<0.05) genes in kidney (blue),
liver (red) and brain frontal cortex (green) of the dKO compared to the WT rats (A).
Hierarchical clustering heatmap shows significant expression in gene expression between
WT and dKO rat kidney, liver and brain frontal cortex tissues (B)
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Table 2-7.
Gene
Symbol
Cyp4v3
Cyp4a8
Cyp4a3
Cyp3a85-ps
Cyp3a73
Cyp2j4
Cyp2g1
Cyp2d5
Cyp2d2
Cyp2d1
Cyp2c12
Cyp2c11
Cyp2b2
Cyp2b1
Cyp26a1
Cyp24a1
Cyp1a1

Significantly changed Cytochrome P450 (CYP) enzymes in dKO rats

Regulation
UP
DOWN
UP
DOWN
DOWN
UP
DOWN
DOWN
DOWN
DOWN
DOWN
UP
UP
UP
UP
UP
UP

Liver
Fold
Change p-Value
0.71

0.00

0.58
0.67
1.34

0.00
0.00
0.01

Brain
Fold
Change
p-Value
1.33
0.02

0.72
0.54

0.00

0.56

0.00

1.24
2.66
1.39

0.04
0.00
0.01

Kidney
Fold
Change p-Value
1.24
0.01
1.50

0.00

1.61

0.00

0.33
0.75
0.71

0.00
0.00
0.00

1.77

0.00

1.79
1.76

0.00
0.00

0.04

Note: List of significantly (p< 0.05) increased (red) or decreased (green) CYP enzymes’
gene expression in the dKO rats.

Table 2-8.
dKO rats

Significantly changed ATP-binding Cassette (ABC) transporters in
Liver

Gene
Symbol
Abca16
Abca9
Abcc10
Abcg1
Abcg3
Abcg3l3
Abcg5

Regulation
DOWN
UP
DOWN
UP
DOWN
DOWN
UP

Fold
Change
0.65
1.35
0.73

p-Value
0.00
0.00
0.01

0.47

0.00

1.50

0.00

Brain
Fold
Change p-Value

Kidney
Fold
Change
p-Value

1.48

0.00

0.76

0.02

Note: List of significantly (p< 0.05) increased (red) or decreased (green) ABC
transporters’ gene expression in the dKO rats.
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Table 2-9.
Gene
Symbol
Slco1c1
Slc8a1
Slc6a6
Slc5a8

Significantly changed SLC transporters in dKO rats

Liver
Common
Fold
pName
Regulation Change Value
OATP1C1 UP
UP
TauT
UP
1.28
0.00
SMCT1
DOWN

Slc5a3 SMIT1
Slc5a10 SGLT5

UP
DOWN

Slc4a7
Slc4a5
Slc45a3
Slc39a12
Slc38a3
Slc38a2
Slc35f1
Slc34a2
Slc30a2
Slc2a12 Glut12
Slc26a11
Slc25a30
Slc25a28 Mitoferrin
Slc25a25
Slc25a23 APC2

UP
UP
UP
UP
UP
UP
DOWN
UP
DOWN
DOWN
DOWN
DOWN
DOWN
UP
DOWN

Slc22a5
Slc22a25
Slc16a6
Slc16a2
Slc15a1

DOWN
DOWN
UP
DOWN
DOWN

0.78
0.68

UP

1.36

OCTN2
MCT7
MCT8
PEPT1

Slc13a5 NaC2

Brain
Fold
pChange Value
1.22
0.02

1.29
1.28

Possible
Substrates
T4, T3

1.26

0.01

0.69

0.00

1.28
0.80

0.02
0.04

1.33

0.00

1.24

0.00

0.65

0.00

0.82

0.04

0.63

0.00

0.82
1.52
0.82

0.05
0.00
0.00

Fe2+

0.71
0.83
0.59

0.00
0.02
0.00

Orphan
T2, T3,T4
di- and tripeptides
Citrate,
succinate,
pyruvate

Taurine
Short chain
fatty acid
Myoinositol
Mannose,
fructose,
glucose

0.00

0.05
1.61

1.48

0.00

1.39

0.00

0.50

0.00

0.83

0.51

Kidney
Fold
pChange Value

0.00

0.04

Glucose

0.00

0.01
0.03
1.28

0.00

0.01

ATP, AMP,
ADP, Pi
L-carnitine

Note: List of significantly (p< 0.05) increased (red) or decreased (green) SLC
transporters gene expression (Table 2-9) in the dKO rats.
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Table 2-10.

Significantly altered top biological pathways based on gene expression changes in dKO compared to WT rats

Brain
Enrichment Term
retina development in camera-type eye

p-Value
5.43E-05

bronchus development
urate biosynthetic process

1.43E-04
1.43E-04

response to glucocorticoid stimulus

1.56E-04

angiogenesis

2.48E-04

retinal cell programmed cell death

4.25E-04

negative regulation of cell volume
trachea formation
vocalization behavior
negative regulation of actin filament bundle
assembly
glomerular visceral epithelial cell development
homeostasis of number of cells within a tissue
positive regulation of endothelial cell migration
embryonic digit morphogenesis

Kidney
Enrichment Term
response to drug
response to organic cyclic
compound
oxidation-reduction process

Liver
p-Value
1.72E-11

Enrichment Term
aging

p-Value
3.33E-07

9.79E-09
2.80E-07

3.06E-06
4.24E-05

3.26E-07
5.23E-07

steroid metabolic process

1.17E-04

3.69E-06

glucose 6-phosphate metabolic process

2.29E-04

4.25E-04
4.25E-04

Aging
positive regulation of
apoptotic process
response to organic
substance
response to mechanical
stimulus
response to food

response to drug
wound healing
antigen processing and presentation of
exogenous peptide antigen via MHC class II

5.86E-06
7.14E-06

2.56E-04
2.77E-04

8.42E-04

response to oxidative stress

8.53E-06

8.42E-04
0.001393
0.001424
0.001424
0.001712

response to nutrient
response to cytokine stimulus
response to glucose stimulus
Ossification
cellular response to cAMP
positive regulation of
cholesterol efflux

1.31E-05
1.44E-05
1.77E-05
2.63E-05
3.70E-05
4.02E-05

negative regulation of signal transduction
response to organic cyclic compound
positive regulation of fatty acid betaoxidation
leukocyte migration involved in
inflammatory response
urate metabolic process
maintenance of protein location in cell
cellular protein complex disassembly
response to estrogen stimulus
positive regulation of transcription from
RNA polymerase II promoter

4.50E-05
5.31E-05

circadian rhythm
drug metabolic process

6.14E-04
7.29E-04

5.38E-05
6.94E-05

7.96E-04
0.001018

9.20E-05

response to glucocorticoid stimulus
glutathione biosynthetic process
phosphorylated carbohydrate
dephosphorylation

response to hypoxia
activation of cysteine-type endopeptidase
activity involved in apoptotic process by
cytochrome c
visual perception

0.001923

response to lipopolysaccharide
cellular response to interferon-gamma

0.002551
0.002845

embryo implantation
cholesterol homeostasis
negative regulation of ERK1
and ERK2 cascade
response to vitamin D

glial cell apoptotic process

0.002879

cholesterol metabolic process

0.002073
0.00231

8.17E-05

3.60E-04
3.60E-04
3.60E-04
3.64E-04
3.64E-04
4.08E-04
5.28E-04

0.001078

Notes: Top 20 most significant biological pathways were identified by enrichment of significantly altered genes in the dKO rat brain frontal
cortex, kidney and liver at p < 0.05.
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Table 2-11.

Significantly altered common biological pathways between all the tissues

Common Biological Pathways
urate biosynthetic process
response to glucocorticoid stimulus
Angiogenesis
response to lipopolysaccharide
circadian rhythm
drug transport
antigen processing and presentation
drug transmembrane transport
antigen processing and presentation of exogenous peptide antigen via MHC class II
protein localization in mitochondrion
cellular response to type I interferon
negative regulation of helicase activity
positive regulation of angiogenesis
male gonad development
mitochondrial electron transport; cytochrome c to oxygen
nucleotide-binding oligomerization domain containing 1 signaling pathway
hypoxanthine biosynthetic process
regulation of mitochondrial fission
negative regulation of apoptotic process
brown fat cell differentiation
response to peptide hormone stimulus
intracellular transport of viral proteins in host cell

Brain
1.43E-04
1.56E-04
2.48E-04
0.002551
0.004231
0.004859
0.005943
0.006026
0.010200
0.011969
0.011969
0.011969
0.013703
0.020563
0.023795
0.023795
0.023795
0.023795
0.039936
0.046865
0.046952
0.047027

p-Value
Liver
0.037835
0.000796
0.047942
0.013290
0.000614
0.011985
0.020920
0.014794
8.17E-05
0.019100
0.019100
0.019100
0.003538
0.006432
0.037835
0.037835
0.037835
0.037835
0.001377
0.017487
0.001474
0.002128

Kidney
0.042625
0.000459
0.002913
0.003599
0.000171
0.015081
0.028569
0.018585
0.000130
0.021544
0.021544
0.021544
0.001348
0.039839
0.042625
0.042625
0.042625
0.042625
0.001713
0.000351
0.000167
0.002700

Note: Top 22 common biological pathways that were identified by enrichment of significantly altered genes in the dKO rat brain
frontal cortex, kidney and liver at p < 0.05.
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Figure 2-16. Possible explanation of observed decrease in corticosterone, a Pgp
substrate, in the dKO rat plasma
Notes: Metabolomic analysis showed a significant decrease in corticosterone in dKO rat
plasma (A). Transcriptomic analysis showed a significant increase in CYP2B gene
expression in the liver of dKO rats, possibly by glucocorticoid mediated pathway
activated by corticosterone.
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Figure 2-17. Possible explanation of activation of peroxisome proliferatoractivated receptor pathway in absence of Bcrp and/or Pgp
Notes: Bcrp substrate daidzein and also its metabolites were significantly increased in the
plasma of dKO rats. Isoflavonoid and Bcrp substrates daidzein and genistein are known
activator of PPARα as well as PPARγ pathways. Gene expression analysis also observed
gene expression changes possibly related to PPAR activation pathway, thus leading to
alteration in fatty acid metabolic pathways.
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Figure 2-18. Possible biological pathways altered in the absence of Bcrp and Pgp
in the dKO rats, based on both transcriptomic and metabolomic evidences
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In silico prediction of BCRP and PGP substrate-like properties for the significantly
altered metabolites in CSF and plasma of dKO rats
Screening of all 169 metabolites significantly altered in CSF and plasma of dKO
rats for their interaction with Bcrp and /or Pgp may not be a feasible option. Also, it is
unlikely that all observed metabolic changes were due to the direct effect of Bcrp and/or
Pgp transport deficiency. Therefore, we used an in silico prediction-based approach to
identify metabolites that are more likely to be substrates of Bcrp and/or Pgp. A Bayesian
machine learning model, built with compounds known to interact with Bcrp and Pgp, was
used to score the metabolites based on their level of interaction (high score for higher
interaction). Compared to the xenobiotics, many of these metabolites are smaller
molecules, and might also have weaker interaction with the transporters, which is also
reflected by their low interaction score. As described in the methods, Bcrp or Pgp
Bayesian interaction score for each metabolite along with their molecular descriptors
(molecular weight, molecular polar surface area, AlogP etc.) were used to predict the
observed log2(fold change) of the metabolites in CSF and plasma. Metabolites in the
plasma, irrespective of their significance and direction of fold change, did not correlate
well with either the Abcg2 or Pgp score along with other descriptors (data not shown). A
significant correlation was observed for the metabolites that are significantly altered in
the CSF of dKO compared WT rats (Figure 2-19A). In particular, metabolites that
significantly increased by > 1.5-fold in the CSF of dKO rats, correlated strongly with the
ABCG2 score, logP and molecular polar surface area of the metabolites (Figure 2-19B).
Raw data for the significantly altered CSF metabolites that are used for this analysis is
presented in Supplement_Chapter 2_Metabolites_Table S4.
Discussion
The goal of the current study is to understand the effect of Bcrp and Pgp efflux
transporters on the rat metabolome, and elucidate their biological functions. A systemic
level understanding of the impact of these transporters on metabolomic and
transcriptomic profiles could be useful to identify their overall endogenous function,
leading to a better understanding of long-term inhibition of these transporters by
xenobiotics or dietary inhibitors, as well as elucidate effects of the well-known BCRP
polymorphism [111] on population physiology and drug treatment outcome.
Bcrp and Pgp are abundant at the blood brain barrier (BBB), blood CSF barrier
(BCSFB) and on enterocytes of small intestine, where they restrict brain permeability and
oral absorption, respectively, of many known drugs and toxic chemicals [46, 149].
Absence of these transporters is expected to increase the concentration of their substrates
in both blood and brain / CSF. Therefore, by comparing the CSF and plasma
metabolomic profiles between WT and Bcrp-Pgp KO (dKO) rats, we aimed to identify
putative endogenous substrates of Bcrp and/or Pgp and their impact on the systemic
metabolome.
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Figure 2-19. Metabolites with significantly higher abundance in dKO CSF
compared to WT rats have structural properties for interaction with BCRP
Notes: ABCG2 or BCRP interaction score from a Bayesian model, molecular weight,
molecular polar surface area and AlogP of each significantly altered metabolites (A) or
only >1.5-fold significantly increased metabolites (B) in CSF were used in a predictive
regression model to predict their fold change (dKO/WT) in CSF. Log2 (Fold change)
actual vs. Log2 (Fold change) predicted compared using a standard least square method.
Significance of the correlation computed at p < 0.05.
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We observed a significant difference in abundance of metabolites in CSF and
plasma between WT and dKO rats. While 90% of the significant metabolites in CSF
increased in dKO rats compared to WT, the plasma metabolome demonstrated 50%
abundance of both increased and decreased metabolites. The majority of the altered
plasma metabolomic signature was represented by the lipid metabolites. Specifically,
long and medium chain fatty acids, dicarboxylate and polyunsaturated fatty acids were
found to be significantly decreased in the plasma of dKO compared to WT rats. Similar
to our observations, in a metabolomic study in mice after treatment with PPARγ agonist
rosiglitazone, the authors reported a decrease in polyunsaturated fatty acids such as mead
acid, oleic acid, phosphatidylethanolamine and phosphatidylcholine [197]. In addition,
our transcriptomic analysis revealed significant alteration of genes related to the PPARγ
pathway [197] such as uncoupling protein 1 (Ucp1, 1.4-fold increase in dKO kidney),
fatty acid binding protein 4 (Fabp4, 2-fold increase in dKO kidney), leptin (Lep, 1.4-fold
increase in dKO kidney) and lipoprotein lipase (lpl, 1.5-fold increase in dKO liver and
1.3-fold increase in dKO kidney). Of particular interest, we observed a 1.5-fold increase
in PPARγ gene expression in both kidney and liver of dKO rats.
In a separate study, treatment with PPARα agonist fenofibrate was reported to
increase the acylcarnitine metabolites including propionyl-, isobutyryl-, 2-methylbutyryland isovalerylcarnitine in the urine of healthy volunteers [222]. A significant increase in
these carnitine analogs was also observed in our dKO rat CSF metabolome signature
(Table 2-3 and Supplement_Chapter 2_Metabolites _ S1B). Interestingly, another
PPARα activity biomarker in mice, nicotinamide [222], was found to be significantly
decreased in the CSF of the dKO rats. Furthermore, we observed a 0.56-fold decrease in
gene expression of carnitine palmitoyl transferase 1a (CPT1a) which is known to be
altered due to PPARα activity [222], in the liver of dKO rats. Alteration in amino acid
and carnitine metabolites in CSF and plasma has been reported by another group of
researchers in rats treated with pan-PPAR agonist tetradecylthioacetic acid [223]. In
addition, a 5-fold increase in 2, 8-quinolinediol in the dKO rat plasma (Figure 2-4), is
commensurate with previous findings in mice, where treatment of mice with PPARα
ligand Wy-14,643 significantly decreased urinary 2, 8-dihydroxyquinoline [224].
Therefore, taken together, our metabolomic and transcriptomic results suggest a possible
induction of the PPARα and PPARγ pathways in rats lacking Bcrp and Pgp transporters,
possibly leading to the observed changes in fatty acid and amino acid metabolites (Table
2-1, Table 2-2, Table 2-3, Supplement_Chapter 2_Metabolites _Table S5 and S6).
This implies that in the absence/inhibition of Bcrp and Pgp in enterocytes, substrates of
these transporters, which are also PPARα/γ agonists, such as dietary isoflavones genistein
[225-229] and daidzein [230, 231] (was increased 2 fold in our dKO rat plasma, Figure
2-11), may be absorbed more, leading to higher PPARα/γ activity in the system (Figure
2-17).
Another striking effect on the plasma lipid metabolome was the overall increase
in lysolipids (Table 2-2). In a recently published report on identification of early
biomarkers of lipopolysaccharide (LPS)-induced sepsis in rats, the authors reported an
alteration in palmitoyl carnitine, acetyl-L-carnitine, propionyl-L-carnitine, branched
chain amino acids, along with a significant increase in methionine, N-acetyl methionine,
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methionine sulfoxide and lysolipids [232]. Our metabolomic data demonstrated an
increase in methionine, N-acetyl methionine and methionine sulfoxide in CSF
(Supplement_Chapter 2_Metabolites _Table S1B) and lysolipids in plasma (Table
2-2) of the dKO rats. In addition, transcriptomic analysis found ‘response to
lipopolysaccharide’ as one of the top 10 significantly altered biological pathways in liver,
kidney and brain of dKO rats (Table 2-11). LPS is a complex large glycolipid found on
the outer membrane of Gram (-) bacteria and can act as an endotoxin. Gut microbiota can
utilize LPS to cause low grade inflammation in the host and thereby associate with
different pathogenesis of the host, such as obesity and cardiovascular risk [233].
Therefore, our findings strongly suggest that the absence of Pgp/Bcrp has affected the gut
microbiota, and the altered microbiota, in turn, is influencing both the plasma and CSF
metabolome in dKO rats. The decrease in the secondary bile acid metabolites, such as
deoxycholate (0.55-fold, 0.1>p>0.05), glycodeoxycholate (0.1 fold, p<0.01),
taurodeoxycholate (0.57 fold, 0.1>p>0.05) and tauroursodexycholate (0.58 fold,
0.1>p>0.05), which are majorly derived by the gut microbiota, in the plasma of dKO rats
(Table 2-1), also indicates a possible change in the gut microbiome in the absence of
Bcrp and Pgp transporters.
Additional evidence of altered gut microbiome, in the absence of Bcrp and Pgp,
comes from the signatures of cresol sulfate and phenol sulfate metabolites. Both are
tyrosine metabolite products of the gut microbiota [234]. While cresol sulfate was
significantly decreased in plasma, phenol sulfate was increased in the CSF of dKO rats
(Table 2-4). Phenol sulfate is produced by E. Coli species of bacteria, which have been
reported to increase in abundance in mice lacking Mdr1a (Pgp) [162, 235]. Thus, a
dysregulation in bacterial abundance in the dKO rats, leading to altered production of
metabolites, might have led to some of these observed metabolomic changes. Our results
also show alteration in other known gut microbiota metabolites in the plasma of dKO
rats, such as the tryptophan metabolite indolelactate (1.5-fold increase) and phenylalanine
and the tyrosine metabolite phenylacetyleglutamine (0.46-fold increase) (Table 2-4).
Some of these metabolites were also found to be significantly increased in the CSF of
dKO rats (Table 2-4). While our findings indicate an alteration in gut microbiome
metabolites in the absence of Bcrp and Pgp transporters in rats, it remains to be
understood which altered microbiome metabolites are due to exclusive alteration in the
gut microbiome itself, and/or due to a change in the efflux transporters for these
metabolites.
Sulfated metabolites, many of which are of gut microbiota origin, were
significantly increased in the CSF and plasma of dKO vs. WT rats (Table 2-5 and Table
2-6). Bcrp is known to be a broad-specificity phytoestrogen sulfate transporter [127].
Dietary isoflavones such as genistein and daidzein, as well as their sulfated metabolites
are also known substrates of Bcrp [93, 225]. Although cresol sulfate has been shown to
be a Bcrp substrate [83], a decrease in plasma abundance of cresol sulfate, which is a gut
microbiota-generated metabolite, indicated a possible alteration in the gut microbiome, as
discussed before. Many sulfated metabolites of gut microbiota origin are also uremic
toxins [212] and are known to interact with Bcrp as well as MRP4 and OAT, e.g., indoxyl
sulfate [126, 141]. Thus, it is also possible to have functional inhibition of multiple efflux
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or uptake transporters, in the absence of Bcrp function, in dKO rat enterocytes, leading to
alterations in sulfated metabolites. Accordingly, in CSF and plasma of dKO rats, we
observed significant changes in p-cresol sulfate (0.5-fold, decrease, plasma),
pyrocatechol sulfate (catechol sulfate, 3.3-fold increase, CSF) and equol sulfate (1.6-fold
increase, plasma), which are known to be gut microbiota-derived uremic toxins [212].
Among them, p-cresol sulfate and equol sulfate are already known Bcrp substrates [83,
127]. We also observed a 2.14-fold higher CSF/plasma ratio of pyrocatechol sulfate in
the dKO rats compared to WT, implying a significant accumulation of this uremic toxin
in the CSF of dKO rats. Hence, due to known affinity of Bcrp towards sulfated
metabolites [121], we think pyrocatechol sulfate may be a putative endogenous Bcrp
substrate. Another such metabolite, 2-aminophenol sulfate, was found to be 3-fold higher
only in the CSF of dKO rats (Table 2-6). In addition, the CSF/plasma ratio of 2aminophenol sulfate was 1.9-fold higher in dKO vs WT rats (Supplement_Chapter
2_Metabolites _Table S2). Known as a uremic toxin [142], this metabolite could also be
of interest as a putative Bcrp substrate.
As discussed before, these uremic toxins and sulfated metabolites can be
substrates of multiple transporters and be part of the Remote Sensing and Signaling [142]
mechanism. In a recently published report, comparing the plasma metabolomics of Oat3
knockout and WT mice, Bush K et.al observed a significant increase in catechol sulfate,
O-methyl catechol sulfate and 2-aminophenol sulfate among many other metabolites in
the plasma of Oat3 knockout mice [140]. Interestingly, we also observed a 3 fold increase
in catechol sulfate and 2-aminophenol sulfate and a 5-fold increase in O-methyl catechol
sulfate in the CSF of dKO compared to WT rats (Table 2-6), but no change in the
expression level of OAT1/3 transporters in any tissue (Table 2-9). In addition, the
CSF/plasma ratio was 2-fold higher for catechol and 2-aminophenol sulfate and 13-fold
higher for O-methyl catechol sulfate in dKO vs WT rats (Supplement_Chapter
2_Metabolites _Table S2). While the increased concentration of catechol and 2aminophenol sulfate in the dKO rat plasma could be explained by inhibition of renal Oat3
or Oat1 transporters, their accumulation in the CSF of Bcrp and Pgp dKO rats cannot be
solely explained by these primarily kidney transporters, raising the possibility that these
metabolites are also substrates of Bcrp and/or Pgp. A recent observation that the
association of methotrexate clearance variability with the liver transporter OATP1B1
polymorphism was primarily related to inhibition of renal methotrexate transporter
OAT1/3 by endogenous metabolites of OATP1B1 [213], further strengthens the Remote
Sensing and Signaling hypothesis.
Similar to previously published findings in single Pgp or Bcrp knockout rats [91],
our transcriptomic analysis did not reveal a drastic compensatory effect in gene
expression of uptake (Table 2-9) or efflux transporters (Table 2-8) in the dKO rats.
However, the Remote Sensing and Signaling hypothesis, discussed above, can lead to
alteration of many transporter activities. One significant observation was the reduction in
Slc22a5 or the Octn2 transporter in kidney, a known carnitine transporter [202], which
might contribute to the observed alterations in carnitine metabolites. Glucocorticoids are
known substrates of Pgp [57]. However, a significant increase (2 fold) in Cyp2b1 gene
expression, which is inducible by glucocorticoids [236] and also metabolizes the same, in
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the liver of dKO rats, might further explain the decrease in corticosterone levels in the
plasma of dKO rats (Figure 2-16).
Due to the significant impact of Bcrp and Pgp transporters on the brain
penetration of their substrates [50, 237], we think CSF might be a better matrix to
identify putative Bcrp and/or Pgp endogenous substrates than plasma. When we used in
silico Pgp and Bcrp scores, along with molecular descriptors (AlogP, molecular weight,
polar surface area) to predict the log2(fold change) of metabolites observed in plasma and
CSF, only significantly altered metabolites in CSF, and not plasma (data not shown),
displayed a better correlation between predicted and observed data (Figure 2-19).
Correlation was also found to be better with only significantly increased metabolites in
the CSF of dKO rats (Figure 2-19B), thus implying that these metabolites in dKO rats
possessed Bcrp substrate-like properties. In addition, Random Forest Analysis identified
metabolites based on their importance in group separation in the CSF of dKO compared
to WT rats (Figure 2-7), which included known Bcrp substrates riboflavin and urate in
the CSF and only riboflavin in the plasma. Of note, our metabolomic analysis identified
ketamine, the drug used for anesthetizing the rats, increased 2-fold in both CSF and
plasma of dKO rats compared to WT. Further investigation revealed that ketamine oral
bioavailability and ketamine-induced loss of righting reflex pharmacodynamic activity
was significantly higher in Bcrp-Pgp dKO and Pgp KO mice, indicating ketamine is a
dual substrate of Bcrp and Pgp [95]. In addition, Kaiser et al. recently reported that
ketamine is a substrate of Pgp in vitro [98], further validating our hypothesis that
metabolomic analysis could identify novel substrates of Bcrp and Pgp. Our observation
that pesticide chlorothalonil metabolites 4-hydroxychlorothalonil was increased in the
plasma of dKO rats, indicates possible risk of exposure to the pesticide in people lacking
BCRP and/or PGP function. Lack of 4-hydroxychlorothalonil in CSF also indicates the
involvement of other efflux mechanism at the BBB that prevents this metabolite from
getting into CSF.
Among the known Bcrp substrates, urate’s signature in the CSF was of particular
interest. Urate was found to be significantly increased only in the CSF of dKO rats
(Figure 2-11). In addition, the CSF/plasma ratio of urate was found to be 3-fold higher in
the dKO compared to WT rats. While elevated serum urate is known to be positively
correlated to gout, cardiovascular and renal diseases, it has been shown to be negatively
correlated to Alzheimer’s and Parkinson’s diseases [238]. Bcrp is a low affinity and high
capacity transporter of uric acid [54] and has also been associated with Alzheimer’s
disease [207]. Thus, altered uric acid in CSF of dKO rats may have varied physiological
consequences. In addition, uric acid has been reported to be both antioxidant as well as
causing oxidative stress [239, 240]. It has also been associated with causing endoplasmic
reticulum stress leading to changes is fatty acid metabolism [241]. Similar findings were
observed in our metabolomic analysis with a significant increase in methionine sulfoxide,
a possible biomarker of oxidative stress [242] along with ‘oxidative stress’ as a
significantly altered biological pathway in the transcriptomic analysis. Furthermore, uric
acid is known to inhibit UMP synthase [243] that can reduce orotidine metabolism, which
might explain the observed increase in orotidine in the CSF and plasma of dKO rats.
Apart from urate and its downstream metabolite allantoin and allantoic acid, xanthosine,

63

adenine containing- and guanine containing- purine metabolites were found to be
significantly increased in the CSF of the dKO rats (Supplement_Chapter 2_Metabolites
_ S6). Similarly, pyrimidine, specifically orotate and uracil containing, metabolites also
significantly increased in the CSF of dKO rats. In an unpublished previous study in the
lab, comparing the CSF of WT and Bcrp KO female rats (n=12), we also observed
increased xanthine along with urate and allantoin in the CSF of Bcrp KO compared to
WT female rats. Thus, alteration in purine metabolite pathway might be related to the
absence of Bcrp transporter. Bcrp is also known to have affinity for purine ring
containing chemicals [221], raising the possibility that some of the purine pathway
metabolites apart from urate could be putative Bcrp substrates.
Comparison of gene expression between WT and dKO rat tissues by microarray
also identified ‘circadian rhythm’ pathway as a significantly altered biological pathway.
This is particularly interesting since Bcrp substrate protoporphyrin IX is a porphyrin
metabolite, and may influence the circadian rhythm pathway. Indeed, cobalt and zinc
conjugated protoporphyrin IX (PPIX) have been shown to be a ligand activator of REVERBα / NR1D1, important for the circadian rhythm pathway [244]. In a previous
experiment in our lab, we observed a 6-fold higher PPIX in the red blood cells (RBCs) of
Bcrp KO female compared to WT female rats (data not shown). Thus, it is possible, PPIX
is mediating the changes in the circadian pathway that we observed in our experiment.
Evidence for this comes from the microarray analysis of the dKO vs WT kidney and liver
that showed changes in expression of Rorα, Per2 and Nr1d1 and ATF3, and the mouse
phenome database showing abnormal sleep behavior in Bcrp knockout mice
(http://www.mousephenotype.org/data/genes/ MGI:1347061#section-associations). Bcrp
gene expression in the mouse intestine was recently reported to be under the control of
circadian clock-activating transcription factor 4 (ATF4) pathway, and authors showed a
clear difference in sulfasalazine absorption when administered orally at Zeitgeber time 2
(ZT2) compared to 14 (ZT14) [245].
While our results indicate an effect of both Bcrp and Pgp transporters on the
endogenous metabolome and biological pathways, further studies are required to dissect
out the effect of the individual transporters. Due to lack of an exhaustive database and
useful analytical methods for our dataset, we have used a knowledge-based integration of
transcriptomic and metabolomic data. Our study design falls under a source-matched
study design for metabolomic and transcriptomic studies [194] usually performed in
animals, and the difficulty of analyzing the data lies in the integration of metabolomic
and transcriptomic information originating from different matrices. In particular, the
plasma metabolome can reflect the overall change from almost all highly perfused
tissues. In this regard, while our data demonstrates an effect of Bcrp and/or Pgp
transporters on the gut microbiome, further studies are needed for better understanding of
this effect. Although our metabolomics comparison identified known Bcrp substrates,
urate, pheophorbide A, riboflavin in the dKO rat CSF and/or plasma, the metabolomic
analysis did not identify PPIX in the rat plasma/CSF. PPIX is a high affinity substrate of
Bcrp, that is otherwise trapped in RBCs [246], suggesting that we could miss some
hydrophobic substrates trapped in other cells that highly express Bcrp.
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In conclusion, our results demonstrate a significant impact of the two efflux
transporters Pgp and Bcrp on the systemic metabolome in rats and have increased our
understanding of the endogenous function of these transporters. To our knowledge, this is
the first study towards understanding the systemic level impact of efflux transporters. We
have also shown that CSF and plasma metabolome can be independent from each other
and the effect of Bcrp and/or Pgp transporters in these two compartments can be very
different. Finally, our results demonstrate the importance for considering the Remote
Sensing and Signaling hypothesis for chronic use of transporter inhibitors, and might
throw some light on pharmacokinetic/ pharmacodynamic variability of many drugs that
are substrates or inhibitors of these transporters.
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CHAPTER 3. KETAMINE PHARMACOKINETICS AND
PHARMACODYNAMICS ARE ALTERED BY PGP AND BCRP EFFLUX
TRANSPORTERS IN MICE*
Introduction
Ketamine is a clinically useful anesthetic that is used either alone or in
combination with other drugs in different surgeries [247]. It is also useful for the
management of neuropathic and postoperative pain [248, 249]. It has been reported
recently that ketamine has long-lasting antidepressant activity at sub-anesthetic doses
[250]. But clinical utility of ketamine is affected by its recreational abuse, which often
reported to cause kidney pathology, ulcerative cystitis [251] and bladder toxicity [252] in
chronic ketamine abusers.
Pharmacologically, ketamine is a N-methyl-D-aspartate (NMDA) receptor
antagonist that binds to the phencyclidine binding pocket of the receptor [253] to elicit
anesthesia. However, ketamine is also known to interact with other pharmacological
targets [247]. For example, ketamine was shown to have rapid onset antidepressant
activity following metabolism to (2R, 6R)-hydroxynorketamine that activates α-amino-3hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) [274].
Ketamine pharmacokinetics (PK) in humans are well-described by a two or three
compartment PK model [254, 255] with a high volume of distribution, high clearance and
low plasma protein binding [253]. Ketamine is metabolized primarily by CYP2B6 and
CYP3A4 to form norketamine, which is further metabolized to hydroxynorketamine and
its glucuronide [256]. Ketamine has a low oral bioavailability that can be partially
explained by its high metabolism observed by the oral route compared to intravenous or
intramuscular routes [255, 257]. In addition, modifications in ketamine metabolism have
been reported to cause potential drug-drug interactions [79].
Breast cancer resistant protein (Bcrp/Abcg2) and P-glycoprotein (Pgp/Abcb1a)
are membrane-bound efflux transporters that are present in a wide variety of tissues such
as blood-brain barrier and blood-cerebrospinal fluid barrier in the brain, intestinal
epithelial cells, and bile canalicular membrane and kidney tubules. These transporters
recognize a wide variety of chemicals as their substrates and reduce substrate systemic
exposure by decreasing absorption (intestine) and increasing elimination (liver and
kidney). Pgp and BCRP expression at the BBB and BCSFB decreases substrate
movement from blood to brain and to CSF, respectively. Thus, inhibition of Bcrp and / or
*Reprinted with permission of the American Society for Pharmacology and Experimental
Therapeutics. All rights reserved. S Ganguly, JC Panetta, JK Roberts, and EG Schuetz.
Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by Pgp and Bcrp Efflux
Transporters in Mice, Drug Metabolism and Dispos (2018), DOI:
https://doi.org/10.1124/dmd.117.078360
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Pgp can lead to systemic overexposure of their substrates and cause toxicity. A wide
variety of drugs as well as chemicals from food or drinks are known to inhibit these
transporters, and can therefore lead to potential drug-drug or drug-food interactions [71,
258, 259]. Moreover, the BCRP Q141K inactivating allele is common in some
populations with as many as 6% of Asians homozygous for this loss of function allele
[111].
Screening drugs in development for Bcrp and Pgp transport and inhibition
capability is one of the FDA required drug approval criteria [31, 71] because of the large
number of Bcrp and Pgp substrates and inhibitors, and the potential for some chemicals
to be dual substrates for both transporters. Some in vivo studies in rodents as well as in
humans have suggested a potential interaction of ketamine with Bcrp and/or Pgp [260,
261]. Given the clinical and recreational use of ketamine, and the significant interest in
ketamine as an effective anti-depressant, we sought to identify if ketamine is a substrate
of Bcrp and/or Pgp. Using mice with and without these two transporters, we report for the
first time that ketamine is an apparent dual Pgp/Bcrp substrate whose pharmacokinetic
and pharmacodynamic properties are affected by both Pgp and Bcrp.
Materials and Methods
Drugs and chemicals
Ketamine hydrochloride injection USP (100 mg/ml) was purchased from JHP
Pharmaceuticals (Rochester, MI), elacridar was purchased from Astatech Inc. (Bristol,
PA), Hydroxypropylmethylcellulose (HPMC) and Tween 80 were purchased from
Sigma-Aldrich (St Louis, MO), Promega Reporter Lysis buffer (5X), PierceTM BCA
protein assay reagent (A and B), bupropion, acetonitrile, formic acid and ammonium
hydroxide were purchased from Fisher Scientific (Pittsburgh, PA). 3H-ketamine was
obtained from American Radiolabeled Chemicals (St.Louis, MO).
Animals and cell lines
Wild-type (WT) and Bcrp/Pgp (Abcg2-Abcb1a) double-knockout (dKO) male
Sprague-Dawley rats, weighing 200 – 250 g, were obtained from SAGE® Labs (Horizon
Discovery – St Louis, MO). Male Bcrp (Abcg2) KO, Pgp (Abcb1a/b) KO, Pgp/Bcrp
(Abcb1a/1b/ Abcg2) double KO (dKO), and Wild-type Friend virus B (FVB) mice were
obtained from Taconic farms (Germantown, NY). Rats used in the experiments were 12
weeks old and mice were 10-16 weeks old. All animals were provided water and food ad
libitum. Ketamine hydrochloride stock solution (100 mg/ml) was diluted with filtered
autoclaved water to the appropriate dilution for dosing. Elacridar (10mg/ml) was
formulated by suspending elacridar in a solution of 0.5 % Hydroxypropylmethylcellulose
(HPMC) with 1% Tween 80. A 1.5 inch 20 GA feeding needle (Fisher Scientific Co.,
Pittsburgh, PA) was used to perform oral dosing. The Institutional Animal Care and Use
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Committee of St. Jude Children’s Research Hospital in accordance with the U.S. National
Institutes of Health guidelines approved all experimental procedures.
MDCKII parental cells and derivative cells stably overexpressing both human
PGP and BCRP were kindly provided by Dr. Alfred H. Schinkel’s lab (The Netherlands
Cancer Institute, Amsterdam) and cultured as described [262].
Drug formulations for animal experiments
Ketamine hydrochloride stock solution (100 mg/ml) was diluted with filtered
autoclaved water to appropriate dilution for oral (PO) or intraperitoneal (IP) dosing.
Elacridar (solution) formulation was prepared by suspending the appropriate amount of
elacridar in 0.5 % Hydroxypropylmethylcellulose (HPMC) with 1% Tween 80 solution to
achieve a final concentration of 10 mg/ml.
Estimation of ketamine exposure in rat CSF and plasma
Male WT and Pgp/Bcrp dKO rats (n= 8 per group) were anesthetized with
intraperitoneal ketamine (100 mg/kg) and xylazine (10 mg/kg) formulated in water, at a
dose volume of 10 ml/ kg of body weight. Cerebrospinal fluid (CSF) was collected from
the cisterna magna immediately after the anesthesia was achieved (~7 minutes), followed
by blood collection by cardiac puncture. Blood samples were centrifuged and plasma
separated from the blood. Both plasma and CSF samples were immediately frozen on dry
ice, stored at -80 0C, and shipped to Metabolon® (Research Triangle Park, NC) for
metabolomic analysis. LC-MS/MS sample analysis, data normalization and analysis were
performed at Metabolon® as described in other reports [186]. Normalized ketamine peak
area intensity values were compared between the WT and dKO rats in both CSF and
Plasma.
Pharmacokinetic study of ketamine in WT, Bcrp KO, Pgp KO and dKO mice after
oral and intraperitoneal dosing at 100 mg/kg
A serum pharmacokinetic study was conducted following ketamine
intraperitoneal and oral dosing (IP and PO PK) of WT, Bcrp KO, Pgp KO and dKO mice
at 100 mg/kg dose of ketamine. For IP PK, six mice from each genotype were divided
into two groups of three mice each. After the animals were dosed IP, blood was collected
from one group of mice at 2, 10 and 40 minutes, and from another group of mice at 5, 20
and 60 minutes. At each time point, 50 µL blood was withdrawn from each mouse from
the saphenous vein into microvette capillary blood collection tubes (Sarstedt, obtained
from Fisher Scientific, Pittsburgh, PA). Samples were kept at room temperature and were
centrifuged at 10,000 rpm for 5 minutes to obtain serum, which was immediately
separated and stored at -80°C until further analysis. For the PO PK study, six mice from
each genotype were separated into two groups (three mice in each group) and after oral

68

dosing blood samples were collected at alternative time points from each group similar to
the IP study. After a two-week washout period, the same oral study was repeated by
altering the groups and time points such that all time-points were collected from each
mouse. The two PO PK data sets were first analyzed separately and compared to identify
any significant inter-day variation, and, after confirming no inter-day difference in PK
profile, the data from the two collection dates were merged to obtain complete PK
profiles for each mouse.
Determination of ketamine concentration in mouse serum by HPLC/UV
Serum samples from the intraperitoneal ketamine PK studies in mice were treated
with chilled acetonitrile (1:5); samples were vortexed and centrifuged for 15 minutes at
4000 rpm to precipitate the protein and extract ketamine. After centrifugation, the
supernatant was collected and further centrifuged for sample cleaning. The resultant final
supernatant was then diluted 1:1 with water: acetonitrile (1:1) and a 10 µL sample was
injected onto the HPLC for further analysis. For PO PK, a 1:2.5 initial dilution with
chilled acetonitrile was used, followed by centrifugation and protein precipitation and recentrifugation of the supernatant for sample cleaning. The final supernatant was injected
onto the HPLC system (Shimadzu Prominence, Kyoto, Japan) consisting of a LC-20AD
binary high pressure gradient pump, SIL-20ACHT auto sampler, and SPD-20AV UVdetector. Bupropion (100 µg/mL) was added as an internal standard to all the samples
prior to extraction and was extracted along with ketamine. Chromatographic separation of
ketamine along with the internal standard was achieved using Hypersil ODS C18 column
(150X4 mm; 5 µm particle size) fitted with Hypersil ODS (C18) Javelin Guard Column
(10X4 mm; 5 µm particle size) and a gradient elution method with a run time of 10
minutes. The mobile phase for elution was 60:40 ammonium formate buffer (20 mM):
acetonitrile [263] and the gradient used was: 0 to 3 minutes 40% acetonitrile, 3 to 8
minutes 60% acetonitrile, 8 to 9 minutes 40% acetonitrile, and the run stopped at 10
minutes. Retention times for ketamine and bupropion were 5.2 and 7.1 minutes,
respectively. The ketamine peak was identified and absorbance was measured at 210 nm
[264]. Analyte/IS height ratio was used for preparation of calibration and measurement of
unknown concentrations. Extraction efficiency was >90% throughout the analysis. The
calibration range for IP PK and PO PK analysis were 0.39 µg/ml-200 µg/ml and 0.19
µg/ml-100 µg/ml, respectively.
Measurement of ketamine brain/serum ratio following IP ketamine
Male FVB WT, Pgp KO and Pgp/Bcrp dKO mice were dosed with IP ketamine
(100 mg/kg) + 1 µCi 3H-ketamine tracer 1 hr before and again 15 min before sacrifice.
Mice were euthanized by CO2 inhalation, blood was collected and serum separated, and
brain tissue was weighed and mixed with an equivalent volume of phosphate buffer
saline (PBS) and homogenized. Brain homogenate and serum were mixed with
scintillation fluid and total radioactivity determined by liquid scintillation counting. The
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H-ketamine brain-to-serum ratio is dpm/gram brain tissue homogenate divided by
dpm/ml of serum.
In another similar study, FVB male mice (WT, Pgp KO and Pgp/Bcrp dKO) were
sacrificed 15 minutes after dosing 100 mg/kg ketamine intraperitoneally. Brain and blood
were collected from each mouse after sacrifice. Brain tissues were weighed,
homogenized with 20 mM ammonium formate buffer, and 9 µL brain tissue homogenate
+ 1 µL IS was extracted using chilled acetonitrile. Supernate from the extracted samples
were mixed with equal volume of acetonitrile/water (1:1) and injected in HPLC-UV for
measurement of ketamine against standards prepared similarly from untreated mouse
brain homogenate. Serum was separated from blood samples and ketamine concentration
was measured by HPLC-UV based method as described previously. Brain/ serum ratio
was obtained by dividing weight normalized brain tissue concentration with the serum
concentration of ketamine.
Pharmacokinetic data analysis and interpretation
Non-compartment analysis. Initial analysis of both IP and PO PK study data
was performed by a non-compartment approach using PK package on R statistical
software [265] to determine whether there were significant differences in ketamine serum
exposure between WT and Bcrp KO, Pgp KO and dKO mice. A serial sacrifice design
was assumed to compute the area under time – concentration curve extrapolated to
infinity (AUCinf) and the associated variability as described [265].
Nonlinear mixed effect modeling. Upon identification of significant exposure
difference between genotypes in the PO PK study by non-compartment analysis, the PO
and IP PK data were combined and analyzed with nonlinear mixed effect modeling
implemented in Monolix 4.3.3 (Lixoft, France) using a stochastic approximation
expectation maximization algorithm [266] combined with a Markov chain Monte Carlo
procedure. Population analysis of our PK data did not find any difference in ketamine
serum PK between WT and Bcrp KO mice and thus, these two genotypes were combined
in the final model. Out of 144 data points in the PO PK study, there were four
concentrations that were below the lowest calibration standard concentration (0.19
µg/mL) and these were removed from the analysis. One- and two-compartment models
were evaluated. The goodness-of-fit-criteria and minimization of Akaike information
criterion were used to select the base model. The effect of over-parameterization was also
assessed using the condition number and Bayesian information criterion. Covariate
analysis included the effect of genotype as a categorical covariate following an
exponential model. The effect of genotype on individual parameters was determined by a
forward addition process with a decrease in OFV ≥ 3.84 considered significant at p =
0.05 for one degree of freedom, based on x2 (chi-square) distribution. Variability in
observed data from the model predicted population mean data is considered to be due to
between-subject variability (BSV) and residual unexplained variability (RUV). The
following equation was used to describe BSV,
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Pi = θpop x exp (ηpop)
where, Pi ¬= PK parameter of the ith individual; θpop = population mean for P; η =
normally distributed between-subject random effect with a mean of zero and variance of
ω2. Constant, proportional and combined constant and proportional error models were
tested for RUV, and the final model used the proportional error model that follows the
following equation,
Yij = Ŷij + Yij *ε
where Yij = observed concentration of ith individual at time j; Ŷij = individual predicted
concentration and ε is the proportional error that is normally distributed with a mean of
zero and variance of σ2.
Diagnostic plots were used for the final assessment of the model. Correlation
between the observed and model predicted concentrations were evaluated and used as
screening criteria for model selection. Population weighted residuals or individual
weighted residuals were plotted against time and population or individual predicted
ketamine concentration. Normalized prediction distribution error plotted against time and
population predicted ketamine concentration was also evaluated for model
misspecification assessment. Apart from the diagnostic plots, final model selection also
included comparison of objective function values and variability associated with
parameter estimates.
Comparison of ketamine-induced duration of Loss of Righting Reflex (dLORR)
between WT, Bcrp KO, Pgp KO and dKO mice
Ketamine-induced dLORR was studied as described [267]. Briefly, animals were
administered ketamine (50, 100 or 200 mg/kg) intraperitoneally or by oral gavage, and
after four minutes waiting time (to reduce manual stimulation), mice were placed on their
back. Loss of righting reflex was defined to have taken place when the mouse could not
right itself for at least 20 seconds. The dLORR was then measured until the mouse woke
up spontaneously and the dLORR was compared between WT, Bcrp KO, Pgp KO and
dKO mice. In a separate study, WT mice were orally administered elacridar (ECD) (100
mg/kg) or vehicle 1.5 hours prior to IP administration of 50 or 100 mg/kg ketamine and
dLORR was measured as described above.
Intracellular uptake of radiolabeled ketamine in MDCKII cells overexpressing
human PGP and BCRP
Madine-Darby canine kidney II (MDCKII) cells +/- BCRP and PGP were plated
at 0.2*106 cells/ well in a 24 well plate. The next day media was removed and cells were
incubated with 3H-ketamine at 37°C. At the selected time points, cells were washed with
chilled PBS, incubated 1 hr with lysis buffer, cell lysates collected, and the intracellular
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concentration of 3H-ketamine and protein concentration determined. Protein
concentration was determined in the lysate by BCA protein assay. Results were expressed
as pmole of ketamine per milligram of protein lysate. First, we determined the time to
reach an equilibrium of intracellular uptake by incubating both WT and transfected cells
with 0.5 µM 3H-ketamine for one hour and measuring the intracellular radioactivity at 2,
5, 15, 30 and 45 minutes. In a separate assay, the concentration-dependent uptake of 3Hketamine up to the time of equilibrium was determined in MDCKII and BCRP-PGPMDCKII cells by incubating the cells with different concentrations of 3H-ketamine until
they reached equilibrium and then measuring intracellular concentration of 3H-ketamine.
The intracellular ketamine concentration was calculated and compared between the
MDCKII and BCRP-PGP-MDCKII cells.
Statistical analysis
GraphPad QuickCalcs was used to perform Grubb’s outlier test to remove outlier
data from the analysis. Statistical analysis of significance for CSF and plasma ketamine
exposure data in rats, all pharmacodynamic (dLORR) data, in vitro cell uptake study data,
and non-compartment analysis were performed in GraphPad Prism software version 5.02.
Ketamine’s CSF and plasma peak intensity in the dKO rats and WT rats was compared
using the unpaired t-test with Welch’s correction. All dLORR study data was analyzed
using Mann-Whitney U test. Intracellular uptake study results were analyzed using an
unpaired t-test. The non-compartment-determined AUCinf was analyzed using a one-way
ANOVA with Newman-Keuls Multiple Comparison Test. Significance for all analyses
was equal to p<0.05.
Results
Deletion of both Bcrp and Pgp results in greater ketamine exposure in the CSF and
plasma of dKO rats
We performed a metabolomic comparison analysis of the CSF and plasma from
WT and Bcrp-Pgp dKO rats anesthetized with a cocktail of ketamine-xylazine. A full
report of the metabolomics results will be published elsewhere. Ketamine levels
(measured by LC-MS/MS) were found to be significantly higher in the CSF (1.74 times)
and plasma (1.93 times) of dKO compared to WT rats (Figure 3-1). These results
suggested that ketamine might be a substrate of Bcrp and/or Pgp. The metabolomic
analysis did not identify the presence of xylazine in either the rat CSF or plasma from
either WT or Pgp/Bcrp KO rats.
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Figure 3-1.
rats

Elevated ketamine CSF and plasma levels in Pgp/Bcrp dKO vs. WT

Notes: Ketamine levels in male Sprague Dawley rats after IP administration of 100
mg/kg ketamine. Data is plotted as median LC-MS/MS peak intensity ± range
(n=8/genotype). The plasma and CSF median peak intensity in dKO rats was compared
to the corresponding median peak intensity from WT rats using the unpaired t-test with
Welch’s correction. * p<0.05
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Ketamine oral (PO) serum exposure is higher in mice lacking Bcrp and Pgp
To determine if Bcrp and Pgp can affect the PK of ketamine, we collected serum
following a 100 mg/ kg IP dosing to WT, Bcrp KO, Pgp KO, and dKO mice. Serum
concentrations of ketamine at the selected time points were found to be similar
betweenall four genotypes (Figure 3-2A). Ketamine serum exposure, as measured by
area under time – concentration curve (AUCinf) by a non-compartment analysis (NCA),
was also found to be similar between all the genotypes (Figure 3-2B).
Since Bcrp and Pgp have a higher impact on their substrates serum/ plasma
exposure after oral compared to IP dosing [268], we collected serum following a 100
mg/kg oral dose of ketamine in WT, Bcrp KO, Pgp KO and dKO mice. Ketamine serum
concentrations were significantly higher in the dKO mice compared to the WT mice
(Figure 3-2C). Ketamine serum exposures (AUCinf), calculated by the non-compartment
analysis method, were found to be significantly higher in dKO (1.96-fold) and Pgp KO
(1.52-fold) mice and slightly higher in Bcrp KO (1.20-fold) mice compared to the WT
mice (Figure 3-2D). Ketamine serum concentration at the 60 minute time point could be
detected in only two out of six WT mice, but in all of the Bcrp KO, Pgp KO and dKO
mice. Thus, the last time point for observed concentration is different between WT and
other knockout mice. Hence, AUCinf was used to compare the exposure between all
genotypes. Both Pgp KO as well as Bcrp KO showed higher concentrations of ketamine
than WT mice at earlier time points, indicating a possible alteration in absorption, and
possibly driving the observed difference in AUCinf with the WT mice. Detailed noncompartment analysis parameters for both IP and PO PK studies are listed in Table 3-1.
While the non-compartment analysis allowed comparison of concentration-time curve
properties, there was no assumption of the compartment, and no information about which
PK parameters could be causing the difference in AUCinf, although there was the
suggestion of an alteration in bioavailability because dividing the oral AUCinf by the IP
AUCinf gave an (F) for the mice that was greatest in the dKO (~27%) > Pgp KO (~24%)
> Bcrp KO (~17%) ~= WT (~14%).
Population pharmacokinetic analysis demonstrates an increase in ketamine oral
bioavailability in Pgp/Bcrp dKO and Pgp KO mice compared to WT and Bcrp KO
mice
To better understand the impact of Bcrp and Pgp mediated efflux on PK
properties of ketamine, we combined both PO and IP PK data in a simultaneous model
using a population pharmacokinetic approach. This model also assumed that
bioavailability after IP dosing was equal to one. The final model was a one-compartment
distribution with zero order absorption for PO and first-order absorption for the IP dosing
and first-order elimination from the central compartment (Figure 3-3). The one
compartment model was sufficient to describe these data (Figure 3-4, Figure 3-5 and
Figure 3-6). The final parameters of population analysis are shown in Table 3-2.
Transporter genotypes had no effect on clearance or volume of distribution. The small
difference in ketamine PK between Bcrp KO versus WT mice observed by non-
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Figure 3-2. Ketamine serum exposure in Pgp/Bcrp dKO mice is significantly
higher than in WT mice after oral dosing
Notes: (A) & (C): Mean ketamine plasma concentrations ± SE over time curves after IP
(n = 3/genotype) and oral (n=6/genotype) ketamine dosing, respectively of FVB WT, Pgp
KO, Bcrp KO and dKO mice. (B) & (D): Ketamine plasma AUCinf ± SE following IP and
oral dosing of FVB WT, Pgp KO, Bcrp KO and dKO mice. The AUC was calculated by
non-compartment analysis using the PK package on R. One way ANOVA with NewmanKeuls Multiple Comparison Test was used to compare AUCinf.. * p< 0.05, ** p< 0.01,
*** p< 0.001.
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Table 3-1.
Noncompartment analysis (NCA) parameters for ketamine IP and PO
PK at 100 mg/kg
Dosing
Route
IP PK
(100
mg/kg)

PO PK
(100
mg/kg)

Parameters
(units)
t1/2 (mins)
Tmax (mins)
Cmax
(µg/mL)
AUC inf
(µg*hr/mL)
t1/2 (mins)
Tmax (mins)
Cmax
(µg/mL)
AUC inf
(µg*hr/mL)

WT
22.93 ±
2.33
10.00
7.88 ±
1.38
296.61 ±
17.07

Bcrp KO
27.75 ±
6.45
5.00
8.60 ± 1.03
298.4 ±
38.43

17.86 ±
4.23
10.00
1.83 ±
0.52
43.91 ±
6.9

22.26 ±
4.07
10.00
1.82 ± 0.54
52.82 ±
*
3.92

Pgp KO
22.72 ±
3.78
10.00
7.90 ±
0.98
278.33 ±
29.1

Double
KO
21.89 ±
3.50
10.00
8.77 ±
1.08
315.15 ±
25.38

30.85 ±
9.54
10.00
2.0 ±
0.34
66.91 ±
***
7.86

26.56 ±
6.25
10.00
3.03 ±
*
0.87
85.93 ±
***
8.20

Notes: All pharmacokinetic parameters were calculated by noncompartment analysis
using PK package in R, with variability calculated using bootstrap t method.
AUCs are compared by one way ANOVA with Newman-Keuls multiple comparison test
to compare all the groups. The results in the table show the comparison between each
transporter genotype vs. WT. * p< 0.05, *** p<0.001.
Cmax of the dKO and WT is compared using Mann Whitney Test, * p < 0.0.5.
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Figure 3-3.

Schematic diagram of the final population model

Note: Ketamine one-compartmental distribution with zero order absorption for PO and
first-order absorption for the IP dosing and first-order elimination from the central
compartment
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Figure 3-4. Diagnostic plots – observed vs. population and individual predicted
ketamine concentrations
Notes: Observed ketamine concentration versus population predicted (A) and (B)
individual predicted ketamine concentration for the final ketamine population PK model.
The solid line represents the line of identity and the gray line represent the spline of the
model. The plots show that the spline is very close to the line of identity, which implies
that the final model was able to successfully predict the observed ketamine
concentrations in serum.
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Figure 3-5.

Diagnostic residual plots

Notes: (A) & (B) – population weighted residual (PWRES) vs. time and predicted
ketamine concentration, respectively. (C) & (D) – Individual weighted residual (IWRES)
vs. time and predicted concentration, respectively. The solid line represents the reference
line at zero and the gray line represents the spline of the model. The plots show there was
no systematic bias in the model over time or concentration range. Majority of the
population residuals were equally distributed around zero and within ± 2, which indicates
that the predicted data is within an acceptable range to the observed data.
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Figure 3-6.

Normalized prediction distribution error (NPDE) plots

Notes: (A) NPDE vs. time and predicted ketamine concentration, respectively. (B) NPDE
vs. time and predicted concentration, respectively. The solid line represents the reference
line at zero and the gray line represents the spline of the model. The plots show a lack of
model misspecification for the final model.
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Table 3-2.

Population PK parameter estimates

Parameters
(Units)
F_pop
θ_Pgp KO
θ_dKO
Tk0_pop (1/hr)
F2_pop
ka_pop (1/hr)
V1_pop (L/Kg)
CL_pop (L/hr/Kg)

Mean Parameter
Estimates
0.175
0.227
0.514
0.104
1 Fixed
19.1
9.32
20.2

S.E.
0.0072
0.062
0.062
0.0092
N.E.
1.6
0.35
0.72

ω_BSV
F
Tk0
F2
ka
V1
CL

0.0276
0.32
N.E.
0.091
0.0857
0.0781

0.077
0.077
N.E.
0.14
0.061
0.056

σ - RUV
Proportional

0.341

0.022

0.175

0.0072

0.22
0.293

0.011
0.015

F_ (WT and Bcrp
KO)
F_ (Pgp KO)
F_ (dKO)

p-Value
0.00028
< 1e-10

Notes: F – oral bioavailability; F_pop – Population mean oral bioavailability; θ_Pgp KO
and θ_dKO – estimated coefficient of the effect of categorical covariate Pgp KO and
dKO on the oral bioavailability; Tk0_pop – population mean oral zero order absorption
rate constant; F2_pop – population mean intraperitoneal bioavailability which was
assumed to be 1; ka_pop – population mean first order absorption rate constant for i.p
route; V1_pop – population mean volume of distribution; CL_pop – population mean
clearance; ω_BSV – between subject variability; σ - RUV – residual unexplained
variability; N.E. – not estimated
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compartment analysis was not observed with the population approach likely due to
variability in the result. However, both Pgp KO and dKO genotypes had a significant
impact on population bioavailability (p<0.001). Oral bioavailability (F) for the WT
population was 17.5%, which significantly increases to 22% in the Pgp KO mice, and
increases further to 29% in the dKO mice. Hence, altered ketamine PK were observed
following oral administration to mice lacking Pgp singly or in combination with Bcrp.
This difference translates to a difference in the post-hoc estimated AUC between these
groups.
Ketamine-induced duration of loss of righting reflex (dLORR) was significantly
increased in mice lacking Bcrp and Pgp
The difference in PO PK between WT and Bcrp and/or Pgp knockout mice, and
higher plasma and CSF abundance of ketamine in the dKO compared to WT rats led us to
investigate if ketamine pharmacodynamics are also affected by Bcrp and Pgp. We used
the ketamine-induced loss of righting reflex (LORR) model in the mouse to study the
effect of Bcrp and Pgp on ketamine pharmacodynamics. Following itraperitoneal
ketamine, the median dLORR in the dKO mice was longer than in WT (2.6-fold), Bcrp
KO (2.1-fold), and Pgp KO (1.3-fold) mice (Figure 3-7A and Table 3-3). In addition, the
median dLORR was 2-fold longer in the Pgp KO compared to the WT mice. These
results indicate that both Pgp and Bcrp influence ketamine pharmacodynamics as
measured by ketamine-induced dLORR.
To determine whether ketamine brain concentrations were different in the
transporter KO vs. WT mice we first administered IP ketamine and measured brain and
serum concentrations at 15 minutes after dosing (n=3 in each genotype group). Our
HPLC-UV analysis shows a median brain/serum ratio of 1.32 in all genotypes and there
is no significant difference in brain/serum ketamine concentration between genotypes (
Figure 3-8). To understand if the total concentration of ketamine and its metabolites are
higher in the knockout mice compared to WT mice, we performed a whole brain
homogenate 3H-ketamine radioactivity study. We administered IP the standard anesthetic
dose of ketamine (100 mg/kg) spiked with 3H-ketamine and measured the 3H-ketamine
brain/serum ratio at 1.25 hr. Brain/serum 3H-ketamine radioactivity ratio was not
significantly different between genotypes with a median ratio of 1.45 in all mice. This
result is similar to what we observed with the HPLC-UV analysis. Although there was a
measurable increase in the level of 3H-ketamine in the brains of Pgp and Pgp/Bcrp dKO
mice, the difference between genotypes did not reach statistical significance (
Figure 3-8), despite the remarkable impact of the transporters on ketamine’s
pharmacodynamic effect (Figure 3-7A), and the significant increase in CSF ketamine
(measured by LC-MS/MS) in Pgp/Bcrp dKO rats (Figure 3-1). Although Pgp KO vs
dKO brain 3H- ketamine radioactivity difference reached statistical significance, the
median dKO/ Pgp KO radioactivity ratio is 0.85, which could be due to differences in
metabolite concentration between these two genotypes or even variability associated with
analysis, dosing or other reasons.
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Figure 3-7. The duration of IP ketamine induced loss of righting reflex (dLORR)
significantly increases in mice with absent or inhibited Pgp and Bcrp
Notes: (A) Comparison of the duration of ketamine (100 mg/kg body weight, IP) induced
dLORR in WT, Bcrp KO, Pgp KO and dKO FVB mice. (B) The duration of ketamine
(50, 100 and 200 mg/kg body weight, intraperitoneal) induced LORR in WT mice with or
without 1.5 hr pretreatment with elacridar (ECD) (100 mg/ kg body weight). Results are
expressed as median dLORR ± range. Significance is calculated using Mann-Whitney
test. * p < 0.05, ** p< 0.01, *** p< 0.001
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Table 3-3.
Descriptive statistics of ketamine induced dLORR in male FVB mice
-/(WT, Bcrp , Pgp -/-, Bcrp-Pgp -/-)
dLORR Time
(minutes)
Minimum
25% Percentile
Median
75% Percentile
Maximum
Mean
Std. Deviation
Std. Error
Lower 95% CI of mean
Upper 95% CI of mean

WT
(n=12)
0.0
0.75
6.0
11.5
15.0
6.5
5.45
1.57
3.04
9.96

Bcrp KO
(n=12)
0.0
3.5
7.5
12.75
17.0
8.0
5.69
1.64
4.38
11.61

Pgp KO
(n=12)
0.0
8.0
12.0*
17.25
20.0
11.58
6.20
1.79
7.64
15.52

dKO
(n=11)
13.0
14.0
16.0***
19.0
22.0
16.73
3.13
0.94
14.62
18.83

Note: Significance is calculated using Mann-Whitney test by comparing the median
dLORR in each genotype with the median dLORR in the WT mice. * p < 0.05, *** p<
0.001. CI = Confidence interval
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Figure 3-8.
dKO mice

Ketamine brain/serum ratios in wild-type, PgpKO and Pgp/Bcrp-

Note: Brain ketamine in mice after IP dosing with ketamine (100 mg/kg) + 1 µCi
ketamine tracer. Results are expressed as median radioactivity (A, B) or brain/serum
radioactivity ratio ± range (C). Brain/serum concentration ratio (D) was measured by
HPLC-UV based method after single intraperitoneal dose of ketamine (100 mg/kg).
Significance is calculated using Mann-Whitney test. * p < 0.05, ** p< 0.01, *** p< 0.001
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Pharmacological inhibition of Bcrp and Pgp by elacridar increased IP ketamineinduced dLORR in WT mice
Since we observed altered PK and PD of ketamine in mice with genetic deletion
of Bcrp and/or Pgp, we investigated whether ketamine PD were also altered by
pharmacological inhibition of these efflux transporters by using elacridar as a dual
inhibitor of Bcrp and Pgp. Elacridar dosing and time schedules for pretreatment were
based on previous reports that clearly demonstrated loss of Bcrp and Pgp function at the
dose selected [269-271]. Wild-type mice were pretreated with vehicle or 100 mg/kg
elacridar and 1.5 hrs later ketamine was dosed IP at 50, 100 and 200 mg/kg (n=6 per dose
group) and duration of LORR measured. The results in WT mice of ketamine treatment
alone (Figure 3-7B, Table 3-4) demonstrated a dose-proportional increase in druginduced dLORR from 50 to 100 mg/kg, but a disproportionately longer increase in
dLORR at 200 mg/kg. Pretreatment with elacridar significantly increased dLORR in the
WT mice treated with either 50 or 100 mg/kg ketamine. Based on the exceedingly long
dLORR with 200 mg/kg ketamine alone, co-treatment at this dose with elacridar was not
attempted to avoid toxicity. These results show that inhibition of Bcrp and Pgp with the
dual inhibitor elacridar significantly increased ketamine-mediated dLORR in WT mice.
Ketamine-induced dLORR was significantly longer in dKO vs. WT mice after oral
dosing of 200 mg/kg ketamine
Because ketamine can be taken orally, we compared the effect of the drug
transporters on its pharmacodynamic effect following oral administration. Oral ketamine
(100 mg/kg) dosing was insufficient to cause a LORR in any of the mice (data not
shown) likely because the ketamine serum concentration was lower following oral vs. IP
dosing (four-fold lower in dKO mice and seven-fold lower in WT mice) (Table 3-1).
Following oral ketamine (200 mg/kg) treatment, WT mice were all awake within 4
minutes, while one of the dKO mice died and the others needed to be warmed to wake
them after 30 minutes, preventing further analysis of this dose (not shown).
Ketamine accumulation is lower in MDCKII cells transfected with human BCRP
and Pgp compared to WT MDCKII cells
The time course of 3H-ketamine cellular uptake was first compared between
MDCKII cells and MDCKII-PGP-BCRP cells stably expressing the human transporters
[262]. The 3H-ketamine cellular concentration was significantly greater in MDCKII
parental cells compared to cells expressing BCRP and PGP at all time points, but uptake
reached equilibrium by 20 minutes (Figure 3-9A). Likewise, the 3H-ketamine
intracellular concentration measured at 20 minutes was higher in the parental MDCKII
cells compared to the dual BCRP/Pgp expressing cells between 0.1 to 5 µM
concentrations but not at 10 µM concentration (Figure 3-9B). The data also indicated
that the magnitude of difference in intracellular 3H-ketamine was greater at lower
concentrations vs. higher concentrations between the MDCKII cells with and without
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Table 3-4.
Descriptive statistics of ketamine induced loss of righting reflex
(LORR) in male WT FVB mice with or without 100 mg/kg oral elacridar 1.5 hours
before intraperitoneal ketamine dosing
dLORR Time
(minutes)
Minimum
25% Percentile
Median
75% Percentile
Maximum
Mean
Std. Deviation
Std. Error
Lower 95% CI of mean
Upper 95% CI of mean

50
mg/kg
(n=6)
0.00
0.00
0.00
2.00
2.00
0.67
1.03
0.42
-0.42
1.75

50 mg/kg
+ ECD
(n=6)
1.00
2.50
3.50*
4.50
6.00
3.50
1.64
0.67
1.78
5.22

100
mg/kg
(n=5)
6.00
6.00
6.00
7.50
8.00
6.60
0.89
0.40
5.49
7.71

100 mg/kg
+ ECD
(n=5)
11.00
12.50
14.00*
17.00
18.00
14.60
2.61
1.17
11.36
17.84

200
mg/kg
(n=5)
33.00
33.00
34.00
42.50
44.00
37.00
5.15
2.30
30.61
43.39

Note: Significance is calculated using the Mann-Whitney test by comparing each ECD
treated ketamine dose group by their corresponding no ECD pretreatment group. * p <
0.05.
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Figure 3-9. 3H-ketamine uptake is lower in the MDCKII BCRP-PGP cells
compared to MDCKII WT cells
Notes: (A) Time dependent uptake of 3H-ketamine in WT and BCRP-PGP transfected
MDCKII cells. Ketamine’s intracellular concentration at each time point was compared
between the WT and BCRP-PGP cells using an unpaired t-test, ** p< 0.01. (B) 3Hketamine uptake in WT and BCRP-PGP transfected MDCKII cells at different ketamine
concentrations. The intracellular concentration of 3H-ketamine at each treatment was
compared between the WT and BCRP-PGP cells using an unpaired t-test, * p< 0.05, **
p< 0.01 and *** p< 0.001.
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drug transporters. In support of these findings, Keiser et al (2018) recently published
(while this manuscript was under review) in vitro studies showing that ketamine is a Pgp
substrate [98].
Discussion
Following the unexpected finding that the concentration of the anesthetic
ketamine was elevated in the CSF and plasma of Pgp-Bcrp dKO compared to wild-type
rats, this study was performed in mice to determine whether PK and PD of ketamine is
affected by these transporters, and thus, if ketamine is a possible dual substrate of these
transporters. We observed ketamine oral exposre increased in the following order: WT <
Bcrp KO < Pgp KO < dKO (Figure 3-2). Likewise, ketamine-induced dLORR was
significantly longer in the dKO > Pgp KO > Bcrp KO > WT mice (Figure 3-7). In
summary, absence of Pgp/Bcrp decreased IP ketamine-induced dLORR (Figure 3-7),
increased ketamine oral clearance (Figure 3-2D, Table 3-2), and inhibition of these
transporters by elacridar increased IP ketamine induced-dLORR in wild-type mice
(Figure 3-7B), demonstrating ketamine is an apparent substrate for both transporters, and
also indicating a possible drug-drug interaction of ketamine with clinical Bcrp-Pgp
inhibitors, such as elacridar.
There is mixed evidence in the literature that ketamine might interact with Pgp or
Bcrp. Ketamine was previously screened for inhibitory activity against BCRP and PGP
[272] using MDCKII cells stably transfected with human BCRP or MDR1 (PGP) and
found to not inhibit either transporter. However, high concentrations of cyclosporine
increased the dLORR in mice [261], which could be due cyclosporine’s ability to inhibit
ketamine metabolizing Cyps as well as Pgp and Bcrp. The finding that female vs. male
rats show a longer ketamine induced dLORR [273] might also reflect the fact that there is
significant sexual dimorphism in rodent Bcrp expression with males vs. females having
significantly higher levels of Bcrp in liver, intestine and kidney [215]. Co-administration
of morphine (a Pgp substrate) and ketamine increased ketamine’s brain concentration
[260], which would be consistent with the ketamine competing with morphine for Pgp
transport.
We used dLORR to compare the ketamine-induced anesthetic/hypnotic effect in
mice with different transporter genotypes as dLORR can be used to assign dosedependent pharmacodynamic effects [267]. Although we observed a significantly
increased IP ketamine induced dLORR in the dKO mice compared to WT, Bcrp KO and
Pgp KO mice (Figure 3-7A), we did not find a significant increase in serum PK after IP
ketamine dosing (Figure 3-2.A) in the transporter single and dKO mice. However, it is
not unprecedented for some Pgp substrates to not show systemic PK differences between
WT and Pgp KO mice following IP dosing (e.g., dasatinib) [268]. Although ketamine
levels were significantly higher in the plasma of Pgp/Bcrp dKO rats ~ 7 min after IP
dosing (Figure 3-1), we were unable to detect a significant difference in ketamine PK
following IP dosing of WT or single transporter KO mice (Figure 3-2A). This might
have resulted from several factors including inter-species variability in
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metabolism/transport and the difference in blood collection time after ketamine between
the two studies. PK parameters of ketamine in mice are not extensively reported in the
literature. From the concentration–time data reported [267] after a 200 mg/kg IP dose,
and [274] after a 10 mg/kg IP dose in mice, ketamine’s plasma half-life (t1/2) is
approximately 25 minutes, which is similar to the results obtained in our study (Table
3-2). The Cmax after IP dosing of 10 mg/kg ketamine was reported between 0.55 µg/ml
and 1 µg/ml [274, 275], while we observed a Cmax of 7.88 ± 1.38 µg/ml (Table 3-1) after
100 mg/kg IP dose of ketamine, which is within the dose linear range of the reported
data. Whereas, Sato et al., after 200 mg/kg IP ketamine dosing in C57Bl/6 mice, reported
a highest concentration of approximately 30 µg/mL at 10 minutes [267], indicating a
possible more than dose proportional increase in ketamine exposure beyond 100 mg/kg
dose. Although ketamine bioavailability in humans after oral dosing has been reported to
be between 7 and 20% [79, 255, 257], bioavailability after oral dosing in mice is not well
established. Assuming 100% bioavailability after IP dosing, bioavailability after oral
dosing in WT mice falls into the same range (F_Pop, Table S1) in our study to that
observed in humans.
We did not find a significant difference in ketamine brain/ plasma ratio between
the mice with different transporter genotypes (Figure 3-8), and the increase of CSF
concentrations in Pgp/Bcrp KO vs. WT rats can largely be explained by the increase in
plasma concentrations (Figure 3-1). These data suggest blood brain barrier Pgp/Bcrp do
not (or may not) impair ketamine brain concentration. So why are the effects of
Pgp/Bcrp on ketamine’s pharmacodynamics consistent following either IP or oral dosing,
mirrored by their dual inhibitor elacridar, and consistent with oral ketamine PK, but
inconsistent with ketamine’s brain concentration? There are several alternative reasons
for not finding a measurable effect of the transporters on ketamine brain concentration at
15 minutes (HPLC-UV) and 1.25 hr (radioactivity). First, most studies that have shown a
significant effect of Pgp/Bcrp on substrate brain concentrations in vivo have measured
drug brain levels 4-24 hrs after drug administration to allow brain accumulation and
hence maximize the difference in brain substrate concentration in the KO vs. WT mice.
However, because of ketamine’s rapid clearance rate (estimated t1/2= 25 min) (Table
3-1), brain concentrations would not be measureable hours after dosing. Second,
ketamine is a high permeability rapid clearance drug and the magnitude of effect of Pgp
and Bcrp is typically greater for substrates with poor apparent permeability coefficients
[31], so the magnitude of transporter effect on this type of substrate would be assumed to
be small. Indeed, terfenadine, another drug with high passive permeability that is a Pgp
substrate, showed no difference in brain uptake clearance, measured by in situ brain
perfusion, between WT and Pgp-KO mice [97]. Third, it was previously shown that i.v
administered ketamine shows significant regional differences in brain exposure (that are
thought to be pertinent to its effect on anesthesia) during loss of righting reflex in rats,
and the difference minimizes as the rats regained righting reflex [276], which might
explain its PD effect, but which would not be captured by measuring ketamine in total
brain homogenate (as we did in this study). Hence, it is possible that regional
concentration difference of ketamine could be driving its dLORR effect, and ketamine
plasma and total brain concentration may not be a good predictor of its PK/PD
relationship in the dLORR model. Fourth, we administered ketamine as the racemic
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mixture but it is entirely possible that the S- and R-ketamine enantiomers (that have
enantiomer specific pharmacology) might interact differently with the transporters
(beyond the scope of this paper). Finally, we think the striking effect of transporter
genotype on ketamine PD, but not systemic or total brain distribution, for brain acting
drugs like ketamine that have high passive permeability may, in fact point to the potential
for missing a Pgp or Bcrp effect if only the PK is measured and used to predict whether
these transporters would influence the drug’s CNS pharmacodynamic activity.
A population PK model was used for simultaneous analysis of IP and PO PK data
to enable estimation of fixed parameters and sources of variability. Assuming a 100%
bioavailability after IP dosing (F2 = 1, Table 3-2), population PO bioavailability in the
current study was estimated to be 17.5%, which is in accordance to the published reports
of ketamine bioavailability in humans after oral dosing. Population analysis of IP and PO
data together identified a change in oral bioavailability in the Pgp and dKO groups. The
mean population clearance for ketamine was found to be 20.2 L/hr/kg and volume of
distribution 9.32 L/kg, suggesting ketamine has very high clearance and volume of
distribution, which is in accordance with previously published results [253].
While our in vivo data clearly shows Pgp and Bcrp alter the POPK and dLORR of
ketamine, we wanted to know if the same is observed in vitro. Previously published
results show ketamine does not have any interaction with PGP, as substrate or inhibitor.
However, our data clearly indicates, in a dual BCRP and PGP transfected MDCKII cell
line, these transporters can effectively reduce ketamine uptake in MDCKII cells at low
ketamine concentration. We think both the selection of ketamine concentration and also
time of in vitro assay will have significant effect on the outcome. Also, our in vitro data
suggests that effect of these transporters will be significant at ketamine exposure lower
than 10 µM or 2.4 µg/ml. A higher clinical ketamine concentration is required for
anesthetic effect of ketamine, whereas, lower concentrations are useful for antidepressant
effect and also often achieved in the ketamine abusers. Thus, our data warrants a possible
drug-drug or food-drug interaction for antidepressant use of ketamine and in ketamine
abusers.
The finding that ketamine appears to be a dual Pgp/Bcrp substrate has a number
of important clinical implications. Ketamine is an anesthetic widely used in animal
studies as well as human pediatric settings where a short-acting rapid-onset anesthesia is
needed. Importantly, it was recently recognized that ketamine can elicit rapid-onset longacting anti-depressant activity. However, ketamine is also a significant drug of abuse,
particularly in Asian countries. Notably, reports have also appeared in the past few years
that chronic ketamine abusers develop serious lower urinary tract symptoms, voiding
problems, ulcerative cystitis, and significant damage to the urinary tract [252], although
there may be individual differences in vulnerability. Both Pgp and Bcrp are expressed in
human kidney at the proximal tubule epithelium where they move substrates into the
urine, and both transporters may be expressed in bladder urothelium [277] at the apical
epithelium. Given our findings that ketamine is an apparent Pgp/Bcrp substrate it is
tempting to speculate that BCRP genetic variation, particularly the BCRP Q141K allele
that leads to loss of functional BCRP protein and that has a high frequency in some
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populations [111] may influence susceptibility to ketamine-induced urinary tract damage.
Equally important is the potential for co-administered Pgp/Bcrp substrates or inhibitors to
affect both ketamine bioavailability and urinary tract damage. Indeed, our studies with
the dual Pgp/Bcrp inhibitor elacridar demonstrated that pharmacological inhibition of the
transporters can affect ketamine PK. Further, cyclosporine, a known Pgp/Bcrp as well as
Cyp inhibitor has similarly been shown to affect ketamine dLORR in mice [261]. Many
therapeutically used drugs and chemicals present in food are inhibitors of Bcrp and Pgp
[259]. Thus, our results suggest a potential interaction of ketamine with these Bcrp-Pgp
inhibitors. Moreover, the proposed use of ketamine as an antidepressant may require
dosing with other antidepressant drugs, some of which are known inhibitors of these
transporters [278].
We conclude that Bcrp and Pgp can affect the PK and PD of ketamine in mice.
Using a pharmacological inhibitor of Bcrp and Pgp function our data clearly demonstrate
DDI potential of ketamine with inhibitors of Bcrp and Pgp. Further studies should be
carried out to understand the impact of these transporters on ketamine PK, PD and DDI
potential in humans and whether persons with polymorphic Bcrp taking Pgp inhibitors
have an increased risk of ketamine-mediated toxicity.
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CHAPTER 4. PHEOPHORBIDE A: IN VIVO BCRP SUBSTRATE TO
IDENTIFY ORAL DRUG-DRUG INTERACTIONS
Introduction
The xenobiotic efflux transporter, breast cancer resistance protein (BCRP),
encoded by the ABCG2 gene, is an ATP-binding cassette (ABC) sub-family G member 2
half transporter that is well characterized for its effect on pharmacokinetics and
pharmacodynamics of multiple drugs [6]. BCRP was originally discovered and named by
Doyle et al. in breast cancer cell line (MCF7) conferring resistance to anthracycline
anticancer drugs [62]. Though originally named for its expression on breast cancer cells,
BCRP is expressed almost ubiquitously on the apical membrane of endothelial and/or
epithelial cells, where it limits tissue or organ permeability of its substrates [103, 104], as
well as on stem cells, where BCRP can provide some survival advantages [109, 129].
Expression of BCRP is now well-established in liver, kidney, intestine and blood-brain
and blood-CSF barriers [135, 279]. It has a significant effect on the bioavailability of its
substrates, administered orally, [177] as well as their brain permeability in mice lacking
Bcrp or in presence of Bcrp inhibitors [94]. Bcrp is also known to efflux its substrates
into milk at the mammary gland in rodents [280] and confer protection to the fetus at
placenta [281]. A wide variety of drugs such as antivirals, antibiotics, calcium channel
blockers and statins, as well as endogenous and dietary metabolites such as riboflavin,
folic acid, uric acid, protoporphyrin IX, pheophorbide A and estrone-3-sulfate are
substrates of Bcrp [6, 9, 54, 101, 124, 129]. Moreover, multiple clinically used drugs,
such as tyrosine kinase inhibitor lapatinib, HIV protease inhibitor ritonavir, calcium
channel blockers, immunosuppressant etc., are known inhibitors of this transporter [121].
Due to its wide range of substrate and inhibitor recognition, as well as significant
effect on the systemic distribution of its substrates, Bcrp is recognized by the FDA and
International Transporter Consortium (ITC) as an important transporter which is prone to
potential clinical drug-drug interactions (DDI) [1, 25, 31, 80, 208]. Except for
biopharmaceutical classification system class I (BCS class I, high solubility and high
permeability) compounds, BCRP substrates (victim) are prone to BCRP inhibitor
(perpetrator)-mediated DDI when they are dosed concomitantly, through the oral route
[1, 71]. It has also been recognized by FDA that the DDI liability related to BCRP needs
to be especially considered if the victim drug has potential toxicity concerns in
distributing tissues [1, 80]. Therefore, a better understanding of systemic inhibition of
BCRP is also required for substrates whose tissue distribution (such as in brain, kidney,
etc.) is controlled by the BCRP transporter.
While ITC and FDA have detailed the decision tree and guidelines for
determination of BCRP substrates, inhibitors and the possibility of clinical DDI [1, 25], it
has also been recognized that clinically used probe-substrates such as rosuvastatin and
sulfasalazine are not specific to BCRP [282-284]. Hence, multiple factors, such as
enzyme inhibition or inhibition of other transporters such as OATP1B1, can lead to
variability in the clinical observation of altered rosuvastatin / sulfasalazine disposition,
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thereby requiring careful consideration for better understanding of the results [71].
Moreover, due to lack of specificity of the clinical inhibitors of BCRP [71], as well as
expression of multiple transporters in the cell lines used for identification of BCRP
substrates and inhibitors [279, 285, 286], translation of in vitro observations to in vivo is
often challenging. In vivo assessment of Bcrp substrates have utilized transporter
knockout models or imaging techniques such as positron emission tomography (PET) and
gamma-scintigraphy which are known to have their own caveats [25]. Therefore, a
suitable assay for Bcrp activity, utilizing a specific and, if possible, same probe, both in
vitro and in vivo, that is also more economical and with potential high-throughput
capabilities, will be of immense value.
Pheophorbide A (PhA) is a breakdown product (catabolite) of chlorophyll and is a
specific dietary substrate of Bcrp [92, 287, 288], with an efflux ratio of 3.15 in cell lines
overexpressing Bcrp [289]. It is a low solubility, low permeability compound with no
reported metabolic instabilities. Therefore, PhA might be a potentially suitable candidate
as an in vitro as well as in vivo probe for investigating Bcrp function according to the
FDA and ITC guidelines [25] [1]. PhA is also a colored compound with absorption
maxima between 670 nm and 680 nm, and fluorescence emission maxima between 675
and 720 nm [290], with typical fluorescence spectra for in vitro studies being 400 nm
(excitation) and 670 nm (emission). However, a higher excitation (654 nm) and emission
(750 nm) has also been reported for PhA [291], indicating that PhA fluorescence can be
detected at the near infrared (NIR) region, thereby making it a suitable candidate for in
vivo fluorescence measurement in whole animals [292].
We therefore hypothesized that PhA can be utilized as an in vivo probe for
assessment of DDI associated with the inhibition of Bcrp at the gastro-intestinal tract
(GIT) in mice. We utilized a live animal fluorescence imaging technique, using PhA, to
screen for orally administrated BCRP inhibitors and predict intestinal BCRP-mediated
DDIs. Our results demonstrate that in vivo fluorescence imaging utilizing PhA can be
used for identification of BCRP inhibitors in order to assess BCRP-mediated clinical
DDIs.
Materials and Methods
Chemicals and reagents
The following chemicals and reagents were purchased: Pheophorbide A (Frontier
Scientific, Newark, DE, USA), lapatinib and curcumin (Cayman Chemicals, Ann Arbor,
MI, USA), elacridar (Astatech Inc., Bristol, PA, USA), pantoprazole (Santa Cruz
Biotech, Dallas, TX, USA), sorafenib and dasatinib (Chemietek, Indianapolis, IN, USA),
chlorophyll A and protoporphyrin IX (Sigma-Aldrich, St. Louis, MO).
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Animals
Wild type (WT) and Bcrp KO Friend Virus B (FVB) male mice (n = 4 each
group, 10 weeks old) were purchased from Taconic Biosciences, Inc. (Hudson, NY) for
the knockout mice study. For all other Bcrp inhibitor studies, control mice of FVB
background (n = 4 for control and each inhibitor treatment group) were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). All mice were fed either regular diet
(Purina catalog# 5013, Largo, FL) or alfalfa-free (AFF) diet (Purina, catalog# AIN-93G,
Largo, FL) for at least three days to reduce background auto-fluorescence, and they were
provided water ad libitum. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of St. Jude Children’s Research Hospital in
accordance with the U.S. National Institutes of Health guidelines.
Cell lines
Madin-Darby Canine Kidney (MDCKII) cells overexpressing human full length
wild type BCRP and the parenteral cell lines were kindly provided by Dr. Alfred
Schinkel and were cultured as described [293].
Determination of Pheophorbide A concentration in rodent food pellet
Six food pellets each from regular diet and AFF diet were weighed and soaked
with half parts of water. After 30 minutes, one gram of food pellet was mixed with 5 mL
methanol and stirred overnight for PhA extraction. The following day, samples were
centrifuged at 15000 g for 15 minutes and the supernatant collected. The supernatant was
further centrifuged, filtered and used for measurement of PhA using a modified HPLCFluorescence Detector (HPLC-RF)-based method published previously [294]. 40 µL of
the final supernatant was injected onto the HPLC system (Shimadzu Prominence, Kyoto,
Japan) consisting of a LC-20AB quaternary high pressure gradient pump, SIL-20ACHT
auto sampler and RF-10 AXL fluorescence-detector. Chromatographic separation of PhA
was achieved using Hypersil ODS C18 column (150X4 mm; 5 µm particle size) fitted
with Hypersil ODS (C18) Javelin Guard Column (10X4 mm; 5 µm particle size) and a
gradient elution method with a run time of 10 minutes. The mobile phase for elution was
80% methanol in 0.5M ammonium acetate (Phase A) and 100% methanol (Phase B) with
a gradient of: 0 to 2 minutes 60 to 95% methanol, 2 to 8 minutes 95% methanol, 8 to 9
minutes 95 to 60% methanol, and the run stopped at 10 minutes. Retention time for PhA
was 3.5 minutes. The PhA peak was identified and fluorescence was measured at 400
(Ex) and 670 (Em) nm. Analyte area was used for calibration and measurement of
unknown concentrations against a known PhA concentration prepared in mobile phase A.
The calibration range was 0.02 µM to 10 µM.
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Treatments
Mice were kept on AFF diet for at least three days to reduce the background
autofluorescence. WT and Bcrp KO mice (10 weeks, n = 4/group) were administrated
PhA (10 mg/kg) by oral gavage, and imaging or blood collection was performed at
appropriate time points up to 6 hrs after dosing. For the inhibitor study, oral doses of the
inhibitors were selected based on clinical relevance or previously demonstrated effects
(Table 1) and formulated for oral dosing by suspending an appropriate amount of the
compound in 0.5% hydroxypropyl-methyl- cellulose (HPMC) and 1% Tween 80 (Sigma,
St. Louis, MO). Bcrp inhibitors elacridar (ECD) (100 mg/kg), lapatinib (LPB) (90
mg/kg), dasatinib (DSB) (10 mg/kg), sorafenib (SFB) (40 mg/kg), curcumin (CCM) (300
mg/kg) and pantoprazole (PPZ) (40 mg/kg) were administrated orally, one hour prior to
oral dosing of PhA. Imaging and blood collection was performed at appropriate times up
to 6 hours after PhA dosing. All animals were fasted up to 6 hours after PhA dosing.
In vivo fluorescence imaging
Mice were anesthetized by isoflurane anesthesia (2%, inhalation) and placed
ventrally in the chamber of Xenogen IVIS 200 (PerkinElmer, USA) imaging system.
Fluorescence images were obtained under anesthesia with a fixed exposure time of one
second and NIR filter setting of 675 nm excitation and 840 nm emission. Mice were
repetitively imaged at 0, 1, 2, 3, 4 and 6 hours after PhA administration. Images were
scaled to a maximum intensity of 1 × 108 photons/s/cm2/sr for visualization. All images
were analyzed with Living Image® v4.5 (PerkinElmer, USA) to obtain the fluorescence
intensity in the selected region of interest (ROI) of fluorescence (flux/sec), which was
selected as a fixed rectangular area around each mouse. For the control and inhibitor
treatment groups, ROI (flux/sec) for each mouse was normalized by its flux measured at
0 hr. For the WT and Bcrp KO mice, ROI of the WT mice at 0 hour was used for
normalizing all fluorescence (ROI) data. Normalized ROI data was used for calculation
of AUCFL 0-6hr¬ in GraphPad Prism v 5.02.
Pharmacokinetic study of PhA
Immediately after the imaging, as mice came out of anesthesia, 50 µL of blood
samples were collected by saphenous vein into a microvette capillary blood collection
tubes (Sarstedt, obtained from Fisher Scientific, Pittsburgh, PA) and serum was separated
by centrifuging the samples at 5000 rpm for 10 min. Blood samples were collected at 1,
2, 4 and 6 hrs for measurement of PhA concentration in serum.
Measurement of PhA concentration in whole serum
A fluorescence-based method was used to measure PhA concentration in whole
serum. A calibration of known PhA concentrations was prepared by spiking known PhA
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concentrations prepared in DMSO into 24 µL of blank serum, collected from mice on
AFF diet. 25 µL of standard serum concentrations and serum samples collected for the
study were diluted to 100 µL with distilled water in a 96 well clear bottom black
polystyrene plate (Cat# 3603, Corning, NY, USA). PhA fluorescence was measured at
400 nm (Ex) and 670 nm (Em) on a Synergy H4 Hybrid Reader (BioTek, Winooski, VT,
USA). All fluorescence values were blank-corrected and unknown sample PhA
concentrations were interpolated from a freshly prepared PhA standard curve (0.02 µM to
10 µM) and the PhA concentration for each mouse was used to measure AUCSerum 0-6hr¬
in GraphPad Prism v 5.02.
Ex vivo fluorescence imaging of mouse intestine
After in vivo imaging, mice were immediately euthanized and blood was collected
by cardiac puncture. The small intestine was dissected out and fluorescence (675 nm
excitation and 840 nm emission) images were obtained before and after flushing out of
intestinal contents with PBS (5 ml, three times). Fluorescence images were obtained
using one second exposure with a filter setting for near infrared. Images were scaled to a
maximum intensity of 1 × 108 photons/s/cm2/sr.
Fluorescence microscopy of intestinal sections
Intestinal segments of WT and Bcrp KO mice on a regular diet were washed with
cold PBS and filled with warm 3% agarose. Paraffin blocks were prepared from agarose
filled intestines, which were precision-cut for preparing slides for fluorescence
microscope imaging (Nikon ECLIPSE Ti)
In vitro assay for measuring IC50 of Bcrp inhibitors
A 96 well plate-based assay utilizing control and BCRP overexpressing MadinDerby Canine Kidney (MDCKII) cells [295], was used for measuring the IC50 of
selected BCRP inhibitor drugs using PhA as a probe BCRP substrate [288]. Briefly,
1*10^4 cells/ well were plated in a 96 well plate and incubated at 37°C till the cells were
at least 80 - 90% confluent. On the day of the experiment, media was removed, cells were
washed with PBS and incubated for 30 min with or without BCRP inhibitors prepared in
100 µL of modified Krebs Ringer buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2,
1.2 mM NaH2PO4, 2.5 mM CaCl2, 2.5 mM NaHCO3 and 10 mM Glucose) [296]. After
incubation with inhibitors, media was removed and cells were incubated with 1 µM PhA
with or without the inhibitor prepared in 100 µL Krebs-Ringer buffer for 2 hrs.
Fumitremorgin C (FTC) at a concentration of 5 µM was used as a standard BCRP
inhibitor. After 2 hrs, cells were washed with chilled Dulbecco’s phosphate buffer saline
(DPBS) twice, 100 µL DPBS added, and fluorescence measured on Synergy H4 Hybrid
Reader at 400 nm (Ex) and 670 nm (Em). Immediately after fluorescence measurement,
100 µL Promega CellTiter-Glo® reagent (Fisher Scientific, Lenexa, KS, USA), was
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added to each well, incubated at 37°C for 5 minutes, and luminescence measured. To
calculate the cell number/well 120000 MDCKII control and BCRP overexpressing cells
were plated per well and diluted with cell culture media 1:1 up to 937 cells/well (n=6
each dilution each cell type), incubated at 37°C for 6 hours for the cells to attach. After 6
hrs, cells are washed with chilled DPBS, after which 100 µL DPBS and CellTiter-Glo ®
reagent at room temperature was added to the cells, incubated for 5 min at 37°C and
luminescence measured. First, the results were background-corrected, normalized with
cell number in each well to calculate PhA fluorescence/ 10^3 cells/ well. Fold change of
PhA accumulation in MDCKII cells in presence of BCRP was calculated by dividing
MDCKII-BCRP fluorescence/cell with that of MDCKII. The % inhibition by BCRP
inhibitors was calculated by the following equation:
% Inhibition =

(Fluorescence Inhibitor – Fluorescence no inhibitor)
(Fluorescence FTC – Fluorescence no inhibitor)

*100

IC50 values of the inhibitors were calculated using GraphPad prism v5.02. All
assays were run at least three times with n = 6 wells per inhibitor or standard inhibitor
concentration in each assay. Results of all experiments were combined (n=18) to
calculate final parameters.
Statistical analysis
All serum PhA concentration–time data were plotted as mean PhA concentration
± SEM and similarly, the whole-body fluorescence data over zero-hour of each individual
mouse (for the inhibitor study), or over WT mice zero-hour fluorescence (for Bcrp KO
study), were plotted as mean ratio ± SEM. GraphPad Prism v5.02 was used to calculate
the area under the concentration – time or fluorescence (flux/sec) ratio – time curve for
individual mice up to 6 hours (AUCSerum 0-6h or AUCFL 0-6h). Mean AUC±SEM are plotted
and compared with the control or WT using the unpaired t-test, significance is calculated
at p<0.05. All calculations were done on GraphPad Prism v5.02.
Results
Bcrp KO mice on a regular diet have higher whole-body fluorescence, arising from
PhA, than WT mice
It has been previously reported that whole body autofluorescence during live mice
imaging can be reduced by feeding the mice alfalfa free (AFF) diet, and also by choosing
an excitation wavelength at the near infrared region (NIR, 700 nm to 1 mm) of light [297,
298]. To determine differences in autofluorescence, we imaged both WT and Bcrp KO
mice and found a higher whole-body autofluorescence in the Bcrp KO compared to the
WT mice, when the mice were fed a regular diet (Figure 4-1A). Alfalfa is known to be a
source of chlorophyll, and its catabolite pheophorbide A (PhA), which is a known BCRP
substrate and has fluorescence excitation and emission in the NIR region. Therefore, to
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Figure 4-1. Autofluorescence derived from dietary PhA is higher in the Bcrp KO
compared to WT mice
Note: Comparison of fluorescence (Ex675/Em840) in WT and Bcrp KO mice fed a
regular diet or AFF diet at least for three days (A). Comparison of fluorescence
(Ex675/Em840) in a regular and AFF diet (B). Fluorescence comparison of known
concentrations of chlorophyll a (CLPa), PhA and a prototypical Bcrp substrate
protoporphyrin IX (PPIX) fluorescence with filter setting (Ex675/Em840) (C).

99

determine the contribution of PhA to the observed autofluorescence, we imaged both WT
and Bcrp KO mice after feeding them an alfalfa free (AFF) diet. We observed a total loss
of whole-body autofluorescence in both WT and Bcrp KO mice (Figure 4-1A). To
confirm if diet was the source of the observed fluorescence, using the same imaging
parameters, we compared the regular and AFF diet pellets and observed fluorescence
only from the regular food pellets (Figure 4-1B). To further confirm the source of
fluorescence as dietary PhA, we compared PhA, chlorophyll a (CLPa) and another
fluorescent Bcrp endogenous substrate protoporphyrin IX (PPIX) at a concentration range
of 0.31 to 10 μM, at the same fluorescence setting (excitation at 670 nm and emission at
840 nm). We found that only PhA can be detected at 0.31μM, which is almost 10-fold
lower than the lowest detectable concentration of CLPa (2.5 μM), and that PhA had a
higher fluorescent intensity then CLPa at each concentration (Figure 4-1C).
Pheophorbide A is present in regular mouse diet, but not in AFF diet
To further verify that the source of fluorescence from regular diet is PhA, and that
its absence reduces whole-body fluorescence in mice, we analyzed the amount of PhA in
mouse food pellets using an HPLC-RF- based method (Figure 4-2). We observed that
PhA is present only in the standard (Figure 4-2A) and the regular food pellet extract
(Figure 4-2B), but not in the AFF pellet extract (Figure 4-2C). Using a calibration of
known concentrations of PhA, we found the PhA concentration in the regular diet to be
1.71 µg/gm of food pellet. Assuming daily food intake for a 30 gm mouse is 6 gms, it can
be estimated that a mouse on a regular diet consumes 343 µg PhA/kg body weight daily.
Bcrp gene deletion leads to higher absorption of PhA in mouse enterocytes
During in vivo live animal imaging, we observed the maximum fluorescence in
the intestinal region of Bcrp KO mice (Figure 4-1A). This was unanticipated since we
expected a higher level of PhA absorbance in the Bcrp KO mice. Therefore, to determine
if this fluorescence was due to trapping of PhA in the intestinal enterocytes we analyzed
the localization of fluorescence in WT and Bcrp KO mice fed a regular diet, by ex vivo
imaging of isolated intestine (Figure 4-3A) and fluorescence microscopy of intestinal
sections (Figure 4-3B). A high fluorescence intensity was observed in the upper
intestinal segment of both WT and Bcrp KO mice (data not shown). But after washing
and removal of food contents, the upper intestinal segment of Bcrp KO mice displayed
considerably higher fluorescence, compared to that in WT mice (Figure 4-3A).
Fluorescence microscopy of transverse sections of a paraffin fixed intestinal segment
showed higher fluorescence in the enterocytes of the Bcrp KO mice, compared to the WT
(Figure 4-3B), confirming that the absence of Bcrp at the enterocytes may lead to higher
PhA absorption in the Bcrp KO mice fed a regular diet.
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Figure 4-2.

PhA is present in the regular mouse diet not in the AFF diet

Notes: Representative HPLC-RF run profile of 2.5 μM known concentration of PhA (A),
methanol extract from regular rodent diet (B), and the alfalfa free (AFF) defined diet (C).
PhA peak or peak position is indicated in each graph.

101

Figure 4-3.

Absence of Bcrp leads to higher absorption of PhA in enterocytes

Notes: Ex vivo image comparison of intestinal segments of WT and Bcrp KO mice on a
regular diet, after flushing out the gut contents with saline (A). Microscopic examination
of cross-sectional images of upper intestine from WT and Bcrp KO mice on regular diet;
blue is Dapi stain for nuclear localization) and red is Pheophorbide A using the Cyanine5
Ex/Em wavelengths (B).
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Oral absorption of PhA is greater in Bcrp KO mice treated with exogenous PhA
To eliminate background fluorescence and increase the uniformity and amount of
PhA exposure, WT and Bcrp KO mice were fed an AFF diet for 3 days, then
administered PhA orally at a dose of 10 mg/kg and fasted for 6 hrs. Representative
images at 2 hrs after PhA dosing displayed significantly greater whole-body fluorescence
in the Bcrp KO compared to WT mice, as shown in Figure 4-4A. The whole-body
fluorescence at different time-points, normalized to the fluorescence in WT mice at
baseline, when plotted against time after dosing, exhibited significantly higher
fluorescence in Bcrp KO mice across all observed time points (1, 2, 4 and 6 hrs) (Figure
4-4B). Quantification of the area under fluorescence ratio time curve up to 6 hrs (AUCFL
0-6h) showed a significant increase (3.5-fold) in fluorescence in the Bcrp KO compared to
WT mice (Figure 4-4C). We also measured the serum concentration of PhA in the same
experiment at 1, 2, 4 and 6 hrs. The serum concentration of PhA in the Bcrp KO mice
was also found to be significantly higher across all observed time points compared to WT
mice (Figure 4-4D) with a 50 fold increase in area under concentration-time curve
calculated up to 6 hrs (AUCSerum 0-6h) (Figure 4-4E). These results, showing a
significantly higher fold increase of PhA fluorescence, both whole-body and serum, in
Bcrp KO mice compared to WT, suggest that orally administered PhA can be utilized to
capture a range of inhibition by Bcrp inhibitors, and thereby identify Bcrp-mediated
drug-drug interactions (DDIs) in mice.
Selected Bcrp inhibitors exhibited comparable in vitro IC50 values with PhA as
reported previously
To further test our hypothesis that PhA can be used as an in vivo probe for
identification of intestinal Bcrp-mediated DDIs, we selected known Bcrp inhibitors as per
FDA guidance based on their [(Clinical dose/250 ml)/IC50 or Igut/IC50] (Table 4-1),
where Igut is the maximum human dose in the apparent human gut fluid volume of 250
ml. While IC50 values of the selected inhibitors (except dasatinib) were reported in the
literature, a wide variety of Bcrp probe substrates as well as cell lines were used for these
IC50 measurements. Using PhA as a BCRP probe substrate, we used MDCKII-BCRP
cell-based assays to determine the IC50 of the selected BCRP inhibitors (Figure 4-5).
Lapatinib (LPB) was found to be the strongest BCRP inhibitor with a measured IC50 of
40 nM, followed by elacridar (ECD) (0.21 µM), sorafenib (SFB) (2.18 µM), curcumin
(CCM) (2.58 µM), pantoprazole (PPZ) (11.19 µM) and dasatinib (DSB) (22.76 µM). The
IC50 of these inhibitors were found to be similar to those reported in the literature using
different BCRP probe substrates (Table 4-1), except for PPZ, for which the observed
IC50 was 2-fold higher than the reported IC50 (5.5 µM). Assuming a 0.8 mL mouse
stomach volume, Cgut/IC50 was ≥ 10 for all the inhibitors (Table 4-1), indicating a
possible drug-drug interaction observation with orally dosed BCRP substrates in mice,
where, Cgut is the selected inhibitor dose/0.8 mL.
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Figure 4-4.

PhA oral absorption is significantly higher in the Bcrp KO mice

Notes: Representative image comparing of PhA fluorescence (Ex675/Em840) in WT and
Bcrp KO mice, 2 hrs after oral administration of 10 mg/kg PhA (A). Fluorescence
intensity over zero- hour WT fluorescence-time profile up to 6 hours following 10 mg/kg
of PhA oral administration in Bcrp WT and KO mice (n=3) (B). Comparison of Area
under the fluorescence ratio time curve up to 6 hrs (AUCFL 0-6h) in Figure B calculated
using GraphPad Prism v5.02 (C). Comparison of PhA serum concentration at 1, 2,4 and 6
hrs from the WT and Bcrp KO mice dosed 10 mg/kg PhA (D) and the associated
AUCSerum 0-6h (E). Results are presented as means ± SEM; and significance is calculated at
p < 0.05 by comparing the means with unpaired t-test. *** P < 0.001.
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Table 4-1.
Results of all in vitro, in vivo experiments and literature data-based
comparisons
Details
Known
parameters from
literature and
database

Clinical
information

Parameters (Units)
Mol. Wt. (gm/mol)
Pred. Sol. (µM)
(DrugBank)
Pred. logP
(DrugBank)
Reported IC50 (µM)

DSB
488.01
26.23

SFB
464.83
3.68

PPZ
383.37
1291.18

ECD
563.65
4.99

CCM
368.38
15.61

LPB
581.06
38.38

2.77

4.12

2.11

6.81

3.62

5.18

3.11

5.52

0.313

1.64

0.0255

40 mg
SD 6
6.5 6
67 6
1.2 6
Yes

400 mg
BID 6
0.327 6
9200 6
1.1 6
Yes

2 gm
SD 6

1250 QD

No

400 mg
BID
6.45 7
1110
2.08
Yes

10
~ 0.7 10
0.25- 2

40
21 1
19

40

Dose (mg)
Cmax (µM)
Igut/IC50
Cmax/IC50
Possible DDI

6

Yes

4.2 6
210000 6
170 6
Yes

100
0.78 8
8
20

300
~0.06 12
1.5
12

90
~ 10 11
0.5-1
3

2.52
0.02
300

0.04
250
90

14000

6

PK information
from mice

Dose (mg/kg)
Cmax (µM)
Tmax (Hr)
t1/2 (Hr)

Prediction of
possible outcome
in mouse based on
selected dose and
observed IC50

Observed IC50 (µM)
Cmax/ IC50
Oral Dose for mice
study (mg/kg)
Cgut (µM)
Cgut/ IC50
Cgut_soluble/ IC50
Expected Oral DDI

22.76
0.03
10

2.18
9.63
40

11.19
40

0.21
3.71
100

639
28
1.2
No

2689
1233
1.7
May be

3260
291
115.4
Possible

5544
26400
23.7
Yes

25449
10098
6.2
Yes

4840
121000
959.5
Yes

In vivo serum
concentration
result

AUCSerum 0-6h
(µM*Hr)
Fold Change over
control
Observed DDI?

0.11 ±
0.002
1.24

0.13 ±
0.02
1.45

0.18 ±
0.01
2.02

0.46 ±
0.08
5.17

0.70 ±
0.1
7.79

1.24 ±
0.09
13.78

No

May be

Yes

Yes

Yes

Yes

AUCFL 0-6h

5.82 ±
1.27
1.2

6.98 ±
1.15
1.44

4.07 ±
0.71
0.84

10.55 ±
2.12
2.17

11.2 ±
1.75
2.31

11.66 ±
1.54
2.4

No

May be

No

Yes

Yes

Yes

Live animal
fluorescence
result

Fold Change over
control
Observed DDI?

Notes: Mol. Wt. = molecular weight; Pred. Sol = Predicted aqueous solubility; Igut = Clinical
dose / 250 mL; Cgut = mouse dose / 0.8 mL (mouse gut fluid volume); Cgut_soluble = Pred.
Solubility
1
12

[166]; 2 [309]; 3[310]; 4[259]; 5[134]; 6[71]; 7[305]; 8[269]; 9[94]; 10[308]; 11[311];

[312]
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Figure 4-5. Determination of IC50 for selected Bcrp inhibitors using PhA as a
probe substrate
Notes: Mean % increase in Pheophorbide A accumulation ± SEM in the MDCKII cells
overexpressing BCRP in presence of selected Bcrp inhibitors was plotted against log
transformed inhibitor concentration. IC50 was determined using GraphPad Prism v5.02.
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Bcrp inhibitors increase whole body and serum fluorescence of PhA
Based on reported literature, the selected drugs were expected to cause drug-drug
interactions with Bcrp substrates when administered concomitantly, via an oral route, and
increase systemic exposure (blood/ plasma / serum AUC) of the substrate. Therefore, we
dosed the inhibitors orally, along with the Bcrp probe substrate PhA, and measured whole
body fluorescence and serum PhA concentrations. Whole-body fluorescence imaging in
mice treated with the Bcrp inhibitors LPB, ECD and CCM displayed higher fluorescence
compared to the control-treated mice (Figure 4-6). After quantification of fluorescence
flux/second and normalization with baseline fluorescence from the same mice, these
values were plotted against time after dosing (Figure 4-7A and B), and AUCFL 0-6h was
calculated for all the inhibitor-treated and control mice. LPB exhibited the maximum fold
increase (2.4-fold) of AUCFL 0-6h over control mice, followed by CCM (2.3-fold), ECD
(2.2-fold) and SFB (1.44-fold) (Figure 4-7C). PPZ showed a decrease in AUCFL 0-6h
compared to control (0.84-fold) and DSB did not significantly increase the AUCFL 0-6h
over control mice.
Serum fluorescence spectra of PhA was measured and compared with a standard
PhA sample to confirm the identity of PhA in each sample. Representative PhA spectra
of control (CT) mice, curcumin (CCM) and lapatinib (LPB) treated mice are showing
PhA peak at 670 nm in each sample corresponding to the standard PhA peak (Figure
4-8).
The PhA serum concentration-time plots after treatment with Bcrp inhibitors
displayed a similar trend as observed with whole body fluorescence (Figure 4-7D and E),
with a similar rank order of inhibitor-mediated increase in AUCSerum 0-6h observed as was
seen for AUCFL 0-6h (Figure 4-7F). LPB treatment had the maximum increase in PhA
fluorescence (13.8-fold), followed by CCM (7.79-fold), ECD (5.2-fold), PPZ (2.02-fold)
and SFB (1.45-fold). No significant effect of DSB was found on serum PhA
concentration consistent with the lack of effect on PhA whole-body fluorescence. PPZ
showed a significant increase in serum PhA AUCSerum 0-6h, but not AUCFL 0-6h,
measured by the whole-body fluorescence data. Whereas Cgut/IC50 for all inhibitors were
≥ 10, Cgut_soluble/IC50 values (Table 4-1) displayed a better correlation with the observed
fold change by Bcrp inhibitors, where Cgut_soluble is the predicted solubility of the
inhibitors obtained from DrugBank database (https://www.drugbank.ca).
Discussion
The ATP-binding efflux transporter Bcrp plays a significant role in controlling
xenobiotic exposure by reducing absorption and increasing elimination of its substrates
[129]. Drug-drug interactions (DDI) associated with Bcrp have been reported for Bcrp
substrates such as topotecan [299], sulfasalazine [259] and rosuvastatin [300]. Based on
the clinical evidence and importance of its transporter effect, Bcrp has been recognized
by FDA and ITC as having the potential for causing clinical DDI [1, 25, 80]. Due to
overlapping substrates and inhibitors of drug transporters as well as metabolizing
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Figure 4-6. Inhibition of BCRP increased whole body fluorescence in control
FVB mice orally dosed with PhA
Note: Six hour representative image comparing fluorescence (Ex675/Em840) in control
mice orally administrated 10 mg/kg of PhA ± Bcrp inhibitors, 1 hr prior to PhA
administration as indicated in the method.
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Figure 4-7. Inhibition of BCRP increased whole body fluorescence as well as the
serum concentration of PhA in control FVB mice
Notes: Whole body fluorescence (flux/sec) was normalized to the zero-hour fluorescence
of the same mice and data plotted as mean fluorescence ratio ± SEM vs. time (hrs), for
the tyrosine kinase inhibitors (A) and other inhibitors (B). AUCFL 0-6h calculated for each
mouse and plotted as mean ± SEM (C). PhA serum concentration- time plot for the
control and tyrosine kinase inhibitors (D) and other inhibitors (E) plotted as mean ±SEM
and the associated AUCSerum 0-6h calculated using GraphPad Prism v5.02 (F). Significance
is calculated by comparing the mean AUC after inhibitor treatment with that of control
AUC by unpaired t-test. Significance is calculated at p<0.05. * p<0.05, **p<0.01,
***p<0.001.
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Figure 4-8. Fluorescence spectra showing identity of the PhA peak used for
determination of PhA concentration in serum
Note: Mean fluorescence ± SD spectrum with excitation at 400nm and emission at 670
nm for the PhA standard prepared in serum, control serum from PhA (10 mg/kg) dosed
mice and inhibitor (LPB and CCM) treated mice.

110

enzymes, interpretation of clinical DDI studies utilizing probe substrates is often difficult.
Therefore, a more selective or specific probe-based assay, or utilization of a biomarker
for elucidation of Bcrp-mediated DDI is highly desirable.
PhA has been documented to be a substrate of human BCRP in cell lines [288]
and we now show it is a substrate for mouse Bcrp as well (Figure 4-3). Mouse
Abcg2/Bcrp has 81% sequence homology with human ABCG2/BCRP [55], and there is
overlapping substrate and inhibitor specificity of human and murine ABCG2 [301].
Hence, the substrate and inhibitor profile of BCRP in humans should be comparable to
that in mice. Bcrp KO mice of FVB background [92] are an established model for
identification of clinical Bcrp substrates and inhibitors. Therefore, our experimental
findings of PhA absorption in WT and Bcrp KO mice can likely be extrapolated to
humans as well.
Using a LC-MS/MS based analytical system to compare the plasma of WT and
Bcrp-Pgp double knockout (dKO) rats, we detected Pheophorbide A (PhA) only in the
plasma of the dKO rats, but not in any WT rat plasma (Chapter 2). This observation,
along with reports that PhA is a selective Bcrp dietary substrate [92, 288], prompted us to
further investigate the possibility of utilizing PhA as an in vivo probe for identification of
DDI associated with Bcrp. By utilizing an HPLC-Fluorescence Detector based analytical
method, we determined PhA content in normal rodent chow to be 1.7 μg/gm of regular
rodent food pellet (Figure 4-2). PhA is a known catabolite of chlorophyll [287], present
in regular human diet. For example, chlorophyll content in 1 cup of spinach is 24 mg, ½
cup of parsley is 19 mg and 1 cup of sugar snap peas is 24 mg
(https://draxe.com/chlorophyll-benefits/). It has also been previously reported that the
plant monooxygenase enzyme can catabolize PhA formation from chlorophyll, thus PhA
is present in the regular diet in human [302, 303]. Therefore, complete absence of PhA in
the plasma of WT rats, fed a regular diet, creates the possibility of utilizing PhA as a
dietary marker of Bcrp transporter function. Also, since PhA is present in regular diet, it
poses a phototoxicity risk due to unwanted exposure to PhA from food when taken with a
Bcrp inhibitor, like pantoprazole.
PhA emits fluorescence at the NIR wavelength, thereby creating the exciting
possibility of utilizing PhA as a probe for in vivo live animal imaging. Whole body
autofluorescence in rodents has been previously reported to be affected by chlorophyll
content of food and alfalfa free (AFF) diet [287]. Using whole animal fluorescence
imaging at 670 nm (Ex) and 840 nm (Em), that corresponded to PhA fluorescence
(Figure 4-1C), we observed a higher whole-body fluorescence in the Bcrp KO mice,
compared to the WT mice (Figure 4-1A). Based on lack of background autofluorescence
when mice are on AFF diet (Figure 4-1A), along with complete absence of PhA in the
AFF diet (Figure 4-2C), we decided to feed mice an AFF diet for at least three days for
the majority of our studies to eliminate the effect of background fluorescence. In
addition, regular food pellet extract, as analyzed by the HPLC-RF based method,
indicated the presence of an additional peak with similar fluorescence intensity as PhA
(Figure 4-2B). Therefore, we administered mice fed an AFF diet an oral gavage of 10
mg/kg PhA, to test the hypothesis that PhA can be used as an in vivo probe for Bcrp
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function and for screening Bcrp inhibitors for oral DDI. Pheophorbide A has already been
reported to be used at a dose of 30 mg/kg intraperitoneally, or 10 mg/kg intravenously,
for photodynamic therapy of oral squamous cell carcinoma (OSCC) in mice [304].
Chlorophyll, the catabolic precursor of PhA, is also present in regular diet in humans, as
discussed above. Therefore, our current findings utilizing the 10 mg/kg PhA oral dose in
mice may have a possible significant human translational significance.
We observed a difference in PhA excitation and emission wavelengths in vivo in
mice (670 nm (Ex) and 840 nm (Em)) vs. in vitro (400-410 nm (Ex) and 670 nm (Em)).
This is not unexpected because live animal fluorescence is affected by a significant
amount of absorbance and scattering of light due to the presence of a complex
environment comprised of plasma proteins and tissue barriers [298]. This is critical since
selecting the Ex/Em wavelength parameters based on in vitro PhA fluorescence would
have resulted in overlooking its fluorescence in vivo.
High fluorescence in the intestinal region, but not systemically, in WT mice is due
to PhA in the luminal contents. PhA is a low solubility and low permeability compound,
and as a Bcrp substrate is poorly absorbed. Indeed, PhA has been reported to be mainly
cleared unabsorbed in feces [287]. Interestingly, ex vivo fluorescence comparison of the
intestinal segments of WT mice fed a normal PhA-containing diet, after flushing out
intestinal contents, revealed a lower fluorescence in the duodenum compared to higher
fluorescence in the jejunum and ileum (i.e., there is lower Bcrp expression in jejunum
and ileum and hence a small amount of PhA is trapped in the lower small intestine of WT
mice) (Figure 4-3A) and is consistent with the gradient of Bcrp expression reported in
rodent intestine (higher in the duodenum than in the ileum), and being the lowest in the
colon [105]. The increased fluorescence in the intestinal region in Bcrp KO mice (Figure
4-3A), in spite of increased systemic absorption from the lumen, was due to trapping of
PhA in the enterocytes in the absence of Bcrp mediated efflux (Figure 4-3B).
We found a higher PhA whole body fluorescence in the Bcrp KO compared to
WT mice, leading to a significantly higher (3.5-fold) area under the fluorescence ratio –
time curve up to 6 hrs (AUCFL 0-6h) (Figure 4-4B and C). Comparing the serum PhA
concentration in the same experiment, we observed a 50-fold increase in PhA area under
serum concentration – time curve up to 6 hours (AUCSerum 0-6h) in the Bcrp KO compared
to WT mice (Figure 4-4D and E). The concentration of PhA detectable in the WT mice
after oral gavage in this study were at the lower limit of quantification (LLOQ), whereas
in Bcrp KO mice serum, the concentration of PhA was significantly higher than LLOQ.
This data is in conformation with our previous observation in rats, where PhA could only
be detected in the Bcrp-Pgp dKO and not in the WT rat plasma, and also reports by
Jonker et al. that Bcrp KO mice are 100-fold more sensitive to developing phototoxicity
from PhA [92]. The difference in fold increase between whole body fluorescence (3.5fold) and serum concentration (50 fold) could be due to a higher background fluorescence
in the whole-body fluorescence imaging, especially from unabsorbed PhA remaining in
the gut, compared to the very low concentration of PhA in serum of WT mice. Thus,
serum fluorescence of PhA might be a more useful tool than whole body fluorescence for
elucidating the DDI of weak inhibitors of Bcrp. On the other hand, the advantages of
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using whole body fluorescence of the Bcrp substrate PhA to screen for oral DDI come
from: (a) the ease and noninvasive nature of its detection, (b) that animals do not need to
be sacrificed can be used repeatedly, (c) the ability to longitudinally monitor changes in
Bcrp substrate tissue distribution into other organs in the presence of systemic inhibition
of Bcrp, and (d) the possibility of transforming it into a better high-throughput method.
The dynamic range of PhA fluorescence, both whole body, and in serum, of WT
and Bcrp KO mice, allowed us to rapidly examine the effect of Bcrp inhibitors on the
whole-body fluorescence as well as serum concentration of PhA. For an orally
administered Bcrp inhibitor drug, if [(dose/250 ml) / IC50 for Bcrp] ≥ 10, or Igut/IC50 ≥
10, FDA recommends analysis of possible oral Bcrp inhibition-mediated DDI [1]. Hence,
we specifically chose drugs that would be predicted to cause a Bcrp-mediated DDI in
vivo. For pantoprazole- (PPZ), elacridar- (ECD), curcumin- (CCM) and lapatinib (LPB)mediated clinical DDI liability, Igut/IC50 was obtained from literature reports, and are
significantly higher than 10 [71]. For sorafenib (SFB), Igut/IC50 when calculated from
maximum reported dose of 400 mg BID data [305] and was found to be > 10 (Table 4-1).
Clinical DDI liability of dasatinib with Bcrp substrates was not reported, and hence was
selected as a negative control in the experiment.
Based on reported pharmacokinetic (PK) parameters in mice, and associated
clinically relevant doses and observed IC50 values, we also calculated the Igut/IC50 in
mice assuming the gut volume in mouse to be 0.8 mL [306]. For the selected inhibitors
Igut/IC50 values in mice are also ≥ 10 and thus, according to FDA criteria, are expected
to show preclinical DDI in mice (Table 4-1). Since, only the soluble fraction of the drug
would be available at the enterocytes to inhibit Bcrp, we also calculated the gut soluble
concentration of the drug/ IC50 (Cgut_soluble/ IC50), based on the predicted solubility
values obtained from DrugBank database (https://www.drugbank.ca). Considering these
Cgut_soluble/ IC50 values, we might potentially rule out DDI for SFB and DSB in mice.
Cgut_soluble/ IC50 for CCM was also < 10. Kusuhara et al. dosed 300 mg/kg CCM 1 hr
prior to sulfasalazine oral dosing in mice and observed an 8-fold increase in sulfasalazine
plasma AUC [259]. We have used the same curcumin dose and thus we expected CCMmediated inhibition of gut Bcrp would increase PhA serum AUC.
FDA also indicated that assessment of DDI is not required if there is no safety
concern for the Bcrp substrate distribution in tissues [1]. Therefore, apart from inhibition
of Bcrp at the gut, consideration is also required for systemic inhibition of Bcrp. To
assess systemic Bcrp inhibition, we considered the reported Cmax/IC50 for the Bcrp
inhibitor drugs [71]. Systemic inhibition for SFB, ECD and LPB were expected based on
the published Cmax in mice (Table 4-1) and observed IC50 values. But, for SFB, reported
Cmax is associated with an enabling formulation [166], compared to a suspension
formulation used in our study. Therefore, we would expect a lower Cmax and thus lack of
systemic DDI in mice. Of note, based on clinically obtained Cmax of sorafenib [305],
Cmax/IC50 is 2, suggesting that a systemic Bcrp inhibition by sorafenib may be expected.
However, for a highly plasma protein bound drug such as sorafenib, unbound fraction in
plasma (Fu) is 0.3% [307]; unbound concentration in plasma may not be sufficient to
exhibit a systemic inhibition of Bcrp.
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Physiochemical properties such as logP and solubility values for the selected
drugs were obtained from DrugBank database (https://www.drugbank.ca) to understand
the possible disposition characteristic and gut solubility. Among the selected inhibitors,
LPB, SFB and ECD have high logP or lipid permeability, thus probably have higher
tissue distribution compared to the other inhibitors. Together with their low IC50 value
for Bcrp, ECD and LPB might show systemic inhibition of Bcrp. On the other hand, PPZ
has the highest predicted solubility, thus probably having fast absorption as well as faster
transit than other selected inhibitors.
Our results with whole body fluorescence imaging (Figure 4-6 and Figure
4-7A-C) show increased whole-body fluorescence of PhA in mice administered the Bcrp
inhibitors LPB, ECD and CCM. The AUCFL 0-6h for LPB, CCM and ECD were 2.4, 2.3
and 2.2-fold significantly higher than the control mice. A similar trend was observed for
the serum concentration data (Figure 4-7D-F), with LPB having the highest fold change
(13.8 fold) increase compared to controls, followed by CCM (7.8 fold), ECD (5.17 fold),
PPZ (2.02 fold) and SFB (1.45 fold). Taken together, the serum concentration and
imaging data provide evidence that PhA can be used for identification of oral DDIs
associated with Bcrp. The only exception between these two methods was the observed
lower AUC FL 0-6h for PPZ. Since PPZ solubility is the highest among all selected
inhibitors, it is possible that it has a faster GI transit compared to the other drugs, leading
to short-lasting inhibition of Bcrp at the upper gastro intestinal tract (GIT). Another
possibility is the effect of altered pH on PhA fluorescence in presence of proton pump
inhibitor PPZ. When mice were administered CCM with PhA, we observed a 7.79-fold
increase in serum fluorescence of PhA, while Kusuhara et al. observed an 8-fold increase
in sulfasalazine plasma exposure in presence of CCM at a dose of 300 to 400 mg/kg
[259], further corroborating that PhA might be utilized as an in vivo probe for Bcrp
function. FDA Drug Interactions & Labeling guideline also mentions that a ≥ 1.5-fold
increase in sulfasalazine AUC when concomitantly dosed with a Bcrp inhibitor should be
considered an in vivo inhibition of Bcrp. According to these criteria, PPZ, ECD, CCM
and LPB showed in vivo inhibition of Bcrp-mediated PhA transport in our studies.
Measurement of serum concentration of PhA by fluorescence spectrometry-based
methods has some advantages of creating a faster and less expensive method for faster
decision-making processes. However, we recognize that this method might be less
specific than an HPLC-RF based method. When we used an HPLC-RF based detection of
PhA for 100 mg/kg oral dose of PhA (data not shown) in WT, Bcrp KO and ECDpretreated mice, PhA could be detected at the maximum concentration only in the serum
of Bcrp KO and ECD-treated WT mice, implying PhA as a source of serum fluorescence.
For our screening studies, we used a 10 mg/kg PhA dose; thus, the expected PhA
concentrations would be below the detection limit of our analytical method. Therefore,
we utilized a whole serum fluorescence spectrometry-based method and confirmed the
detection of PhA by obtaining similar fluorescence spectra between PhA standard
concentration, blank serum and inhibitor-treated serum (Figure 4-8) groups, implying
absence of any other fluorescent molecule.

114

In our experiments, the Bcrp inhibitors were administered to the mice 1 hr prior to
PhA dosing. A similar (1-hr prior) dosing schedule was also utilized to investigate CCMmediated DDI with sulfasalazine in mice [259]. However, according to the FDA
guidelines, a concomitant dosing of the two drugs is suggested. Due to fast absorption of
compounds like dasatinib, with a reported Tmax as early as 15 minutes in mice [308], it is
possible that in our study we have underestimated the effect of Bcrp inhibition at the GIT.
Therefore, further investigation and careful observation might be required for
identification of DDIs of weaker Bcrp inhibitors such as dasatinib.
Further studies are also required to find out if PhA can be used as a probe for
systemic Bcrp inhibition as well, such as with lapatinib known to exhibit systemic Bcrp
inhibition. For utilization of this method to its fullest potential, a better understanding of
PhA pharmacokinetic properties would also be required with more emphasis on its tissue
distribution and clearance.
To our knowledge, this is the first report that shows a fluorescent Bcrp substrate
PhA can be utilized for identification of in vivo DDI due to inhibition of Bcrp at the GIT
and creates an opportunity for a high throughput in vivo Bcrp inhibitor assay. Also,
utilization of serum fluorescence by simple spectrometry makes this method unique in
that minimal technical resources are required for identification of Bcrp substrates.
Furthermore, this method is in conformation with the 3R principal (replacement,
reduction and refinement), as it would reduce the requirement of invasive studies thus
significantly reducing the number of lab animals, at the same time creating high quality
reliable data.
In conclusion, our study shows that dynamic fluorescence imaging in live animals
utilizing PhA as a Bcrp probe can be used for identification of Bcrp inhibitors and to
understand the DDI liability of such inhibitors. Further studies are required to determine
if we can use this compound as a dietary marker of BCRP activity in the clinic, and that
may be further utilized to understand systemic Bcrp inhibition.
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CHAPTER 5.

SUMMARY AND DISCUSSION
Summary

The overall goal of this research work was to understand the function of BCRP
and PGP efflux drug transporters in context of their endogenous, xenobiotic and dietary
substrates. We found (1) a significant impact of Bcrp and Pgp on the endogenous
metabolome encompassing dietary, gut microbiome as well as host-derived metabolites,
(2) a distinct effect of these transporters on the pharmacokinetics and pharmacodynamics
of the anesthetic/analgesic drug ketamine, and (3) that dietary Bcrp substrate
Pheophorbide A may be utilized as an in vivo marker for possible identification of Bcrp
inhibition-mediated drug-drug interactions.
We compared the CSF and plasma metabolomes as well as gene expression in
kidney, liver and brain frontal cortex between wild-type (WT) and Bcrp-Pgp double
knockout (dKO) rats to understand the systemic effect of these transporters in rats
(Chapter 2). Our results showed a significant difference in both CSF and plasma
metabolomic signatures between the WT and dKO rats. The most significant feature in
the plasma metabolome was altered fatty acid metabolites, which was further supported
by the altered genes and metabolites associated with the peroxisome proliferator activity
receptor (PPAR) pathway. We also observed changes in gut microbiota-derived
metabolites in both CSF and plasma of dKO rats, indicating a possible change in the gut
microbiome, as well as an effect of Bcrp and/or Pgp in regulating the absorption of
microbiota-derived metabolites in blood, and also their permeability in CSF.
Transcriptomic analysis further revealed alterations in pathways related to fatty acid
metabolism, lipopolysaccharide response (again indicating an altered microbiome),
circadian rhythm as well as oxidative stress response in the dKO rats, when compared to
WT rats. Analysis of the altered CSF metabolites, utilizing an in silico approach and
literature-based evidence, identified metabolites which may be putative Bcrp substrates.
Overall our results identified a significant impact of Bcrp and Pgp drug transporters on
the endogenous metabolome and biological pathways, without any dramatic
compensatory changes in transporter or enzyme expression.
Apart from alteration of known Bcrp endogenous substrates, such as riboflavin
and urate, we observed a significantly higher abundance of ketamine, an
anesthetic/analgesic drug used in this study to anesthetize the rats, in the plasma and CSF
of dKO rats. Thereafter, utilizing mice with genetic deletion of Bcrp, Pgp and both BcrpPgp, we showed that pharmacokinetics (PK) as well as pharmacodynamics (PD) of
ketamine were affected by both Bcrp and Pgp transporters (Chapter 3). A recently
published article also confirmed our finding that ketamine is a substrate of Pgp [98].
Our plasma metabolomics identified Pheophorbide A (PhA), a catabolite of
chlorophyll found in regular rodent diet, only in the plasma of dKO rats, but not in WT
rat plasma. Thereafter, we developed a PhA fluorescence-based in vivo assay using mice
fed an alfalfa-free diet (devoid of PhA) and exogenously administered with PhA, to
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identify possible oral drug-drug interactions (DDIs) associated with Bcrp inhibition
(Chapter 4). We observed an increased PhA fluorescence, both whole-body and in serum,
of Bcrp-knockout mice, and in mice pre-treated with known Bcrp inhibitors, compared to
WT mice, administered with PhA, suggesting that our assay might identify possible oral
DDIs due to inhibition of Bcrp at mouse enterocytes.
Perspectives and Future Directions
While drug transporters are important for transporting xenobiotic substrates, and
thereby involved in therapeutic resistance, drug-drug or food-drug interactions, they are
also important for transporting endogenous metabolite(s) and involved in many important
physiological functions [14]. Therefore, a clear understanding of the endogenous function
of transporters will help better elucidate the effect of loss of function mutation or
pharmacological inhibition of these transporters, leading to identification of drugmetabolite-transporter interactions.
Xenobiotics are often substrates of multiple transporters and/or enzymes.
Therefore, an altered transport function due to a secondary effect of absence or inhibition
of other transporter(s) may lead to pharmacokinetic or pharmacodynamic changes of
transporter substrates and/or DDIs. For example, Martinez et al. recently published that
association of methotrexate clearance (cleared mainly by urinary excretion) and
OATP1B1 polymorphism (a transporter of the liver) can be explained by communication
of OATP1B1 transporter, via its endogenous metabolites, with OAT1/3 transporters
involved in methotrexate excretion at the kidney [213].
Several uremic toxins that are substrates/inhibitors of OAT1/3, BCRP and MRP4,
are also metabolites of the gut microbiota [234] [141] [126]. Several clinically used nonantibiotic drugs are also known to alter the gut microbiome [313]. Therefore, it can be
hypothesized that loss-of-function mutation and/or pharmacological inhibition of
transporter(s) can lead to remote signaling via the gut microbiome metabolites to alter the
function of other transporter(s), leading to a change in not only metabolite homeostasis,
but also altered pharmacokinetics of their xenobiotic substrates.
BCRP and PGP efflux transporters are highly expressed at the enterocytes in
gastrointestinal tract, regulating the oral absorption of their substrates [11, 115, 177, 258,
259, 270]. Hence, while considering the effect of gut microbiota on systemic metabolites,
a special consideration is needed for these efflux transporters that control the oral
absorption of many different chemical class of compounds.
The transporters are also highly expressed at the blood brain barrier (BBB) and
blood CSF barrier (BCSFB), regulating the brain or CSF permeability of their substrates
[169, 171] [144] [46, 155]. Their effect on brain accumulation of BCRP and PGP
substrates is so dramatic probably because of (i) lack of efficient metabolic clearance
from brain, compared to liver that takes care of peripheral blood concentration and (ii)
rate of clearance from brain is slower than from peripheral blood due to lower flow rate
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of CSF. Specifically, in adult humans, the total CSF volume turnover is about 4 times a
day, with a CSF synthesis rate of 0.35-0.4 ml/min [314], compared to blood flow rate to
brain which is about 700 ml/min, and to liver which is 1.4 L/min (http://rmipharmacokinetics.com/Physiological_parameters).
Therefore, the effect of dietary and microbiome metabolites, that are PGP and/or
BCRP substrates/inhibitors, might be highly significant in brain as well. To this effect,
our metabolomic analysis in rats identified abundance of many sulfate metabolites,
possibly dietary or microbiome-generated, and the known Bcrp substrate urate in the CSF
of dKO rats, compared to WT rats. Since Bcrp has high affinity for sulfated metabolites
[127]; our results raise the possibility that BCRP might also be involved in controlling
gut-brain chemical interactions. A recent finding showed that sulfated steroids, such as
estradiol sulfate, in female mice urine, can activate vomeronasal sensory neurons (VSNs),
which are part of accessory olfactory system (AOS), involved in social interaction in
mice [315]. Therefore, BCRP, which is known to be a transporter of sulfated steroids
[316], might have a more significant role to play at different tissues including brain, than
being a mere xenobiotic transporter.
It is well known that the absence of Pgp in mice leads to an irritable bowel
syndrome phenotype [51], and possible modification of the gut microbiome in absence of
Pgp could be the leading cause for this phenotype [162]. Gut microbiome is also reported
to change in gout patients, who have hyperuricemia [139]. Bcrp is involved in the
intestinal secretion of uric acid, a decrease of which can lead to hyperuricemia [138]
[114] and precipitation of gout in humans with BCRP polymorphism [24]. Therefore,
alteration in the gut microbiome is possible in the absence or chronic inhibition of BCRP
and/or PGP transporters, leading to an altered metabolome in the host. Gut microbiome
has also been recently associated with disease conditions related to CNS [317] [318]
[319]. While Bcrp and/or Pgp knockout mice do not show any obvious phenotype of
CNS pathology, a behavioral understanding of rodent models of these diseases is not so
common and more studies need to be done to understand the role of transporters in the
CNS.
Recently published reports have highlighted the importance of understanding
pharmacometabolomics, i.e., the effect of drug treatment on the metabolome, or a
metabotype of drug action [180, 185]. Lin et al. showed that pharmacometabolomic
understanding can also help predict population variability in busulfan clearance [214].
Studies by Dr. Elizabeth de Lange’s group at Leiden University further showed that
integrated metabolomics and PK/PD studies can be greatly useful and provide significant
insight into CNS drug discovery [320, 321]. Therefore, the concept of utilizing
metabolomics for predicting drug pharmacokinetics and pharmacodynamics may not be a
far-fetched hypothesis in near future. Knowledge integration of metabolomics of drug
transporters and associated biomarker information, if possible, could be extremely helpful
in understanding population variability in PK, drug response as well as toxicity
associated with treatment and/or disease.
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To our knowledge, this is the first study reporting the metabolomic impact of
Bcrp and Pgp drug transporters in rodents. In a preliminary experiment comparing the gut
microbiome between WT and Bcrp KO mice by 16S ribosomal RNA sequencing of fecal
samples, we have observed a significant difference in percentage abundance of gut
microbial populations, as was suggested by our CSF and plasma metabolomic findings in
rats (data not shown). Future studies should be directed towards metabolomic analysis of
fecal, plasma and urine samples from these mice for integration with the microbiome
abundance data leading to a better understanding of host-microbiome metabolomic
interactions in absence of Bcrp transporter. Furthermore, metabolomic analyses of
different models of gene deletion or inhibition of other transporters in a variety of
matrices would be required for a better understanding of the Remote Sensing and
Signaling concept [20].
We unexpectedly found an increase in ketamine abundance in plasma as well as
CSF of Bcrp-Pgp dKO rats compared to WT rats and later confirmed that
pharmacokinetics (PK) and pharmacodynamics (PD) of ketamine are affected by these
transporters in mice [95]. Unlike prototypical Bcrp-Pgp substrates, ketamine whole brain
homogenate concentration was found to be similar between WT, Bcrp or Pgp KO and
dKO mice, whereas its anesthetic effect as measured by loss of righting reflex (dLORR)
was found to be significantly higher in the dKO mice, followed by Pgp KO mice,
compared to WT mice. Treatment with known Bcrp-Pgp inhibitor elacridar (ECD) also
increased dLORR in the WT mice. Due to high passive permeability of ketamine, effect
of efflux transporters in brain may not be similar to other substrates that show increased
brain accumulation in absence of these transporters. The same was observed for another
Pgp substrate terfenadine [97], another high permeability Pgp substrate, with no
difference in brain uptake clearance between WT and Pgp KO mice. This raises the
possibility of overlooking the effect of these transporters on certain compounds when
only PK is considered as a discerning factor. In this regard, FDA guidance on assessing
DDI states that the effect on distributing tissue(s)/organ(s) toxicity or efficacy needs to be
considered when assessing DDIs. Therefore, we believe that the PD or toxicity of a drug,
along with its PK, should be an additional factor of consideration during DDI assessment.
In addition, long-term administration of ketamine is well-known to cause toxicity in the
urinary bladder and kidney [252] [322] [323]. Therefore, based on our current knowledge
of the effect of Pgp, Bcrp and OCT1/2 transporters on ketamine [98] [95], it will be
interesting to see if these transporters play any role on the peripheral tissue toxicity of
ketamine.
While our current investigation does not specifically identify any biomarker for
Bcrp/Pgp activity, we identified several putative endogenous substrates of Bcrp and/or
Pgp which might be interesting candidates for further investigation. However, our studies
with PhA as a dietary marker of gastrointestinal Bcrp activity showed the possibility of
utilizing a fluorescent substrate/marker for high-throughput screening of Bcrp inhibitors
in vivo. A 50-fold window of difference in serum concentration of PhA between WT and
Bcrp KO mice created a prospect for identification of Bcrp substrates in vivo by
measuring serum fluorescence. Our results from rats on regular diet showed that PhA is
detectable only in the plasma of Bcrp-Pgp dKO rats, but none in WT rats. This is
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interesting, as it creates an opportunity to utilize dietary PhA, which is a chlorophyll
catabolite, to be utilized as a dietary biomarker of BCRP activity in humans as well, since
chlorophyll is a dietary component in humans. A future modification of this study with
more soluble PhA analogues that are also Bcrp substrates and gives a better tissue
distribution and absorption compared to PhA can also be useful to assess systemic
inhibition of Bcrp and associated increase in tissue concentration of its substrates.
In conclusion, this research work created a new understanding of the endogenous
role of Bcrp and Pgp efflux transporters, their effect on the PK and PD of the
anesthetic/analgesic drug ketamine, and development of an assay for identification of
Bcrp inhibitors in mice. Further studies need to be done with focused goals specifically
(i) to elucidate the effect of the transporters on microbiome and associated metabolic
changes, (ii) how peripheral toxicity can be modified by efflux transporters Bcrp and
Pgp, with a model substrate ketamine, (iii) modification of the existing protocol of PhA
in vivo assay, with carefully selected Bcrp substrate(s) and inhibitors for developing a
robust fluorescence-based assay that can detect systemic as well as oral Bcrp inhibition in
vivo, and (iv) elucidating the pharmacometabolomics of drugs that interact with Bcrp and
Pgp transporters, thereby creating better understanding of long term systemic inhibition
of these transporters.
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